US 20090 143280A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0143280 A1 Kristiansen (43) Pub. Date: Jun. 4, 2009

(54) ANT-CANCER COMBINATION TREATMENT Related U.S. Application Data AND KIT OF-PARTS (60) Provisional application No. 60/690,482, filed on Jun. 15, 2005, provisional application No. 60/761,743, (75) Inventor: Bjorn Kristiansen, Frederikstad filed on Jan. 25, 2006. (NO) (30) Foreign Application Priority Data Correspondence Address: Jun. 15, 2005 (DK) ...... PA 2005 OO882 BROWDY AND NEIMARK, P.L.L.C. Jan. 25, 2006 (DK)...... PA 2006 OO116 624 NINTH STREET, NW Publication Classification SUTE 300 (51) Int. Cl. WASHINGTON, DC 20001-5303 (US) A638/16 (2006.01) A 6LX 3L/75 (2006.01) (73) Assignee: MediMush A/S, Horsholm (DK) A6II 3L/20 (2006.01) A63L/7088 (2006.01) (21) Appl. No.: 11/917,521 A6IP35/00 (2006.01) (52) U.S. Cl...... 514/8: 514/54: 514/558: 514/44 (22) PCT Fled: Jun. 14, 2006 (57) ABSTRACT In one aspect the present invention relates to pharmaceutical (86) PCT NO.: PCT/DKO6/OO339 kits of parts Suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidi S371 (c)(1), omycete bioactive agent in Solid or liquid form, and, option (2), (4) Date: Sep. 12, 2008 ally instructions for a dosing regime. Patent Application Publication Jun. 4, 2009 Sheet 1 of 2 US 2009/O143280 A1

Fig. 1

E. coli K12

5 culture time (h) Patent Application Publication Jun. 4, 2009 Sheet 2 of 2 US 2009/O143280 A1

Fig. 2

Bioactive agent 50 -- MRC-5 --Kelly 100------MT-1 SS moto C-26. g MRC-5 -- FEMX

50 Kel

FEMX O C-26 OO O. O.2 O3 0.4 O.5 mgiml US 2009/O 143280 A1 Jun. 4, 2009

ANT-CANCER COMBINATION TREATMENT or humans (Borchers et al., “Mushrooms, Tumors and Immu AND KIT OF-PARTS nity: an update'. Experimental Biology and Medicine 229: 393-406).

0001 All patent and non-patent references cited in the SUMMARY OF THE INVENTION present application are hereby incorporated by reference in their entirety. 0006. The present invention relates to a pharmaceutical kit of parts comprising TECHNICAL FIELD OF THE INVENTION 0007 a) an anti-cancer medicament, 0002 The present invention relates to pharmaceutical kits 0008 b) a Basidiomycete bioactive agent in solid or of parts Suitable for treating neoplastic diseases such as can liquid form, and, optionally C. 0009 c) instructions for a dosage regime for said kits of parts. BACKGROUND OF THE INVENTION 0010. In another aspect, the present invention relates to a method of treatment comprising the step of administering Medicinal Mushrooms said pharmaceutical kit of parts simultaneously (optionally in 0003 Mushrooms have been used for medicinal purposes a co-formulation) or sequentially according to a set dosage for centuries in many cultures. Several members of the regime. Basidiomycete mushroom class, such as for e.g. members of 0011. Another aspect of the present invention relates to the Agaricus mushroom family have been used for medicinal use of a medicament. Such as an anti-cancer medicament, and and health-related purposes. a Basidiomycete bioactive agent in Solid or liquid form in the 0004. A number of researchers have suggested anticancer, manufacture of a kit of parts for the treatment of an individual antitumour or antimutagenic properties of e.g. Agaricus in need thereof. Such as an individual Suffering from, or at risk mushrooms (Kimura, Y. In Vivo 2005, Vol 19, Iss 1, p 37-60; of Suffering from, a neoplastic disease such as cancer. Kim et al., Food Science and Biotechnology 2004, Vol 13, Iss 0012 Another aspect of the present invention relates to a 6, p. 852; Kim et al., Food Science and Biotechnology 2004, method for enhancing a therapeutic effect of an anti-cancer Vol 13, Iss 3. p 347-352; Guterrez et al., Texicology in Vitro drug, comprising co-administering (simultaneously or in any 2004, Vol 18, Iss 3. p 301-309; Ribeiro et al., Mutation order) with said anti-cancer drug (such as any of the anti Research Reviews in Mutation Research 2003, Vol 54, Iss cancer drugs described herein) a Basidiomycete bioactive 2-3, p 195.201; Pinheiro et al., Food and Chemical Toxicol agent (Such as any of the Basidiomycete bioactive agents ogy 2003, Vol. 41, Iss 11, p 1543-1550; (Inhibiting tumour described herein). growth) Lee et al., Experimental Animals 2003, Vol. 52, p 0013 Bioactive agents produced by Agaricus sp. (any 371-375; Luiz et al., Mutation research-Fundamental and basidiomycetous fungal species of the genus agaricus of the Molecular Mechanisms of Mutagenesis 2003, Vol. 528, Iss family agaricaceae and the order agaricales and the Subclass 1-2, p 75-79; Bellini et al., Texicology in Vitro 2003, Vol 17, agaricomycetidae), Schizophyllum sp. (any basidiomycetous Iss 4, p. 465-469; Ashida et al., Food Factors in Health Pro fungal species of the genus schizophyllum of the family motion and Disease Prevention 2003, Vol. 851, p. 235-248; Schizophyllaceae and the order agaricales and the Subclass (antigenotoxic effect) de Oliveira et al., Food and Chemical agaricomycetidae), Lentinus sp. (any basidiomycetous fungal Toxicology 2002, Vol. 40, Iss 12, p 1775-1780; Kuo et al., species of the genus lentinus of the family polyporaceae and Journal of Laboratory and clinical medicine 2002, Vol. 140, the order polyporales and the Subclass agaricomycetidae (L. Iss3, p 176-187: Oshiman et al., Planta Medica 2002, Vol. 68, edodes is also termed Lentinula edodes, which is placed in the lss 7, p 610-614; Meloni et al., Mutation Research Genetic family Marasmiaceae, in the order Agaricales and the Sub Toxicology and Environmental Mutagenesis 2001, Vol. 496, class agaricomycetidae)), Trametes sp. (any basidiomycetous Iss 1-2, p 5-13: Osaki et al., Yakugaku Zasshi Journal of the fungal species of the genus trametes of the family polypora Pharmaceutical Society of Japan 1994, Vol. 114, Iss 5, p ceae and the order polyporales and the Subclass agarico 342-350; Itoh et al., Japanese Journal of Pharmacology 1994, mycetidae), Ganoderma sp. (any basidiomycetous fungal Vol. 66, Iss 2, p 265-271. Ito et al., Anticancer Research species of the genus ganoderma of the family ganodermata 1997, Vol. 17, Iss 1A, p 277-284: Fujimiya et al., Cancer ceae and the order polyporales and the Subclass agarico Immunology Immunotherapy 1998, Vol. 46, Iss 3. p 147-159; mycetidae), and Grifola sp. (any basidiomycetous fungal spe Fujimiya et al., Journal of the Japanese Society for Food cies of the genus grifola of the family meripilaceae and the Science and Technology—Nippon Shokuhin Kagaku order polyporales and the Subclass agaricomycetidae) are Kogaku Kaishi 1998. Vol 45, Iss 4. p 246-252: Ebina et al., preferred in one embodiment of the present invention. Biotherapy 1998, Vol. 11, Iss 4. p 259-265; Fujimiya et al., Anticancer Research 1999, Vol. 19, Iss 1A, p 113-118; FIGURE LEGENDS Mizuno et al., Biochemistry and Molecular Biology Interna tional 1999, Vol. 47, Iss 4, p. 707-717: Takaku et al., Journal of 0014 FIG. 1: bacteriostatic effect of different dilutions Nutrition 2001, Vol. 131, Iss 5, p. 1409-1413: Ohno et al., (1:10, 1:20 and 1:40) of the bioactive agent obtained by the Biological and Pharmaceutical Bulletin 2001, Vol. 24, Iss 7, p method as described in example 1 on E. coli K12. A culture 820-828; Delmanto et al., Mutation Research—Genetic Toxi without the bioactive agent was used as control (Ref). The cology and Environmental Mutagenesis 2001, Vol. 496, Iss experiment is described in detail in Example 4. 1-2, p 15-21). 0015 FIG. 2: cancer-cell specific cytotoxicity of different 0005. There is however a surprising paucity of epidemio concentrations of LentineX—comprising an embodiment of logic and experimental studies that address the biologic the bioactive agent of the present invention—on 4 different activities of mushrooms after oral administration to animals human and mouse cancer cell lines. The MRC-5 cell line from US 2009/O 143280 A1 Jun. 4, 2009

normal human fetal lung fibroblasts was used as control. The ease. Also included are agents capable of reducing or elimi experiment is described in detail in Example 5. nating any side effect(s) that may be caused by some cancer treatmentS. DEFINITIONS 0028 Neoplasm: tissue composed of cells that grow in an 0016 Mycelium: Mass of hyphae constituting the body abnormal way. Neoplasms may be benign or malignant (thallus) of the fungus. (metastatic). Benign tumors remain localized as a discrete 0017 Agaricus sp.: A basidiomycetous fungal species of mass. A system has been devised to classify malignant tissue the genus agaricus of the family agaricaceae and the order according to the degree of malignancy, from grade 1, barely agaricales and the Subclass agaricomycetidae. malignant, to grade 4, highly malignant. One preferred neo 0018 Schizophyllum sp.: A basidiomycetous fungal spe plasm type treated is a cancer. An individual Suffering from a cies of the genus schizophyllum of the family Schizophyl neoplastic disease is defined as having at least one neoplasm. laceae and the order agaricales and the Subclass agarico mycetidae. Neoplastic diseases as used herein includes any abnormal and 00.19 Lentinus sp.: A basidiomycetous fungal species of uncontrolled cell growth (mitosis) that results in the produc the genus lentinus of the family polyporaceae and the order tion of a tumour (i.e. a neoplasm). polyporales and the Subclass agaricomycetidae. L. edodes is 0029 Kit of parts: a kit of parts as used in the present also termed Lentinula edodes, which is placed in the family invention provides the Basidiomycete bioactive agent and Marasmiaceae, in the order Agaricales and the Subclass agari anti-cancer medicament for administration in combination. comycetidae. By the phrase “in combination with another substance(s) 0020 Trametes sp.: A basidiomycetous fungal species of and/or therapeutic method(s) is meant herein the Basidi the genus trametes of the family polyporaceae and the order omycete bioactive agent is administered to the individual thus polyporales and the Subclass agaricomycetidae. treated before, during (including concurrently with prefer 0021 Ganoderma sp.: A basidiomycetous fungal species ably co-formulated with) and/or after treatment of an indi of the genus ganoderma of the family ganodermataceae and vidual with the anti-cancer medicament. The combined active the order polyporales and the Subclass agaricomycetidae. Substances may be used for simultaneous, sequential or sepa 0022 Grifola sp.: A basidiomycetous fungal species of the rate administration. In all cases, it is preferred that any of the genus grifola of the family meripilaceae and the order poly herein-mentioned medicaments and bioactive agents are porales and the Subclass agaricomycetidae. administered in pharmaceutically effective amounts, i.e. an 0023 Fruiting bodies or fruit bodies: Any one of a variety administration involving a total amount of each active com of complex, spore-bearing fungal structures. ponent of the medicament or pharmaceutical composition or 0024 Basidiomycete cell: A cell from a fungus of the class method that is sufficient to show a meaningful patient benefit. Basidiomycete of the Phylum Basidiomycota, wherein the The formulations may conveniently be presented in unit dos cell can be derived from any part of the fungus, such as age form by methods known to those skilled in the art. It is fruiting body, hyphae, spores and mycelium. The Basidi preferred that the kit may for example contain the active omycete cell can be a single hyphae, spores, aggregates of compounds in dosage forms for administration. A dosage mycelium, or partly differentiated mycelium, or comprised in form contains a Sufficient amount of one or more of the active fungal mycelium. compound(s) such that a desirable effect can be obtained 0.025 Bioactive agent: Any agent, drug, compound, com when administered to a subject. Thus, it is preferred that the position of matter or mixture which provides some pharma medical packaging comprises an amount of dosage units cor cologic, often beneficial, effect that can be demonstrated responding to the relevant dosage regimen. Accordingly, in in-vivo or in vitro. As used herein, this term further includes one embodiment, the medical packaging comprises a phar any physiologically or pharmacologically active Substance maceutical composition comprising the compounds as that produces a localized or systemic effect in a patient. Fur defined above or a pharmaceutically acceptable salt thereof ther examples of bioactive agents include, but are not limited and pharmaceutically acceptable carriers, vehicles and/or to, agents comprising or consisting of an oligosaccharide, excipients, said packaging having from 7 to 21 dosage units, agents comprising or consisting of a polysaccharide, agents or multiples thereof, thereby having dosage units for one comprising or consisting of an optionally glycosylated pep week of administration or several weeks of administration. tide, agents comprising or consisting of an optionally glyco The medical packaging may be in any Suitable form—for Sylated polypeptide, agents comprising or consisting of an example for oral or parenteral administration. In another pre oligonucleotide, agents comprising or consisting of a poly ferred embodiment the packaging is in the form of a cartridge, nucleotide, agents comprising or consisting of a lipid, agents Such as a cartridge for an injection pen, the injection pen being comprising or consisting of a fatty acid, agents comprising or Such as an injection pen known from insulin treatment. Pref consisting of a fatty acid ester and agents comprising or erably, the kit-of-parts contains instructions indicating the consisting of secondary metabolites. use of the dosage form to achieve a desirable affect and the 0026 Anti-cancer medicament: a medicament comprising amount of dosage form to be taken over a specified time an anti-cancer activity oranti-neoplastic activity, i.e. effective period. Accordingly, in one embodiment the medical packag in treating or preventing a cancer. Often the efficacy is tested ing comprises instructions for administering the pharmaceu in a clinical trial to test whether a new treatment has an tical composition. It is envisaged that at least one (Such as 2 or anti-cancer effect, for example, whether it shrinks a tumour or 3) anti-cancer medicament(s) and at least one (such as 2 or 3) improves blood test results, and whether it works against a Basidiomycete bioactive agents may be used for the manu certain type of cancer. facture of any of the “kit of parts' described herein for admin 0027 Bioactive agents comprising an immune stimulating istration to an individual in need thereof. Preferably, said kit activity: Agents effective in the stimulation or restoration of of parts is for treatment or prophylaxis of a neoplastic disease, the ability of the immune system to fight infection and dis Such as cancer. US 2009/O 143280 A1 Jun. 4, 2009

0030 Polysaccharides: the term “polysaccharide' as used 0.053 calusterone/Methosarb (Pharmacia & Upjohn herein covers polysaccharides as well as polysaccharides Company) containing and/or covalently linked to peptides, polypeptides 0.054 capecitabine/Xeloda (Roche) or the like. Such as proteopolysaccharides. 0.055 carboplatin/Paraplatin (Bristol-Myers Squibb) 0031 Polysaccharides comprising monosaccharides: A 0056 carmustine/BCNU, BiCNU (Bristol-Myers polysaccharide is said to comprise monosaccharides, wherein Squibb) said monosaccharides are covalently linked to form said 0057 carmustine with Polifeprosan 20 Implant/Gliadel polysaccharide. Hydrolysing a polysaccharide will yield the Wafer (Guilford Pharmaceuticals Inc.) monosaccharides that formed said polysaccharide in free 0.058 celecoxib/Celebrex (Searle) form. The monosaccharide content of a polysaccharide can 0059) chlorambucil/Leukeran (GlaxoSmithKline) thus be determined by hydrolysing the polysaccharide and 0060 cisplatin/Platinol (Bristol-Myers Squibb) measuring the presence of individual monosaccharides. The 0061 cladribine/Leustatin, 2-CdA (R. W. Johnson monosaccharide content of a mixture of polysaccharides is Pharmaceutical Research Institute) determined by determining the monosaccharide content of 0062 cyclophosphamide Cytoxan/Neosar (Bristol the entire mixture. Myers Squibb) 0032 Polypeptide: the term “polypeptide' as used herein 0.063 cytarabine/Cytosar-U (Pharmacia & Upjohn covers proteins, peptides and polypeptides, wherein said pro Company) teins, peptides or polypeptides may or may not have been (0.064 dacarbazine/DTIC-Dome (Bayer) post-translationally modified. Post-translational modifica 0065 dactinomycin/actinomycin D Cosmegen (Merck) tion may for example be phosphorylation, methylation, glu 0.066 Darbepoetin alfa/Aranesp (Amgen, Inc) cosylation, 0067 daunorubicin/daunomycin/Daunorubicin (Bed 0033 Ratio: A polysaccharide or a mixture of polysaccha ford Labs) rides are said to comprise e.g. galactose, mannose, and glu 0068 daunorubicin/daunomycin/Cerubidine (Wyeth cose in a given ratio, when hydrolysation of said polysaccha Ayerst) ride or said mixture of polysaccharide yields galactose, 0069 Denileukin/diftitox/Ontak (Seragen, Inc) mannose and glucose in said given ratio. Galactose, mannose, 0070 dexrazoxane/Zinecard (Pharmacia & Upjohn and glucose in the ratio 1:a to b:c to d, means that for every Company) part galactose, mannose is present in the range of a to b parts 0071 docetaxel/Taxotere (Aventis Pharmaceutical) and glucose is present in the range of c to d parts, whereina, 0.072 doxorubicin Adriamycin/Rubex (Pharmacia & b, c and d indicates numerical values. Thus, by way of Upjohn Company) example a polysaccharide mixture comprising galactose, 0.073 DROMOSTANOLON E PROPIONATE/MAS mannose, and glucose in the ratio 1:5 to 25:1 to 50, means that TERON E INJECTION (SYNTEX) for every part galactose, the polysaccharide mixture com 0074 Elliott's B Solution (Orphan Medical, Inc) prises in the range of 5 to 25 parts mannose and in the range 0075 epirubicin/Ellence (Pharmacia & Upjohn Com if 1 to 50 part glucose pany) 0.076 etoposide phosphate (Bristol-Myers Squibb) DETAILED DESCRIPTION OF THE INVENTION 0.077 etoposide/VP-16/Vepesid (Bristol-Myers Squibb) Anti-Cancer Medicament 0078 exemestane/Aromasin (Pharmacia & Upjohn 0034. In one aspect, the present invention relates to a kit of Company) parts comprising: 0079 Filgrastim/Neupogen (Amgen, Inc) 0035) a) an anti-cancer medicament, 0080 floxuridine/FUDR (Roche) 0036 b) a Basidiomycete bioactive agent in solid or 0081 fludarabine/Fludara (Berlex Laboratories Inc.) liquid form, and, optionally I0082 fluorouracil/5-FU/Adrucil (ICN Puerto Rico) 0037 c) instructions for a dosing regime. 0.083 fulvestrant/Faslodex (IPR) 0038 Said anti-cancer medicament may be any medica 0084 gemcitabine/Gemzar (Eli Lilly) ment with an anti-cancer effect in the individual thus treated. 0085 gemtuzumab?ozogamicin/Mylotarg (Wyeth 0039 Thus, said anti-cancer medicament may for Ayerst) example be selected from the group consisting of I0086 goserelin acetate/Zoladex Implant (AstraZeneca 0040 Aldesleukin/Proleukin (Chiron Corp) Pharmaceuticals) 0041 Alemtuzumab/Campath (Millennium and ILEX I0087 hydroxyurea/Hydrea (Bristol-Myers Squibb) Partners, LP) I0088. Ibritumomab Tiuxetan/Zevalin (IDEC Pharma 0042 alitretinoin/Panretin (Ligand Pharmaceuticals) ceuticals Corp) 0043 allopurinol/Zyloprim (GlaxoSmithKline) 0089 idarubicin/Idamycin (Adria Laboratories) 0044) altretamine/Hexylen (US Bioscience) 0090 ifosfamide/IFEX (Bristol-Myers Squibb) 0045 amifostine/Ethyol (US Bioscience) (0.091 imatinib mesylate/Gleevec (Novartis) 0046) anastrozole/Arimidex (AstraZeneca) 0092 Interferon alfa-2a/Roferon-A (Hoffmann-La 0047 arsenic trioxide/Trisenox (Cell Therapeutic) Roche Inc) 0048 Asparaginase/Elspar (Merck & Co., Inc) (0.093 Interferon alfa-2b/Intron A (Schering Corp) 0049 BCG Live/TICE BCG (Organon Teknika Corp) 0094) irinotecan/Camptosar (Pharmacia & Upjohn 0050 bexarotene capsules/Targretin (Ligand Pharma Company) ceuticals) (0.095 letrozole/Femara (Novartis) 0051 bleomycin/Blenoxane (Bristol-Myers Squibb) 0.096 leucovorin Welicovorin/Leucovorin (Immunex 0052 busulfan/Busulfex (GlaxoSmithKline) Corporation) US 2009/O 143280 A1 Jun. 4, 2009

0097 levamisole/Ergamisol (Janssen Research Foun (0145 vinblastine/Velban (Eli Lilly) dation) 0146) Vincristine/Oncovin (Eli Lilly) 0.098 lomustine/CCNU/CeeBU (Bristol-Myers 0147 vinorelbine/Navelbine (GlaxoSmithKline), and Squibb) 0.148. Zoledronate/Zometa (Novartis) 0099 meclorethamine/nitrogen mustard/Mustargen 0149. In a preferred embodiment of the present invention, (Merck) 0100 megestrol acetate/Megace (Bristol-Myers said anti-cancer drug is Aldesleukin/Proleukin (Chiron Corp) Squibb) 0150. In another preferred embodiment of the present 0101 melphalan/L-PAM/Alkeran (GlaxoSmithKline) invention, said anti-cancer drug is Alemtuzumab/Campath 0102 mercaptopurine/6-MP Purinethol (GlaxoSmith (Millennium and ILEX Partners, LP), such as for the treat Kline) ment or prophylaxis of B-cell chronic lymphocytic leukaemia 0103 mesna/Mesnex (Asta Medica) (B-CLL). 0104 methotrexate (Lederle Laboratories) 0151. In another preferred embodiment of the present 0105 methoxsalen/Uvadex (Therakos) invention, said anti-cancer drug is alitretinoin/Panretin 010.6 mitomycin C/Mutamycin (Bristol-Myers (Ligand Pharmaceuticals). Such as for the treatment or pro Squibb) phylaxis of cutaneous lesions in sarcoma patients, such as in 0107 mitomycin C/MitoZytrex (Supergen) patients suffering from AIDS-related Kaposi's sarcoma. 0.108 mitotane/Lysodren (Bristol-Myers Squibb) 0152. In another preferred embodiment of the present 0109 mitoxantrone/Novantrone (Lederle Laborato invention, said anti-cancer drug is allopurinol/Zyloprim ries) (GlaxoSmithKline), such as for the treatment of patients with 0110 nandrolone phenpropionate/Durabolin-50 (Orga leukaemia and/or lymphoma and/or one or more solid tumor non) malignancies who are receiving cancer therapy which causes 0111 Nofetumomab/Verluma (Boehringer Ingelheim elevations of serum and urinary uric acid levels. Pharma KG (formerly Dr. Karl 0153. In another preferred embodiment of the present (O112 Thomae GmbH)) invention, said anti-cancer drug is altretamine/Hexylen (US 0113 Oprelvekin/Neumega (Genetics Institute) Bioscience). Such as for treatment or prophylaxis of ovarian 0114 oxaliplatin/Eloxatin (Sanofi Synthelabo) CaCC. 0115 paclitaxel/Taxol (Bristol-Myers Squibb) 0154) In another preferred embodiment of the present 0116 pamidronate/Aredia (Novartis) invention, said anti-cancer drug is amifostine/Ethyol (US 0117 pegademase/Adagen (Pegademase Bovine) (En Bioscience). Such as for treatment or prophylaxis of post Zon) radiation Xerostomia for e.g. head and neck cancer and/or 0118 Pegaspargase/Oncaspar (Enzon, Inc) ovarian cancer (preferably advanced) and/or non-small cell 0119 Pegfilgrastim/Neulasta (Amgen, Inc) lung cancer. I0120 pentostatin/Nipent (Parke-Davis Pharmaceutical 0.155. In another preferred embodiment of the present Co.) invention, said anti-cancer drug is anastroZole/Arimidex (AS I0121 pipobroman/Vercyte (Abbott Labs) traZeneca). Such as for the treatment of breast cancer, for 0.122 plicamycin/mithramycin/Mithracin (Pfizer Labs) example hormone receptor positive early breast cancer, I0123 porfimer sodium/Photofrin (QLT Phototherapeu advanced breast cancer, locally advanced or metastatic breast tics Inc.) CaCC. 0.124 procarbazine/Matulane (Sigma Tau Pharms) 0156. In another preferred embodiment of the present 0.125 quinacrine/Atabrine (Abbott Labs) invention, said anti-cancer drug is trioxide/TrisenoX (Cell 0.126 Rasburicase/Elitek (Sanofi-Synthelabo, Inc) Therapeutic). I0127 Rituximab/Rituxan (Genentech, Inc) 0157. In another preferred embodiment of the present I0128 Sargramostim/Prokine (Immunex Corp) invention, said anti-cancer drug is Asparaginase/Elspar I0129 streptozocin/Zanosar (Pharmacia & Upjohn (Merck & Co., Inc), such as for the treatment of pediatric Company) patients. I0130 talc/Sclerosol (Bryan) 0158. In another preferred embodiment of the present I0131 tamoxifen/Nolvadex (AstraZeneca Pharmaceuti invention, said anti-cancer drug is Live/TICE BCG (Organon cals) Teknika Corp). I0132 temozolomide/Temodar (Schering) 0159. In another preferred embodiment of the present I0133) teniposide/VM-26/Vumon (Bristol-Myers invention, said anti-cancer drug is beXaroteine capsules/Tar Squibb) gretin (Ligand Pharmaceuticals), Such as for treatment of 0.134 testolactone/Teslac (Bristol-Myers Squibb) cutaneous manifestations of cutaneous T-cell lymphoma, 0.135 thioguanine/6-TG/Thioguanine (GlaxoSmith preferably via oral administration. Kline) 0160. In another preferred embodiment of the present 0.136 thiotepa/Thioplex (Lederle Laboratories) invention, said anti-cancer drug is bleomycin/Blenoxane 0.137 topotecan/Hycamtin (GlaxoSmithKline) (Bristol-Myers Squibb), such as for treatment of malignant 0.138 topotecan/Hycamtin (GlaxoSmithKline) pleural effusion (MPE) and prevention of recurrent pleural I0139 toremifene/Fareston (Orion Corp) effusions. 0140 Tositumomab/Bexxar (Corixa Corporation) 0.161. In another preferred embodiment of the present 0141 Trastuzumab/Herceptin (Genentech, Inc) invention, said anti-cancer drug is buSulfan/BuSulfex (Glaxo 0.142 tretinoin/ATRA/Vesanoid (Roche) SmithKline). Such as prior to hematopoietic progenitor cell 0143 Uracil Mustard (Roberts Labs) transplantation for chronic myelogenous leukemia, prefer 0144 valrubicin/Valstar (Medeva) ably via oral administration. US 2009/O 143280 A1 Jun. 4, 2009

0162. In another preferred embodiment of the present (Seragen, Inc), Such as for treatment of T-cell lymphoma, invention, said anti-cancer drug is calusterone/Methosarb preferably of individuals whose malignant cells express the (Pharmacia & Upjohn Company). CDC25 component of the IL-2 receptor. 0163. In another preferred embodiment of the present 0179. In another preferred embodiment of the present invention, said anti-cancer drug is capecitabine/Xeloda invention, said anti-cancer drug is dexraZoxane/Zinecard (Roche), such as for treatment of breast cancer, preferably (Pharmacia & Upjohn Company). Such as to aid in reducing metastatic breast cancer, or colorectal carcinoma, preferably the severity of cardiomyopathy associated with doxorubicin metastatic colorectal carcinoma. administration in women with metastatic breast cancer. 0164. In another preferred embodiment of the present 0180. In another preferred embodiment of the present invention, said anti-cancer drug is Carboplatin/Paraplatin invention, said anti-cancer drug is docetaxel/Taxotere (Aven (Bristol-Myers Squibb), such as for treatment of ovarian car tis Pharmaceutical). Such as for treatment of breast cancer, cinoma. preferably locally advanced or metastatic breast cancer, or 0.165. In another preferred embodiment of the present non-Small cell lung cancer, preferably locally advanced or invention, said anti-cancer drug is carmustine/BCNU, metastatic non-Small cell lung cancer. BiCNU (Bristol-Myers Squibb) 0181. In another preferred embodiment of the present 0166 In another preferred embodiment of the present invention, said anti-cancer drug is doxorubicin/Adriamycin invention, said anti-cancer drug is carmustine with Polifep Rubex (Pharmacia & Upjohn Company), such as for treat rosan 20 Implant/Gliadel Wafer (Guilford Pharmaceuticals ment of AIDS-related Kaposi's sarcoma or metastatic carci Inc.). Such as to prolong Survival in patients with recurrent noma of the ovary. glioblastoma multiforme who qualify for Surgery. 0182. In another preferred embodiment of the present 0167. In another preferred embodiment of the present invention, said anti-cancer drug is Dromostanolone propi invention, said anti-cancer drug is celecoxib/Celebrex onate/Masterone injection (SYNTEX). (Searle). Such as for treatment of familial adenomatous poly 0183 In another preferred embodiment of the present posis. invention, said anti-cancer drug is Elliott's B Solution (Or 0.168. In another preferred embodiment of the present phan Medical, Inc), Such as for treatment or prophylaxis of invention, said anti-cancer drug is chlorambucil/Leukeran miningeal leukaemia or lymphocytic lymphoma. (GlaxoSmithKline), such as for treatment of chronic lympho 0184. In another preferred embodiment of the present cytic leukaemia. invention, said anti-cancer drug is Epirubicin/Ellence (Phar (0169. In another preferred embodiment of the present macia & Upjohn Company), such as for treatment or prophy invention, said anti-cancer drug is cisplatin/Platinol (Bristol laxis of breast cancer. Myers Squibb), such as for treatment of ovarian tumour pref 0185. In another preferred embodiment of the present erably metastatic ovarian tumour, testicular tumour, prefer invention, said anti-cancer drug is etoposide phosphate (Bris ably testicular tumour, transitional cell bladder cancer. tol-Myers Squibb), such as for treatment or prophylaxis of 0170 In another preferred embodiment of the present refractory testicular tumours, Small cell lung cancer. invention, said anti-cancer drug is cladribine/Leustatin, 0186. In another preferred embodiment of the present 2-CdA (R. W. Johnson Pharmaceutical Research Institute), invention, said anti-cancer drug is etoposide/VP-16/Vepesid Such as for treatment of active hairy cell leukaemia. (Bristol-Myers Squibb), such as for treatment or prophylaxis 0171 In another preferred embodiment of the present of refractory testicular tumours, Small cell lung cancer. invention, said anti-cancer drug is cyclophosphamide 0187. In another preferred embodiment of the present Cytoxan/Neosar (Bristol-Myers Squibb) invention, said anti-cancer drug is exemestane/Aromasin 0172. In another preferred embodiment of the present (Pharmacia & Upjohn Company). Such as for treatment or invention, said anti-cancer drug is cytarabine/Cytosar-U prophylaxis of breast cancer, preferably for treatment of (Pharmacia & Upjohn Company) advanced breast cancer. 0173. In another preferred embodiment of the present 0188 In another preferred embodiment of the present invention, said anti-cancer drug is dacarbazine/DTIC-Dome invention, said anti-cancer drug is Filgrastim/Neupogen (Bayer). (Amgen, Inc), such as for treatment of nonmyeloid malignan 0.174. In another preferred embodiment of the present cies undergoing myeloablative chemotherapy followed by invention, said anti-cancer drug is dactinomycin/actinomycin marrow transplantation. D Cosmegen (Merck) 0189 In another preferred embodiment of the present 0.175. In another preferred embodiment of the present invention, said anti-cancer drug is floxuridine/FUDR (Roche) invention, said anti-cancer drug is Darbepoetin alfa Aranesp 0190. In another preferred embodiment of the present (Amgen, Inc), such as for treatmentofanemia associated with invention, said anti-cancer drug is fludarabine/Fludara (Ber chemotherapeutic regimes. lex Laboratories Inc.). Such as for treatment or prophylaxis of 0176). In another preferred embodiment of the present B-cell lymphocytic leukaemia. invention, said anti-cancer drug is daunorubicin/daunomy 0191 In another preferred embodiment of the present cin/Daunorubicin (Bedford Labs), such as in liposomal form, invention, said anti-cancer drug is fluorouracil/5-FU/Adrucil for example for the treatment of HIV-related Kaposi's sar (ICN Puerto Rico), such as to prolong survival. COa. 0.192 In another preferred embodiment of the present 0177. In another preferred embodiment of the present invention, said anti-cancer drug is fulvestrant/Faslodex invention, said anti-cancer drug is daunorubicin/daunomy (IPR), such as for treatment or prophylaxis of breast cancer, cin/Cerubidine (Wyeth Ayerst), such as for treatment of leu preferably in post-menopausal women. kaemia. 0193 In another preferred embodiment of the present 0178. In another preferred embodiment of the present invention, said anti-cancer drug is gemcitabine/Gemzar (Eli invention, said anti-cancer drug is Denileukin/diftitox/Ontak Lilly). Such as for treatment or prophylaxis of adenocarci US 2009/O 143280 A1 Jun. 4, 2009 noma of the pancreas or non-Small cell lung cancer, prefer 0208. In another preferred embodiment of the present ably locally advanced or metastatic adenocarcinoma of the invention, said anti-cancer drug is meclorethamine/nitrogen pancreas or non-Small cell lung cancer. mustard/Mustargen (Merck) 0194 In another preferred embodiment of the present 0209. In another preferred embodiment of the present invention, said anti-cancer drug is gemtuzumab?oZogamicin/ invention, said anti-cancer drug is megestrol acetate/Megace Mylotarg (Wyeth Ayerst), such as for treatment or prophy (Bristol-Myers Squibb) laxis of CD33 positive acute myeloid leukaemia in patients 0210. In another preferred embodiment of the present who are preferably 60 years of age or older. invention, said anti-cancer drug is melphalan/L-PAM/Alke 0.195. In another preferred embodiment of the present ran (GlaxoSmithKline), such as for treatment or prophylaxis invention, said anti-cancer drug is goserelin acetate/Zoladex of multiple myeloma. Implant (AstraZeneca Pharmaceuticals). Such as for treat 0211. In another preferred embodiment of the present ment or prophylaxis of breast cancer, preferably advanced invention, said anti-cancer drug is mercaptopurine/6-MP stage breast cancer. Purinethol (GlaxoSmithKline) 0196. In another preferred embodiment of the present 0212. In another preferred embodiment of the present invention, said anti-cancer drug is hydroxyurea/Hydrea invention, said anti-cancer drug is mesna/Mesnex (Asta (Bristol-Myers Squibb). Medica) such as for treatment or prophylaxis of ifosfamide 0197) In another preferred embodiment of the present induced hemorrhagic cystitis. invention, said anti-cancer drug is Ibritumomab Tiuxetan/ 0213. In another preferred embodiment of the present Zevalin (IDEC Pharmaceuticals Corp), such as for treatment invention, said anti-cancer drug is methotrexate (Lederle or prophylaxis of non-Hodgkin's lymphoma, for example Laboratories). Such as for treatment or prophylaxis of patients with Rituximab refractory follicular non-Hodgkin’s OSteOSarCOma. lymphoma. 0214. In another preferred embodiment of the present 0198 In another preferred embodiment of the present invention, said anti-cancer drug is methoXSalen/Uvadex invention, said anti-cancer drug is idarubicin/Idamycin (Therakos). Such as for treatment or prophylaxis of skin mani (Adria Laboratories), such as for treatment or prophylaxis of festations of cutaneous T-cell lymphoma (CTCL). acute myeloid leukaemia, for example in adults. 0215. In another preferred embodiment of the present 0199. In another preferred embodiment of the present invention, said anti-cancer drug is mitomycin C/Mutamycin invention, said anti-cancer drug is ifosfamide/IFEX (Bristol (Bristol-Myers Squibb). Myers Squibb), such as for treatment of germ cell testicular 0216) In another preferred embodiment of the present CaCC. invention, said anti-cancer drug is mitomycin C/MitoZytrex 0200. In another preferred embodiment of the present (Supergen). Such as for treatment or prophylaxis of dissemi invention, said anti-cancer drug is imatinib mesylate/Gleevec nated adenocarcinoma of the stomach or pancreas. (Novartis). Such as for treatment of chronic myelogeneous 0217. In another preferred embodiment of the present leukaemia or gastrointestinal stromal tumours. invention, said anti-cancer drug is mitotane/LySodren (Bris 0201 In another preferred embodiment of the present tol-Myers Squibb) invention, said anti-cancer drug is Interferon alfa-2a/Rof 0218. In another preferred embodiment of the present eron-A (Hoffmann-La Roche Inc), such as for treatment or invention, said anti-cancer drug is mitoxantrone/Novantrone prophylaxis of malignant melanoma, Non-Hodgkin's Lym (Lederle Laboratories). Such as for treatment or prophylaxis phoma, condylomata acuminate, hairy cell leukaemia or of prostrate cancer or acute nonlymphocytic leukaemia AIDS-related Kaposi's sarcoma. (ANLL) in adults. 0202 In another preferred embodiment of the present 0219. In another preferred embodiment of the present invention, said anti-cancer drug is Interferon alfa-2b/Intron A invention, said anti-cancer drug is nandrolone phenpropi (Schering Corp). onate/Durabolin-50 (Organon). 0203. In another preferred embodiment of the present 0220. In another preferred embodiment of the present invention, said anti-cancer drug is irinotecan/Camptosar invention, said anti-cancer drug is Nofetumomab/Verluma (Pharmacia & Upjohn Company). Such as for treatment or (Boehringer Ingelheim Pharma KG (formerly Dr. Karl Tomae prophylaxis of carcinoma of the colon or rectum, preferably GmbH). metastatic carcinoma of the colon or rectum. 0221. In another preferred embodiment of the present 0204. In another preferred embodiment of the present invention, said anti-cancer drug is doxorubicin/Adriamycin invention, said anti-cancer drug is letrozole/Femara (Novar PFS. tis), carcinoma of the colon or rectum, Such as for treatment or 0222. In another preferred embodiment of the present prophylaxis of breast cancer, preferably in post-menopausal invention, said anti-cancer drug is Oprelvekin/Neumega (Ge WOC. netics Institute), preferably administered after myelosuppres 0205. In another preferred embodiment of the present sive chemotherapy in patients with nonmyeloid malignancies invention, said anti-cancer drug is Leucovorin/Wellcovorin 0223) In another preferred embodiment of the present (Immunex Corporation). Such as for treatment or prophylaxis invention, said anti-cancer drug is oxaliplatin/Eloxatin of colorectal cancer, preferably advanced colorectal cancer. (Sanofi Synthelabo), such as for treatment or prophylaxis of 0206. In another preferred embodiment of the present carcinoma of the colon, preferably metastatic carcinoma of invention, said anti-cancer drug is levamisole/Ergamisol the colon. (Janssen Research Foundation). Such as for treatment or pro 0224. In another preferred embodiment of the present phylaxis of colon cancer, preferably after Surgical resection. invention, said anti-cancer drug is paclitaxel/Taxol/Paxene 0207. In another preferred embodiment of the present (Bristol-Myers Squibb), such as for treatment or prophylaxis invention, said anti-cancer drug is lomustine/CCNU/CeeBU of advanced AIDS-related Kaposi's sarcoma, breast cancer, (Bristol-Myers Squibb). metastatic breast cancer, carcinoma of the ovary, AIDS-re US 2009/O 143280 A1 Jun. 4, 2009

lated Kaposi's sarcoma, metastatic carcinoma of the ovary, 0241. In another preferred embodiment of the present non-Small cell lung cancer or node-positive breast cancer. invention, said anti-cancer drug is temozolomide/Temodar 0225. In another preferred embodiment of the present (Schering). Such as for the treatment or prophylaxis of refrac invention, said anti-cancer drug is pamidronate/Aredia (No tory anaplastic astrocytima. vartis). Such as for treatment or prophylaxis of osteolytic bone 0242. In another preferred embodiment of the present metastases of breast cancer. invention, said anti-cancer drug is teniposide/VM-26/Vumon 0226. In another preferred embodiment of the present (Bristol-Myers Squibb), such as for the treatment or prophy invention, said anti-cancer drug is pegademase/Adagen (Pe laxis of refractory childhood acute lymphoblastic leukaemia. gademase Bovine) (Enzon). 0243 In another preferred embodiment of the present 0227. In another preferred embodiment of the present invention, said anti-cancer drug is testolactone/Teslac (Bris invention, said anti-cancer drug is Pegaspargase/Oncaspar tol-Myers Squibb) (Enzon, Inc). 0244. In another preferred embodiment of the present 0228. In another preferred embodiment of the present invention, said anti-cancer drug is thioguanine? 6-TG/ invention, said anti-cancer drug is Pegfilgrastim/Neulasta Thioguanine (GlaxoSmithKline) (Amgen, Inc), Such as for treatment or prophylaxis of non 0245. In another preferred embodiment of the present myeloid malignancies. invention, said anti-cancer drug is thiotepa/Thioplex (Lederle 0229. In another preferred embodiment of the present Laboratories) invention, said anti-cancer drug is pentostatin/Nipent (Parke 0246. In another preferred embodiment of the present Davis Pharmaceutical Co.), such as for treatment or prophy invention, said anti-cancer drug is topotecan/Hycamtin laxis of hairy cell leukaemia, for example alpha interferon (GlaxoSmithKline), such as for the treatment or prophylaxis refractory hairy cell leukaemia. of metastatic carcinoma of the ovary, or Small cell lung can 0230. In another preferred embodiment of the present C. invention, said anti-cancer drug is pipobroman/Vercyte (Ab 0247. In another preferred embodiment of the present bott Labs) invention, said anti-cancer drug is toremifene? Fareston 0231. In another preferred embodiment of the present (Orion Corp), such as for the treatment or prophylaxis of invention, said anti-cancer drug is plicamycin/mithramycin/ advanced breast cancer in postmenopausal women. Mithracin (Pfizer Labs) 0248. In another preferred embodiment of the present 0232. In another preferred embodiment of the present invention, said anti-cancer drug is Tositumomab/BeXXar invention, said anti-cancer drug is porfimer Sodium/Photofrin (Corixa Corporation), such as for the treatment or prophy (QLT Phototherapeutics Inc.), such as for the treatment or laxis of non-Hodgkin's lymphoma. prophylaxis of partially obstructing or completely obstruct 0249. In another preferred embodiment of the present ing esophogeal cancer. invention, said anti-cancer drug is Trastuzumab/Herceptin (Genentech, Inc), Such as for the treatment or prophylaxis of 0233. In another preferred embodiment of the present metastatic breast cancer. invention, said anti-cancer drug is procarbazine/Matulane 0250 In another preferred embodiment of the present (Sigma Tau Pharms) invention, said anti-cancer drug is tretinoin/ATRA/Vesanoid 0234. In another preferred embodiment of the present (Roche). Such as for the treatment or prophylaxis of acute invention, said anti-cancer drug is quinacrine/Atabrine (Ab promyeocytic leukaemia. bott Labs) 0251. In another preferred embodiment of the present 0235. In another preferred embodiment of the present invention, said anti-cancer drug is Uracil Mustard (Roberts invention, said anti-cancer drug is Rasburicase/Elitek Labs) (Sanofi-Synthelabo, Inc), such as for the treatment or prophy 0252. In another preferred embodiment of the present laxis of patients suffering from leukaemia, lymphoma or Solid invention, said anti-cancer drug is valrubicin/Valstar tumor malignancies. (Medeva), such as for the treatment or prophylaxis of BCG 0236. In another preferred embodiment of the present refractory carcinoma in situ (CIS) of the urinary bladder. invention, said anti-cancer drug is Rituximab/Rituxan (Ge 0253) In another preferred embodiment of the present nentech, Inc) invention, said anti-cancer drug is vinblastine/Velban (Eli 0237. In another preferred embodiment of the present Lilly) invention, said anti-cancer drug is Sargramostim/Prokine 0254. In another preferred embodiment of the present (Immunex Corp) invention, said anti-cancer drug is Vincristine/Oncovin (Eli 0238. In another preferred embodiment of the present Lilly) invention, said anti-cancer drug is streptozocin/Zanosar 0255. In another preferred embodiment of the present (Pharmacia & Upjohn Company) invention, said anti-cancer drug is vinorelbine/Navelbine 0239. In another preferred embodiment of the present (GlaxoSmithKline), such as for the treatment or prophylaxis invention, said anti-cancer drug is talc/Scierosol (Bryan), of non-Small cell lung cancer, such as unresectable, advanced Such as for the treatment or prophylaxis of malignant pleural non-Small cell lung cancer. effusion in Symptomatic patients. 0256 In another preferred embodiment of the present 0240. In another preferred embodiment of the present invention, said anti-cancer drug is Zoledronate/Zometa (No invention, said anti-cancer drug is tamoxifen/Nolvadex (AS vartis). Such as for the treatment or prophylaxis of multiple traZeneca Pharmaceuticals), Such as for the treatment or pro myeloma or patients with documented bone metastases from phylaxis of breast cancer, for example following mastectomy Solid tumours. and axillary dissection in postmenopausal women, or for 0257. In one preferred embodiment of the present inven metastatic breast cancer, for example in men. tion, the anti-cancer drug is not carboplatin. US 2009/O 143280 A1 Jun. 4, 2009

0258. In one aspect of the present invention, the Basidi 0270. In one embodiment of the present invention, said omycete bioactive agent is administered in combination with neoplastic disease is benign. In another embodiment of the a chemotherapeutic agent, such as any of the following: an present invention, said neoplastic disease is metastatic, Such alkylating agent, a Nitrosourea, an antimetabolite, Anthracy as stage 3-4 metastatic disease. cline or a related drug, a topoisomerase II inhibitor, a mitotic 0271 In one preferred embodiment of the present inven inhibitor, a corticosteroid hormone. tion, the neoplastic disease is selected from the group con 0259 Thus, in one preferred embodiment, the Basidi sisting of Acute Lymphoblastic Leukemia, Acute Myeloid omycete bioactive agent is administered in combination with Leukemia, Adrenocortical Carcinoma, AIDS-Related Can an alkylating agent, Such as one or more of the following: cers, AIDS-Related Lymphoma, Anal Cancer, Astrocytoma buSulfan, cisplatin, carboplatin, chlorambucil, cyclophospha (e.g. Childhood Cerebellar or Childhood Cerebral), Basal mide, ifosfamide, dacarbazine (DTIC), mechlorethamine (ni Cell Carcinoma, Extrahepatic Bile Duct Cancer, Bladder trogen mustard), melphalan, and temozolomide. Cancer, Bone Cancer, Osteosarcoma/Malignant Fibrous His 0260. In another preferred embodiment, the Basidiomac tiocytoma, Brain Stem Glioma, Brain Tumor, Breast Cancer, ete bioactive agent is administered in combination with a Male Breast Cancer, Bronchial Adenomas/Carcinoids, Bur Nitrosourea, such as one or more of the following: carmustine kitt's Lymphoma, Carcinoid Tumor, Carcinoma of Unknown (BCNU) and lomustine (CCNU). Primary, Primary Central Nervous System Lymphoma, Cere 0261. In another preferred embodiment, the Basidi bral Astrocytoma/Malignant Glioma, Cervical Cancer, omycete bioactive agent is administered in combination with Childhood Cancers, Chronic Lymphocytic Leukemia, an antimetabolite, such as one or more of the following: Chronic Myelogenous Leukemia, Chronic Myeloprolifera 5-fluorouracil, capecitabine, 6-mercaptopurine, methotrex tive Disorders, Colon Cancer, Cutaneous T-Cell Lymphoma, ate, gemcitabine, cytarabine (ara-C), fludarabine, and pem Endometrial Cancer, Ependymoma (such as Childhood etrexed. Ependymoma), Esophageal Cancer, Ewing's Family of 0262. In another preferred embodiment, the Basidi Tumors, Extracranial Germ Cell Tumor (such as Childhood omycete bioactive agent is administered in combination with Extracranial Germ Cell Tumor), Extragonadal Germ Cell an Anthracycline or a related drug, such as one or more of the Tumor, Eye Cancer (Intraocular Melanoma or Retinoblas following: daunorubicin, doxorubicin (Adriamycin), epirubi toma), Gallbladder Cancer, Gastric (Stomach) Cancer, Gas cin, idarubicin, and mitoxantrone. trointestinal Carcinoid Tumor, Gestational Trophoblastic 0263. In another preferred embodiment, the Basidi Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Can omycete bioactive agent is administered in combination with cer, Hepatocellular (Liver) Cancer, Hodgkin’s Lymphoma, a topoisomerase II inhibitor. Such as one or more of the Hypopharyngeal Cancer, Hypothalamic and Visual Pathway following: topotecan, irinotecan, etoposide (VP-16), and Glioma (such as Childhood Hypothalamic and Visual Path teniposide. way Glioma), Intraocular Melanoma, Islet Cell Carcinoma 0264. In another preferred embodiment, the Basidi (Endocrine Pancreas), Kaposi's Sarcoma, Kidney (Renal omycete bioactive agent is administered in combination with Cell) Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, a mitotic inhibitor, Such as one or more of the following: a Lung Cancer (Non-Small Cell or Small Cell), Lymphoma taxane (for example paclitaxel, docetaxel), a Vinca alkaloid (such as AIDS-Related Lymphoma, Burkitt's Lymphoma, (vinblastine, Vincristine, and vinorelbine). Cutaneous T-Cell Lymphoma, Non-Hodgkin's Lymphoma), 0265. In another preferred embodiment, the Basidi Macroglobulinemia (such as Waldenström's Macroglobu omycete bioactive agent is administered in combination with linemia), Malignant Fibrous Histiocytoma of Bone/Osteosa a corticosteroid hormone, such as one or more of the follow rcoma, Medulloblastoma (such as Childhood Medulloblas ing: prednisone or dexamethasone. toma), Melanoma, Merkel Cell Carcinoma, Mesothelioma 0266. In another preferred embodiment, the Basidi (such as Adult Malignant Mesothelioma or childhood omycete bioactive agent is administered in combination with Mesothelioma), Metastatic Squamous Neck Cancer with a targeted therapy, such as one or more of the following: Occult Primary, Multiple Endocrine Neoplasia Syndrome imatinib (Gleevec), gefitinib (Iressa), erlotinib (Tarceva), rit (such as occurring in childhood), Multiple Myeloma/Plasma uximab (Rituxan), and bevacizumab (Avastin). Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syn 0267 In another preferred embodiment, the Basidi dromes, Myelodysplastic/Myeloproliferative Diseases, omycete bioactive agent is administered in combination with Myeloma (such as Multiple Myeloma), Chronic myelopro a sexhormone, Such as one or more of the following: anti liferative disorders, Nasal Cavity and Paranasal Sinus Cancer, estrogens (such as tamoxifen, fulvestrant), aromatase inhibi Nasopharyngeal Cancer, Nasopharyngeal Cancer (such as tors (such as anastroZole, exemestane, letrozole), progestins Childhood Nasopharyngeal Cancer), Neuroblastoma, (such as megestrol acetate), anti-androgens (such as bicaluta Oropharyngeal Cancer, Osteosarcoma/Malignant Fibrous mide, flutamide), and LHRH agonists (such as leuprolide, Histiocytoma of Bone, Ovarian Cancer (such as Childhood goserelin). Ovarian Cancer), Ovarian Epithelial Cancer, Ovarian Germ 0268. In another preferred embodiment, the Basidi Cell Tumor, Ovarian Low Malignant Potential Tumor, Pan omycete bioactive agent is administered in combination with creatic Cancer, Pancreatic Cancer, Paranasal Sinus and Nasal one or more of the following: L-asparaginase, dactinomycin, Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pheochro mocytoma, Pineoblastoma and Supratentorial Primitive Neu thalidomide, and tretinoin. roectodermal Tumors, Pituitary Tumor, Pleuropulmonary Disease Treated Blastoma, Prostate Cancer, Renal Pelvis and Ureter Transi tional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma 0269. The methods, uses, and kit-of-parts described herein (such as Childhood Rhabdomyosarcoma), Salivary Gland may be used to treat any individual Suffering from, or at risk Cancer, Adult-onset soft tissue Sarcoma, Soft Tissue Sar of Suffering from, a neoplastic disease. coma (such as Childhood Soft Tissue Sarcoma), uterine Sar US 2009/O 143280 A1 Jun. 4, 2009

coma, Sezary Syndrome, Skin Cancer (Such as non-Mela 0287. In one embodiment, the present invention provides noma skin cancer), Merkel Cell Skin Carcinoma, Small methods for preventing or inhibiting or reducing the growth Intestine Cancer, Supratentorial Primitive Neuroectodermal of Helicobacter by administering the bioactive agent accord Tumors (such as occurring in Childhood), Cutaneous T-Cell ing to the present invention. The bioactive agent can be Lymphoma, Testicular Cancer, Thymoma and Thymic Car administered to an individual in need thereof alone or in cinoma, Thyroid Cancer, Transitional Cell Cancer of the combination with other therapeutic agents like antibiotics and Renal Pelvis and Ureter, Trophoblastic Tumor (such as Ges inhibitors of acid secretion. By the phrase “in combination' tational Trophoblastic Tumor), Urethral Cancer, Endometrial with therapeutic agents is meant herein that one or more uterine cancer, Uterine Sarcoma, Vaginal Cancer, Visual bioactive agent(s) according to the present invention is Pathway and Hypothalamic Glioma (such as Childhood administered to the individual thus treated before and/or dur Visual Pathway and Hypothalamic Glioma), Waldenström’s ing (including concurrently with) and/or after treatment of an Macroglobulinemia or Wilms Tumor. individual with one or more therapeutic agents. In all cases of 0272. One aspect of the present invention relates to the combination treatment described herein, the bioactive agent palliative treatment of terminal cancer States in an individual can be administered in the form of food. In all cases of in need thereof, such as wherein said individual is suffering combination treatment described herein, the combination from advanced-stage cancer, preferably terminal cancer. may be in the form of kit-in-part systems, wherein the com 0273. In accordance with the above, in one aspect of the bined active Substances may be used for simultaneous, present invention, the kit-of-parts is Suitable for treating or sequential or separate administration. In all cases, it is pre preventing any of the following aerodigestive tract cancer ferred that any of the herein-mentioned medicaments are forms: administered in pharmaceutically effective amounts, i.e. an administration involving a total amount of each active com 0274 Pancreatic cancer ponent of the medicament or pharmaceutical composition or 0275 cancer of the upper GI tract, such as stomach method that is sufficient to show a meaningful patient benefit. cancer and/or esophagus cancer. The combination of a bioactive agent according to the present 0276 head and neck cancer, in particular cancer of the invention and therapeutic agents provide improvements over thyroid or cancer of the salivary glands. therapy with the therapeutic agent alone, in particular for 0277 lung cancer, in particular Small lung cell cancer. patients that do not respond to therapy with the therapeutic 0278. In another preferred embodiment of the present agent alone or in combination with other treatment regimes. invention, the kit of parts according to the present invention is 0288 Thus, the present invention provides a method of for the treatment or prevention of lower GI cancer, such as treating an infection with Helicobacter in a Subject, particu colorectal cancers, in particular colon cancer. larly human Subjects, comprising administering a therapeu 0279. In another preferred embodiment of the present tically effective amount of a bioactive agent according to the invention, the kit-of-parts is for the treatment or prevention of present invention alone or in combination with other thera an endocrine cancer, i.e. a cancer in an endocrine organ of an peutic agents. individual's body. 0289. In one embodiment, the other therapeutic agent is an 0280. In one preferred embodiment, said cancer is liver antibiotic. In another embodiment the antibiotic is amoxicil CaCC. lin. In a further embodiment the antibiotic is clarithromycin. 0281. The invention is also useful for treating individuals In yet another embodiment the antibiotic is metronidazole. In Suffering from the following cancer forms: another embodiment the therapeutic agent is an inhibitor of 0282 cancer of the ovaries acid secretion like an H inhibitor or a proton pump inhibitor. 0283 breast cancer. In a further embodiment the H inhibitor is omeprazol. Fur 0284. In a further preferred embodiment of the present ther embodiments of the invention provide methods where invention, the treatment with Basidiomycete bioactive agent one or more antibiotic is co-administered with an inhibitor of is for the treatment or prevention of undesirable side-effects acid secretion. caused in whole or in part by an anti-cancer treatment, such as 0290. In one embodiment of the invention the subject hav chemotherapy or radiotherapy or combinations thereof. ing a Helicobacter infection is suffering from a peptic ulcer. 0285. In one embodiment it is preferred that the Basidi Peptic ulcers, as contemplated in the current invention omycete bioactive agent is administered before the anti-can include, but are not limited to, circumscribed breaks in the cer treatment (for example prophylactically). In this embodi continuity of the mucosal layer of the gastrointestinal tract. ment the treatment may be started before any anti-cancer These breaks in the continuity of the mucosal layer can treatment initiates. It may be administered continuously dur include breaks that do not extend below the epithelium, also ing the anti-cancer treatment or it may be administered at referred to as "erosions' or breaks that do extend below the intervals, for example between periods with anti-cancer epithelium. The peptic ulcers may be acute, or chronic. Fur therapy. By administering during and in particular between ther, peptic ulcers can be located in any part of the gastrointes the periods of anti-cancer therapy, the risk that the treated tinal tract that is exposed to acid-pepsin gastric juice, includ individual acquires infections and other complications may ing esophagus, stomach, duodenum and after be reduced due to the better health conditions. gastroenterostomy, the jejunum. Helicobacter pylori 0291. In another embodiment the subject having the Heli 0286 Helicobacter is a gram-negative bacterium with cobacter infection is suffering from, or at risk of developing, polar flagella, using oxygen as an electron acceptor, which cancer of the gastrointestinal tract. As stated above, the por cannot utilize carbohydrates as an energy source. Helico tions of the gastrointestinal tract where cancer may be present bacter is used herein interchangeably with “Helicobacter or may develop are any areas where the gastrointestinal tract sp.”. In a preferred embodiment the Helicobacter sp. is Heli is exposed to acid-pepsin gastric juice, including esophagus, cobacter pylori. stomach, duodenum and after gastroenterostomy, the US 2009/O 143280 A1 Jun. 4, 2009 10 jejunum. As used herein the term "cancer of the gastrointes infection' can be used to mean an amount of the administered tinal tract' is used as one of ordinary skill in the art would bioactive agent that can reduce or prevent the formation or recognize the term. Examples of "cancer of the gastrointes efficacy of the virulence of the Helicobacter. By virulence is tinal tract include, but are not limited to, neoplasias (or meant the ability of the Helicobacter to combat the host neoplasms), hyperplasias, dysplasias, metaplasias or hyper organism's or cells natural defenses to the Helicobacterinfec trophies. The neoplasms may be benign or malignant, and tion. they may originate from any cell type, including but not limited to epithelial cells of various origin, muscle cells and Antibody Therapy endothelial cells. 0292. The treatment can be used for patients with a pre 0295. In one embodiment, the present invention provides existing Helicobacter infection, or for patients pre-disposed methods for enhancing the antitumor activity of antibody to a Helicobacter infection. Additionally, the bioactive agent therapy by administering a bioactive agent according to the of the present invention can be used to alleviate symptoms of present invention in combination with the antibody therapy. a Helicobacter infection in patients, or as a preventative mea By the phrase “in combination' with antibody therapy is Sure in patients. meant herein that one or more bioactive agent(s) according to 0293 As used herein, the phrase Helicobacter infection is the present invention is administered to the individual thus used to mean an interaction between Helicobacter and the treated before and/or during (including concurrently with) host organism (subject). The infections may be localized, and/or after treatment of an individual with a therapeutic meaning that the Helicobacter grows and remains near the antibody. In all cases of combination treatment described point of initial interaction. The infection may also be gener herein, the bioactive agent can be administered in the form of alized, where the Helicobacter may become more wide spread beyond the initial point of interaction, including food. In all cases of combination treatment described herein, spreading to the Surrounding tissue or organ and even being the combination may be in the form of kit-in-part systems, distributed and growing throughout the entire host organism. wherein the combined active substances may be used for As used herein the term interaction (of a host and Helico simultaneous, sequential or separate administration. In all bacter) is used to mean a process where the Helicobacter cases, it is preferred that any of the herein-mentioned medi grows in or around a particular tissue. Helicobacter is con caments are administered in pharmaceutically effective sidered to have infected the subject if the bacteria is able to amounts, i.e. an administration involving a total amount of penetrate the surface of cells of a particular tissue and grow each active component of the medicament or pharmaceutical within the cells of the tissue. An example of this type of composition or method that is sufficient to show a meaningful infection includes, but is not limited to Helicobacterpenetrat patient benefit. The combination of a bioactive agent accord ing and growing within the epithelial cells lining the lumen of ing to the present invention and therapeutic monoclonal anti the stomach. Additionally, the Helicobacter can also be said bodies provide improvements over monoclonal antibody to have infected the host organism by growing extracellularly therapy alone, in particular for patients that do not respond to to the tissue cells. monoclonal antibody therapy alone or in combination with other treatment regimes. 0294 The method of the current invention comprises administering an antibacterially effective amount of the bio 0296. Thus, the present invention provides a method of active agent to treat a Helicobacter infection. As used herein, treating cancer in a Subject, particularly human Subjects, “an antibacterially effective amount to treat a Helicobacter comprising co-administering a therapeutically effective infection' is intended to mean an amount affective to prevent, amount of a monoclonal antibody and a therapeutically effec inhibit, retard or reverse the growth of Helicobacter, and/or tive amount of a bioactive agent according to the present reduce the number of viable Helicobacter cells within the invention. stomach or at a site of infection. “Antibacterially effective 0297. In one embodiment, the monoclonal antibody is an amount to treat a Helicobacterinfection' is also used to mean anti-CD20 monoclonal antibody. In another embodiment, the an amount effective to kill, reduce or ameliorate any existing monoclonal antibody is rituximab. In another embodiment, infections of Helicobacter. Thus, according to the present methods of the present invention treat non-Hodgkin’s lym invention, an “antibacterially effective amount to treat a Heli phoma. Further embodiments of the present invention pro cobacter infection of the bioactive agent of the present vide methods where monoclonal antibody rituximab and a invention can be used as a treatment of a pre-existing Heli bioactive agent according to the present invention are admin cobacter infection. Effective amounts for use in these treat istered once weekly for e.g. up to eight consecutive weeks. In ments can completely or partially prevent a pre-existing Heli another embodiment, the rituximab is administered once cobacter infection from spreading to Surrounding tissue and weekly and the a bioactive agent according to the present beyond, and they can also be used to slow the growth and/or invention is administered up to five times weekly for up to spread rate of the Helicobacter in the subject. Furthermore, eight consecutive weeks. Another embodiment of present the “antibacterially effective amounts to treat a Helicobacter invention provides that the bioactive agent dose is from 10 to infection of the bioactive agent of the current invention can 500 mulg/kg/dose. In certain embodiments of the present prevent a Helicobacter infection in Subjects. Another aspect invention, the patient has previously been treated with ritux of an “antibacterially effective amount to treat a Helicobacter imab and showed no appreciable tumor remission or regres infection', as used in the current invention, means that the Sion. In other embodiments, the patient has relapsed after bioactive agent administered to the Subject is capable of pre receiving rituximab therapy. venting or reducing the cellular or physiological damage to 0298. In another aspect, the present invention provides a the infected or Surrounding tissue, caused by the toxins pro method of treating cancer in a Subject comprising co-admin duced by the Helicobacter. In still another aspect, the phrase istering a therapeutically effective amount of an anti-CD20 “antibacterially effective amount to treat a Helicobacter monoclonal antibody and a therapeutically effective amount US 2009/O 143280 A1 Jun. 4, 2009

of a bioactive agent according to the present invention, tions of suppressive cells like anti-CD25 or CTLA-4. For wherein administering the bioactive agent results in an opti example, anti-CTLA4 mAbs in both mice and humans are mal immunological response. thought to either Suppress function of immune-suppressive 0299. In another aspect, the present invention provides a regulatory T cells (Tregs) or inhibit the inhibitory signal method for treating cancer in a subject comprising co-admin transmitted through binding of CTLA-4 on T cells to B7-1 or istering a monoclonal antibody that binds to a Her-2/neu B7-2 molecules on APCs or tumor cells. CTLA-4 is receptor and a bioactive agent according to the present inven expressed transiently on the surface of activated T cells and tion. In one embodiment, the Subject is a human patient. The constitutively expressed on Treg cells. Cross-linking monoclonal antibody can e.g. be trastuzumab. CTLA-4 leads to an inhibitory signal on activated T cells, and 0300. One aspect of the present invention provides a antibodies against CTLA-4 block the inhibitory signal on T method of treating cancer in a Subject comprising co-admin cells leading to sustained T cell activation (Phan et al., PNAS, istering a monoclonal antibody that binds to a cytotoxic T 100:8372-8377, 2003.) lymphocyte-associated antigen 4 (CTLA-4) and a bioactive 0304 Preferred antibodies for use in the combination agent according to the present invention. In certain embodi therapy: Although monoclonal antibodies are preferred, any ments, the Subject is a human patient. In one embodiment of of the embodiments described herein may also use polyclonal the present invention, the anti-CTLA-4 monoclonal antibody antibodies instead of, or in combination with, monoclonal is administered at a dose of 3 mg/kg every three weeks for antibodies. In one embodiment of the combination invention, four cycles and the bioactive agent is administered one to five naked antibodies (i.e. antibodies without any drug or radio times weekly for up to eight weeks. The present invention active material attached to them) are used. In another embodi also provides embodiments where the dose of he bioactive ment of the present invention, conjugated antibodies are used agent is from 10 to 500 mulg/kg/dose. (joined e.g. to one or more of a chemotherapy drug, a radio 0301 One of the mechanisms associated with the antitu active particle, or a toxin). For example, the antibody used mor activity of monoclonal antibody therapy is antibody may be a conjugated monoclonal antibody. Another preferred dependent cellular cytotoxicity (ADCC). In ADCC, mono embodiment uses one or more of a chemolabeled mono clonal antibodies bind to a target cell (e.g. cancer cell) and clonal antibody, a monoclonal antibody with radioactive par specific effector cells expressing receptors for the mono ticles attached, an immunotoxin. clonal antibody (e.g. NK cells, monocytes and granulocytes) 0305 Preferred immunotoxins include, but are not bind the monoclonal antibody/target cell complex resulting in restricted to, an antibody attached to one or more of a bac target cell death. A bioactive agent according to the present terial toxins such as diphtherial toxin (DT) or pseudomonal invention is believed to enhance effector cell function, exotoxin (PE40), a plant toxin Such as ricin A or saporin. thereby increasing monoclonal antibody therapy efficacy. Preferred is e.g. gemtuzumab ozogamicin (Mylotarg) or other Thus, the dose and schedule of bioactive agent administration antibodies attached to calicheamicin, or BL22. in combination with MAbs can be based on the ability of the bioactive agent to elevate parameters associated with differ 0306. It is preferred that the antibody is targeted to a mol entation and functional activity of cell populations mediating ecule known to be associated with cancerous processes. For ADCC, including but not limited to, NK cells, macrophages example, the antibody may bind specifically one or more of and neutrophils. These parameters can be evaluated using the following targets: vascular endothelial growth factor-A assays of NK, macrophage and neutrophil cell cytotoxicity, (VEGF-A), epidermal growth factor receptor (EGFR), CD20 ADCC (NK cell fraction or total mononuclear cells, or effec antigen, the HER2 protein, the CD52 antigen, the VEGF tor molecules essential to the ability of cells to implement protein, erbB-2, EGFR, erbB-2, cathepsin L, cyclin E. Ras, ADCC (e.g., FasL, granzymes and perforin). p53, BCR-ABL, Bcl-2, caspase-3. 0302 Combination therapy with a bioactive agent accord 0307 Table 1 is a non-exclusive list of monoclonal anti ing to the present invention and a monoclonal antibody may in bodies approved or being tested for which combination one embodiment be indicated when a first line treatment has therapy with a bioactive agent according to the present inven failed and may be considered as a second line treatment. tion is possible. Other preferred antibodies may be selected However, based on the enhanced antitumor activity of the from, but are not restricted to, the group consisting of: bioactive agent in combination with a monoclonal antibody, Alemtuzumab (Campath), bevacizumab (Avastin, Genentech the present invention also provides using the combination as Inc.). OncoScint (Such as for colorectal and ovarian cancer), a first line treatment in patient populations that are newly ProstaScint (Such as for prostate cancer), Tositumomab diagnosed and have not been previously treated with antican (Bexxar), cer agents “de novo patients' and patients that have not pre Cetuximab (Erbitux, ImClone Systems Inc.), Gemtuzumab viously received any monoclonal antibody therapy "naive oZogamicin (Mylotarg), Rituximab (Rituxan, Rochef Genen patients.” tech), anti-erbB-2 schv, Ibritumomab tiuxetan (Zevalin), 0303 A bioactive agent according to the present invention Panitumumab (formerly known as “ABX-EGF, Abgenix, is also useful in combination therapy with monoclonal anti Fremont Calif.), Ibritumomab tiuxetan (Zevalin), EMD bodies in the absence of any directantibody mediated ADCC 72000 (Vanhoefer et al., J. Clin Oncol 2004; 22:175-184), of tumor cells. Antibodies that block an inhibitory signal in Ibritumomab Tioxetan, and Trastuzumab (Herceptin). the immune system can lead to augmented immune 0308 Further suitable antibodies and protocols for use of responses. Examples include (1) antibodies against mol any of the antibodies described herein can be found in e.g. US ecules of the B7R family that have inhibitory function such 2005/0244413 (Adolfetal.) and US 2005/0265966 (Wane et as, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), al.), U.S. Pat. No. 5,338,661 (Jensenius), and “Recombinant programmed death-1 (PD-1), B and T lymphocyte attenuator Polyclonal Antibodies for Cancer Therapy” (Sharon et al., (BTLA); (2) antibodies against inhibitory cytokines like Journal of Cellular Biochemistry 96:305-313 (2005)), all of IL-10, TGFP; and (3) antibodies that deplete or inhibit func which are incorporated herein by reference. US 2009/O 143280 A1 Jun. 4, 2009 12

TABLE 1. Target Drug Name Clinical Indication Company IL-2RC(CD25) Zenapax transplant Roche IL-1R AMG108 osteoarthritis Amgen RANK-L AMG162 Osteoporosis Amgen Blys LympoSTAT-B SLE, RA HGS CD4OL (CD39) Initiated AID Celltech IDEC TRAIL-R1 HGS-ETR1 C8CES HGS TRAIL-R2 HGS-ETR2 Solid tumors HGS CD30 SGN3O NHL Seattle Genetics CD40 SGN4O MM Seattle Genetics HER2 Herceptin Breast cancer Genentech EGF-R ABX-EGF CRC, NSCLC, RCC Abgenix EMD72OOO Solid tumors Merck MDX-214 EGF-R-positive Medarex OS Erbitux CRC mclone VEGF-R CDP791 Solid tumors Celltech PDGF-R CDP860 Solid tumors Celltech/ZymoGenetics CD11a (CL) Raptiva psoriasis Genentech C4-integrin Antegrin CD, MS PDL, Biogen-IDEC C437 integrin MLMO2 CD, UC Millenium C.5 B3 integrin Vitaxin psoriasis, prostate cancer AMELilly CD2 (LFA3/Fc) Amevive psoriasis Biogen/IDEC CD152 CTLA-4/lg RA Bristol Meyers CD152 CTLA-4 C8CES Medarex CD49a integrin C1 RALuous Biogen/IDEC CD49e integrin C.5 C8CES Protein Design Labs MUC1 Theragyn MUC18 (TIM-like) ABX-MA1 melanoma TAG-72 Mucin Anatumomab C8CES CD3 Ecromeximab melanoma Kyowa Hakko TRX4 type1 IDDM TolerRx Nuvion UC PDL OrthoCloneOKT3 organ transplant Ortho biotech CD4 HuMax-CD4 T-cell lymphoma GenMab CD19 MT103 NHL Medimmune CD64 (Fe GR1) AntiCD64 C8CES Medarex CD33 MyloTarg AML Celltch/Whyeth ZAmyl AML Protein Design Labs CD22 ymphocide NHL, AID Immunomedics CEA CEA-Cide C8CES Immunomedics CD2O Rituxan NHL Genentech CD52 Campath MS, NHL, T-cell lymph Genzyme, IDEX CD44 Bivatuzumab C8CES Boehringer Ingelhelm CD23 (Fe Ep R) DEC152 allerhic asthma, rhinitis Biogen/IDEC LRR:

CD14 COSIC14 Sepsis ICOS EpCAM Panorex colorectal cancer CentOcor Lewis-Y—Ag SGN15 C8CES Seattle Genetics CD8O B7.1 psoriasis/NHL Biogen/IDEC

0309 Dosage of the bioactive agent may be varied as et al. Biofactors 2004 21 (1-4) 407-09 both of which are known to one skilled in the art and as disclosed in detail incorporated herein by reference). P450s are a class of drug and Xenobiotic-metabolizing enzymes mainly expressed in elsewhere herein. Preferably, administration is intravenous the liver. Carcinogens such as polyaromatic hydrocarbons administration or oral administration. Antibodies may also be and heterocyclic amines are metabolized to their carcino given intravenously in one embodiment, for example co genic forms by CYPs. Moreover the suppression of P450 formulated with the bioactive agent. caused by polysaccharides, such as Lentinan, is advantageous 0310. For example, the antibody and/or bioactive agent for chemotherapy patients, as it prolongs the duration and may be given at a dosage of 5 mg/kg, every other week, or intensifies the action of drugs. may be administered with a 400 mg/m loading dose and 0312 Thus in one embodiment the present invention is weekly doses of 250 mg/m over 1 hour. directed to a bioactive agent capable of Suppressing the expression of P450s. In a further embodiment the bioactive agent of the present invention is used in a combination Cytochrome P450 therapy with a chemotherapeutic drug. In all cases of combi 0311. It has been shown, that the polysaccharide Lentinan nation therapy described herein, the bioactive agent can be from Lentinus edodes and polysaccharides from Agaricus administered in the form of food. blazei can suppress the expression of cytochrome P450s Dendritic Cells (CYPs) and thus can prevent cancer (Hashimoto et al. Biosci. 0313. It has been demonstrated that chemoimmuno Biotechnol. Biochem. 2004, 66 (7) 1610-1614 and Okamoto therapy using S-1, an oral fluoropyrimidine anticancer drug, US 2009/O 143280 A1 Jun. 4, 2009

combined with lentinan is effective in modifying dendritic 0331 13. The bioactive agent according to item 7, wherein cells (DCs) in vivo and in vitro (Mushiake et al. Cancer the further monosaccharide units are glucuronic acid and Immunol. Immunother. 2005 February: 54 (2) 120-128). galactose. 0314. The survival period of Colon-26-bearing mice 0332 14. The bioactive agent according to item 7, wherein treated with S-1 and Lentinan was significantly more pro the further monosaccharide units are glucuronic acid and longed than that of mice treated with S-1 alone (P<0.05). The aOSC. frequency of CD86. DCs infiltrated into Colon-26 was 0333 15. The bioactive agent according to item 7, wherein increased in mice treated with S-1 and lentinan, and splenic the further monosaccharide units are glucuronic acid and DCs harvested from mice treated with S-1+LNT showed arabinose. more potent T-cell proliferation activity than that of DCs from 0334 16. The bioactive agent according to item 7, wherein mice treated with S-1 alone (P<0.05). the further monosaccharide units are glucuronic acid and 0315. Furthermore, the activity of cytotoxic T lympho Xylose. cytes (CTLs) in splenocytes of mice treated with S-1 and 0335 17. The bioactive agent according to item 7, wherein Lentinan was specific and more potent than that of CTLS from the further monosaccharide units are galactose and man mice treated with S-1 alone (P<0.05). OS. 0316 The results suggest that modulation of specific 0336 18. The bioactive agent according to item 7, wherein immunity with Lentinan has a significant role in enhanced the further monosaccharide units are galactose and arabi anti-tumour effects through the modification of DC function. OS. The combination therapy of S-1 and bioactive agents accord 0337. 19. The bioactive agent according to item 7, wherein ing to the invention presents a promising chemoimmuno the further monosaccharide units are galactose and Xylose. therapy, which may lead to better survival for cancer patients. 0338 20. The bioactive agent according to item 7, wherein Thus in one embodiment the present invention is directed to a the further monosaccharide units are mannose and arabi combination therapy of S-1 and the bioactive agent according OS. to this invention in cancer patients. In all cases of combination 0339. 21. The bioactive agent according to item 7, wherein therapy described herein, the bioactive agent can be admin the further monosaccharide units are mannose and Xylose. istered in the form of food. 0340 22. The bioactive agent according to item 7, wherein Bioactive Species According to the Invention the further monosaccharide units are arabinose and Xylose. 0341) 23. The bioactive agent according to item 7, wherein 0317. In one aspect there is provided a bioactive agent as the further monosaccharide units are glucuronic acid, disclosed in the items herein below: galactose and mannose. 0318 1. The bioactive agent according to a first item com 0342 24. The bioactive agent according to item 7, wherein prises or consists of an agent selected from an oligosaccha the further monosaccharide units are glucuronic acid, ride, a polysaccharide and an optionally glycosylated galactose and arabinose. polypeptide. 0343 25. The bioactive agent according to item 7, wherein 0319 2. The bioactive agent according to item 1, wherein the further monosaccharide units are glucuronic acid, the bioactive agent comprises or consists of a polysaccha galactose and Xylose. ride. 0344, 26. The bioactive agent according to item 7, wherein 0320 3. The bioactive agent according to item 1, wherein the further monosaccharide units are glucuronic acid, man the bioactive agent comprises or consists of an oligosac nose and arabinose. charide. 0321 4. The bioactive agent according to item 1, wherein 0345 27. The bioactive agent according to item 7, wherein the bioactive agent comprises or consists of an optionally the further monosaccharide units are glucuronic acid man glycosylated polypeptide. nose and Xylose. 0322 5. The bioactive agent according to item 2, wherein 0346 28. The bioactive agent according to item 7, wherein the polysaccharide is a homopolymer. the further monosaccharide units are glucuronic acid, ara 0323 6. The bioactive agent according to item 2, wherein binose and Xylose. the polysaccharide is a heteropolymer. 0347 29. The bioactive agent according to item 7, wherein 0324 7. The bioactive agent according to items 2, wherein the further monosaccharide units are galactose, mannose the polysaccharide comprises glucose monosaccharide and arabinose. units, optionally in combination with further monosaccha 0348 30. The bioactive agent according to item 7, wherein ride units selected from the group of units consisting of the further monosaccharide units are galactose, mannose glucuronic acid, galactose, mannose, arabinose and Xylose, and Xylose. including any combination thereof. 0349 31. The bioactive agent according to item 7, wherein 0325 8. The bioactive agent according to item 7, wherein the further monosaccharide units are galactose, arabinose the further monosaccharide units are all glucuronic acid. and Xylose. 0326 9. The bioactive agent according to item 7, wherein 0350 32. The bioactive agent according to item 7, wherein the further monosaccharide units are all galactose. the further monosaccharide units are mannose, arabinose 0327 10. The bioactive agent according to item 7, wherein and Xylose. the further monosaccharide units are all mannose. 0351 33. The bioactive agent according to item 7, wherein 0328 11. The bioactive agent according to item 7, wherein the further monosaccharide units are glucuronic acid, the further monosaccharide units are all arabinose. galactose, mannose and arabinose. 0329 12. The bioactive agent according to item 7, wherein 0352 34. The bioactive agent according to item 7, wherein the further monosaccharide the further monosaccharide units are glucuronic acid, 0330 30 units are all xylose. galactose, mannose and Xylose. US 2009/O 143280 A1 Jun. 4, 2009

0353. 35. The bioactive agent according to item 7, wherein 0374 56. The bioactive agent according to item 38, the further monosaccharide units are glucuronic acid, wherein the further monosaccharide units are glucuronic galactose, arabinose and Xylose. acid, galactose and Xylose. 0354 36. The bioactive agent according to item 7, wherein 0375 57. The bioactive agent according to item 38, the further monosaccharide units are glucuronic acid, man wherein the further monosaccharide units are glucuronic nose, arabinose and Xylose. acid, mannose and arabinose. 0355 37. The bioactive agent according to item 7, wherein 0376 58. The bioactive agent according to item 38, the further monosaccharide units are galactose, mannose, wherein the further monosaccharide units are glucuronic arabinose and Xylose. acid mannose and Xylose. 0356) 38. The bioactive agent according to item 2, wherein 0377 59. The bioactive agent according to item 38, the backbone of the polysaccharide comprises glucose wherein the further monosaccharide units are glucuronic monosaccharide units in combination with further acid, arabinose and Xylose. monosaccharide units selected from the group of units 0378 60. The bioactive agent according to item 38, consisting of glucuronic acid, galactose, mannose, arabi wherein the further monosaccharide units are galactose, nose and Xylose, including any combination thereof. mannose and arabinose. 0357 39. The bioactive agent according to item 38, 0379 61. The bioactive agent according to item 38, wherein the further monosaccharide units are all glucu wherein the further monosaccharide units are galactose, ronic acid. mannose and Xylose. 0358 40. The bioactive agent according to item 38, 0380) 62. The bioactive agent according to item 38, wherein the further monosaccharide units are all galactose. wherein the further monosaccharide units are galactose, 0359 41. The bioactive agent according to item 38, arabinose and Xylose. wherein the further monosaccharide units are all mannose. 0381 63. The bioactive agent according to item 38, 0360 42. The bioactive agent according to item 38, wherein the further monosaccharide units are mannose, wherein the further monosaccharide units are all arabinose. arabinose and Xylose. 0361 43. The bioactive agent according to item 38, 0382 64. The bioactive agent according to item 38, wherein the further monosaccharide units are all xylose. wherein the further monosaccharide units are glucuronic 0362 44. The bioactive agent according to item 38, acid, galactose, mannose and arabinose. wherein the further monosaccharide units are glucuronic 0383 65. The bioactive agent according to item 38, acid and galactose. wherein the further monosaccharide units are glucuronic 0363 45. The bioactive agent according to item 38, acid, galactose, mannose and Xylose. wherein the further monosaccharide units are glucuronic 0384 66. The bioactive agent according to item 38, acid and mannose. wherein the further monosaccharide units are glucuronic 0364 46. The bioactive agent according to item 38, acid, galactose, arabinose and Xylose. wherein the further monosaccharide units are glucuronic 0385 67. The bioactive agent according to item 38, acid and arabinose. wherein the further monosaccharide units are glucuronic 0365 47. The bioactive agent according to item 38, acid, mannose, arabinose and Xylose. wherein the further monosaccharide units are glucuronic 0386 68. The bioactive agent according to item 38, acid and Xylose. wherein the further monosaccharide units are galactose, 0366) 48. The bioactive agent according to item 38, mannose, arabinose and Xylose. wherein the further monosaccharide units are galactose 0387 69. The bioactive agent according to item 2, wherein and mannose. the backbone of the polysaccharide comprises a plurality 0367 49. The bioactive agent according to item 38, of monosaccharide units, and wherein the side chains of the wherein the further monosaccharide units are galactose polysaccharide comprises further monosaccharide units and arabinose. selected from the group of units consisting of glucuronic 0368 50. The bioactive agent according to item 38, acid, galactose, mannose, arabinose Xylose and glucose, wherein the further monosaccharide units are galactose including any combination thereof. and Xylose. 0388 70. The bioactive agent according to item 69, 0369 51. The bioactive agent according to item 38, wherein the further monosaccharide units are all glucu wherein the further monosaccharide units are mannose and ronic acid. arabinose. 0389) 71. The bioactive agent according to item 69, 0370 52. The bioactive agent according to item 38, wherein the further monosaccharide units are all galactose. wherein the further monosaccharide units are mannose and 0390 72. The bioactive agent according to item 69, Xylose. wherein the further monosaccharide units are all mannose. 0371 53. The bioactive agent according to item 38, 0391) 73. The bioactive agent according to item 69, wherein the further monosaccharide units are arabinose wherein the further monosaccharide units are all arabinose. and Xylose. 0392 74. The bioactive agent according to item 69, 0372 54. The bioactive agent according to item 38, wherein the further monosaccharide units are all xylose. wherein the further monosaccharide units are glucuronic 0393 75. The bioactive agent according to item 69, acid, galactose and mannose. wherein the further monosaccharide units are all glucose. 0373 55. The bioactive agent according to item 38, 0394 76. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, galactose and arabinose. acid and galactose. US 2009/O 143280 A1 Jun. 4, 2009

0395 77. The bioactive agent according to item 69, 0416) 98. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and mannose. acid, arabinose and Xylose. 0396 78. The bioactive agent according to item 69, 0417. 99. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and arabinose. acid, arabinose and glucose. 0397 79. The bioactive agent according to item 69, 0418 100. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and Xylose. acid, Xylose and glucose. 0398. 80. The bioactive agent according to item 69, 0419 101. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are galactose, acid and glucose. mannose and arabinose. 0399 81. The bioactive agent according to item 69, 0420 102. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and mannose. mannose and Xylose. 0400. 82. The bioactive agent according to item 69, 0421 103. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and arabinose. mannose and glucose. 04.01 83. The bioactive agent according to item 69, 0422 104. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and Xylose. arabinose and Xylose. 0402 84. The bioactive agent according to item 69, 0423 105. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and glucose. arabinose and glucose. 0403 85. The bioactive agent according to item 69, 0424 106. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose and wherein the further monosaccharide units are galactose, arabinose. Xylose and glucose. 0404 86. The bioactive agent according to item 69, 0425 107. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose and wherein the further monosaccharide units are mannose, Xylose. arabinose and Xylose. 04.05 87. The bioactive agent according to item 69, 0426 108. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose and wherein the further monosaccharide units are mannose, glucose. arabinose and glucose. 0406 88. The bioactive agent according to item 69, 0427 109. The bioactive agent according to item 69, wherein the further monosaccharide units are arabinose wherein the further monosaccharide units are mannose, and Xylose. Xylose and glucose. 04.07 89. The bioactive agent according to item 69, 0428 110. The bioactive agent according to item 69, wherein the further monosaccharide units are arabinose wherein the further monosaccharide units are arabinose, and glucose. Xylose and glucose. 0408 90. The bioactive agent according to item 69, 0429 111. The bioactive agent according to item 69, wherein the further monosaccharide units are Xylose and wherein the further monosaccharide units are glucuronic glucose. acid, galactose, mannose and arabinose. 04.09 91. The bioactive agent according to item 69, 0430. 112. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, galactose and mannose. acid, galactose, mannose and Xylose. 0410 92. The bioactive agent according to item 69, 0431) 113. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, galactose and arabinose. acid, galactose, mannose and glucose. 0411 93. The bioactive agent according to item 69, 0432) 114. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, galactose and Xylose. acid, galactose, arabinose and Xylose. 0412 94. The bioactive agent according to item 69, 0433 115. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, galactose and glucose. acid, galactose, arabinose and glucose. 0413 95. The bioactive agent according to item 69, 0434 116. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid, mannose and arabinose. acid, galactose, Xylose and glucose. 0414. 96. The bioactive agent according to item 69, 0435 117. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid mannose and Xylose. acid, mannose, arabinose and Xylose. 0415 97. The bioactive agent according to item 69, 0436 118. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid mannose and glucose. acid, mannose, arabinose and glucose. US 2009/O 143280 A1 Jun. 4, 2009

0437 119. The bioactive agent according to item 69, ride units, such as from 50 to 1000 monosaccharide units, wherein the further monosaccharide units are glucuronic for example from 60 to 1000 monosaccharide units, such as acid, mannose, Xylose and glucose. from 70 to 1000 monosaccharide units, for example from 0438 120. The bioactive agent according to item 69, 80 to 1000 monosaccharide units, such as from 90 to 1000 wherein the further monosaccharide units are glucuronic monosaccharide units, for example from 100 to 1000 acid, arabinose, Xylose and glucose. monosaccharide units, such as from 2 to 500 monosaccha 0439 121. The bioactive agent according to item 69, ride units, for example from 3 to 500 monosaccharide wherein the further monosaccharide units are galactose, units, such as from 4 to 500 monosaccharide units, for mannose, arabinose and Xylose. 0440 122. The bioactive agent according to item 69, example from 5 to 500 monosaccharide units, such as from wherein the further monosaccharide units are galactose, 6 to 500 monosaccharide units, for example from 7 to 500 mannose, arabinose and glucose. monosaccharide units, such as from 8 to 500 monosaccha 0441 123. The bioactive agent according to item 69, ride units, for example from 9 to 500 monosaccharide wherein the further monosaccharide units are galactose, units, such as from 10 to 500 monosaccharide units, for mannose, Xylose and glucose. example from 11 to 500 monosaccharide units, such as from 12 to 500 monosaccharide units, for example from 13 0442 124. The bioactive agent according to item 69, to 500 monosaccharide units, such as from 14 to 500 wherein the further monosaccharide units are galactose, monosaccharide units, for example from 15 to 500 arabinose, Xylose and glucose. monosaccharide units, such as from 20 to 500 monosac 0443) 125. The bioactive agent according to item 69, charide units, for example from 25 to 500 monosaccharide wherein the further monosaccharide units are mannose, units, such as from 30 to 500 monosaccharide units, for arabinose, Xylose and glucose. example from 40 to 500 monosaccharide units, such as 0444 126. The bioactive agent according to item 69, from 50 to 500 monosaccharide units, for example from 60 wherein the further monosaccharide units are glucuronic to 500 monosaccharide units, such as from 70 to 500 acid, galactose, mannose, arabinose and Xylose. monosaccharide units, for example from 80 to 500 0445 127. The bioactive agent according to item 69, monosaccharide units, such as from 90 to 500 monosac wherein the further monosaccharide units are glucuronic charide units, for example from 100 to 500 monosaccha acid, galactose, mannose, arabinose and glucose. ride units, such as from 2 to 250 monosaccharide units, for 0446 128. The bioactive agent according to item 69, example from 3 to 250 monosaccharide units, such as from wherein the further monosaccharide units are glucuronic 4 to 250 monosaccharide units, for example from 5 to 250 acid, galactose, mannose, Xylose and glucose. monosaccharide units, such as from 6 to 250 monosaccha 0447 129. The bioactive agent according to item 69, ride units, for example from 7 to 250 monosaccharide wherein the further monosaccharide units are glucuronic units, such as from 8 to 250 monosaccharide units, for acid, galactose, arabinose Xylose and glucose. example from 9 to 250 monosaccharide units, such as from 0448 130. The bioactive agent according to item 69, 10 to 250 monosaccharide units, for example from 11 to wherein the further monosaccharide units are glucuronic 250 monosaccharide units, such as from 12 to 250 acid, mannose, arabinose Xylose and glucose. monosaccharide units, for example from 13 to 250 0449 131. The bioactive agent according to item 69, monosaccharide units, such as from 14 to 250 monosac wherein the further monosaccharide units are galactose, charide units, for example from 15 to 250 monosaccharide mannose, arabinose Xylose and glucose. units, such as from 20 to 250 monosaccharide units, for 0450 132. The bioactive agent according to item 2, example from 25 to 250 monosaccharide units, such as wherein the polysaccharide from 30 to 250 monosaccharide units, for example from 40 0451 25 comprises a repetitive backbone macromomer to 250 monosaccharide units, such as from 50 to 250 comprising from 2 to 6, such as 2, 3, 4, 5 or 6 different monosaccharide units, for example from 60 to 250 monosaccharide units and having from 1 to 3 monosaccha monosaccharide units, such as from 70 to 250 monosac ride units selected from glucose, mannose and galactose. charide units, for example from 80 to 250 monosaccharide 0452. 133. The bioactive agent according to item 2, units, such as from 90 to 250 monosaccharide units, for wherein the polysaccharide comprises an average of from example from 100 to 250 monosaccharide units, such as 1 to 1000 monosaccharide units in the backbone between from 2 to 100 monosaccharide units, for example from 3 to each branching point, such as from 2 to 1000 monosaccha 100 monosaccharide units, such as from 4 to 100 monosac ride units, for example from 3 to 1000 monosaccharide charide units, for example from 5 to 100 monosaccharide units, such as from 4 to 1000 monosaccharide units, for units, such as from 6 to 100 monosaccharide units, for example from 5 to 1000 monosaccharide units, such as example from 7 to 100 monosaccharide units, such as from from 6 to 1000 monosaccharide units, for example from 7 8 to 100 monosaccharide units, for example from 9 to 100 to 1000 monosaccharide units, such as from 8 to 1000 monosaccharide units, such as from 10 to 100 monosac monosaccharide units, for example from 9 to 1000 charide units, for example from 11 to 100 monosaccharide monosaccharide units, such as from 10 to 1000 monosac units, such as from 12 to 100 monosaccharide units, for charide units, for example from 11 to 1000 monosaccha example from 13 to 100 monosaccharide units, such as ride units, such as from 12 to 1000 monosaccharide units, from 14 to 100 monosaccharide units, for example from 15 for example from 13 to 1000 monosaccharide units, such as to 100 monosaccharide units, such as from 20 to 100 from 14 to 1000 monosaccharide units, for example from monosaccharide units, for example from 25 to 100 15 to 1000 monosaccharide units, such as from 20 to 1000 monosaccharide units, such as from 30 to 100 monosac monosaccharide units, for example from 25 to 1000 charide units, for example from 40 to 100 monosaccharide monosaccharide units, such as from 30 to 1000 monosac units, such as from 50 to 100 monosaccharide units, for charide units, for example from 40 to 1000 monosaccha example from 60 to 100 monosaccharide units, such as US 2009/O 143280 A1 Jun. 4, 2009 17

from 70 to 100 monosaccharide units, for example from 80 example from 15 to 16 monosaccharide units, such as from to 100 monosaccharide units, such as from 90 to 100 2 to 14 monosaccharide units, for example from 3 to 14 monosaccharide units, such as from 2 to 50 monosaccha monosaccharide units, such as from 4 to 14 monosaccha ride units, for example from 3 to 50 monosaccharide units, ride units, for example from 5 to 14 monosaccharide units, Such as from 4 to 50 monosaccharide units, for example Such as from 6 to 14 monosaccharide units, for example from 5 to 50 monosaccharide units, such as from 6 to 50 from 7 to 14 monosaccharide units, such as from 8 to 14 monosaccharide units, for example from 7 to 50 monosac monosaccharide units, for example from 9 to 14 monosac charide units. Such as from 8 to 50 monosaccharide units, charide units, such as from 10 to 14 monosaccharide units, for example from 9 to 50 monosaccharide units, such as for example from 11 to 14 monosaccharide units, such as from 10 to 50 monosaccharide units, for example from 11 from 12 to 14 monosaccharide units, for example from 13 to 50 monosaccharide units, such as from 12 to 50 to 14 monosaccharide units, such as from 2 to 12 monosac monosaccharide units, for example from 13 to 50 charide units, for example from 3 to 12 monosaccharide monosaccharide units, such as from 14 to 50 monosaccha units, such as from 4 to 12 monosaccharide units, for ride units, for example from 15 to 50 monosaccharide example from 5 to 12 monosaccharide units, such as from units, such as from 20 to 50 monosaccharide units, for 6 to 12 monosaccharide units, for example from 7 to 12 example from 25 to 50 monosaccharide units, such as from monosaccharide units, such as from 8 to 12 monosaccha 30 to 50 monosaccharide units, for example from 40 to 50 ride units, for example from 9 to 12 monosaccharide units, monosaccharide units, such as from 2 to 25 monosaccha Such as from 10 to 12 monosaccharide units, for example ride units, for example from 3 to 25 monosaccharide units, from 11 to 12 monosaccharide units, such as from 2 to 10 Such as from 4 to 25 monosaccharide units, for example monosaccharide units, for example from 3 to 10 monosac from 5 to 25 monosaccharide units, such as from 6 to 25 charide units, such as from 4 to 10 monosaccharide units, monosaccharide units, for example from 7 to 25 monosac for example from 5 to 10 monosaccharide units, such as charide units. Such as from 8 to 25 monosaccharide units, from 6 to 10 monosaccharide units, for example from 7 to for example from 9 to 25 monosaccharide units, such as 10 monosaccharide units, such as from 8 to 10 monosac from 10 to 25 monosaccharide units, for example from 11 charide units, for example from 9 to 10 monosaccharide to 25 monosaccharide units, such as from 12 to 25 units, such as from 2 to 8 monosaccharide units, for monosaccharide units, for example from 13 to 25 example from 3 to 8 monosaccharide units, such as from 4 monosaccharide units, such as from 14 to 25 monosaccha to 8 monosaccharide units, for example from 5 to 8 ride units, for example from 15 to 25 monosaccharide monosaccharide units, such as from 6 to 8 monosaccharide units, such as from 20 to 25 monosaccharide units, such as units, for example from 7 to 8 monosaccharide units in the from 2 to 20 monosaccharide units, for example from 3 to backbone between each branching point. 20 monosaccharide units, such as from 4 to 20 monosac 0453 134. The bioactive agent according to item 2, charide units, for example from 5 to 20 monosaccharide wherein the polysaccharide has a molecular weight in the units, such as from 6 to 20 monosaccharide units, for range of from 5,000 g/mol to about 1,000,000 g/mol, such example from 7 to 20 monosaccharide units, such as from as a molecular weight in the range of from 5,000 g/mol to 8 to 20 monosaccharide units, for example from 9 to 20 about 900,000 g/mol, for example a molecular weight in monosaccharide units, such as from 10 to 20 monosaccha the range of from 5,000 g/mol to about 800,000 g/mol, such ride units, for example from 11 to 20 monosaccharide as a molecular weight in the range of from 5,000 g/mol to units, such as from 12 to 20 monosaccharide units, for about 900,000 g/mol, for example a molecular weight in example from 13 to 20 monosaccharide units, such as from the range of from 5,000 g/mol to about 800,000 g/mol, such 14 to 20 monosaccharide units, for example from 15 to 20 as a molecular weight in the range of from 5,000 g/mol to monosaccharide units, such as from 2 to 18 monosaccha about 750,000 g/mol, for example a molecular weight in ride units, for example from 3 to 18 monosaccharide units, the range of from 5,000 g/mol to about 700,000 g/mol, such Such as from 4 to 18 monosaccharide units, for example as a molecular weight in the range of from 5,000 g/mol to from 5 to 18 monosaccharide units, such as from 6 to 18 about 1270,000 g/mol, for example a molecular weight in monosaccharide units, for example from 7 to 18 monosac the range of from 5,000 g/mol to about 600,000 g/mol, such charide units. Such as from 8 to 18 monosaccharide units, as a molecular weight in the range of from 5,000 g/mol to for example from 9 to 18 monosaccharide units, such as about 550,000 g/mol, for example a molecular weight in from 10 to 18 monosaccharide units, for example from 11 the range of from 5,000 g/mol to about 500,000 g/mol, such to 18 monosaccharide units, such as from 12 to 18 as a molecular weight in the range of from 5,000 g/mol to monosaccharide units, for example from 13 to 18 about 450,000 g/mol, for example a molecular weight in monosaccharide units, such as from 14 to 18 monosaccha the range of from 5,000 g/mol to about 400,000 g/mol, such ride units, for example from 15 to 18 monosaccharide as a molecular weight in the range of from 5,000 g/mol to units, such as from 2 to 16 monosaccharide units, for about 350,000 g/mol, for example a molecular weight in example from 3 to 16 monosaccharide units, such as from the range of from 5,000 g/mol to about 300,000 g/mol, such 4 to 16 monosaccharide units, for example from 5 to 16 as a molecular weight in the range of from 5,000 g/mol to monosaccharide units, such as from 6 to 16 monosaccha about 250,000 g/mol, for example a molecular weight in ride units, for example from 7 to 16 monosaccharide units, the range of from 5,000 g/mol to about 200,000 g/mol, such Such as from 8 to 16 monosaccharide units, for example as a molecular weight in the range of from 5,000 g/mol to from 9 to 16 monosaccharide units, such as from 10 to 16 about 100,000 g/mol, for example a molecular weight in monosaccharide units, for example from 11 to 16 the range of from 5,000 g/mol to about 80,000 g/mol, such monosaccharide units, such as from 12 to 16 monosaccha as a molecular weight in the range of from 5,000 g/mol to ride units, for example from 13 to 16 monosaccharide about 60,000 g/mol, for example a molecular weight in the units, such as from 14 to 16 monosaccharide units, for range of from 5,000 g/mol to about 50,000 g/mol, such as US 2009/O 143280 A1 Jun. 4, 2009 18

a molecular weight in the range of from 5,000 g/mol to for example a molecular weight in the range of from 15,000 about 40,000 g/mol, for example a molecular weight in the g/mol to about 600,000 g/mol, such as a molecular weight range of from 5,000 g/mol to about 35.000 g/mol, such as in the range of from 15,000 g/mol to about 550,000 g/mol, a molecular weight in the range of from 5,000 g/mol to for example a molecular weight in the range of from 15,000 about 30,000 g/mol, for example a molecular weight in the g/mol to about 500,000 g/mol, such as a molecular weight range of from 5,000 g/mol to about 25.000 g/mol, such as in the range of from 15,000 g/mol to about 450,000 g/mol, a molecular weight in the range of from 5,000 g/mol to for example a molecular weight in the range of from 15,000 about 20,000 g/mol, for example a molecular weight in the g/mol to about 400,000 g/mol, such as a molecular weight range of from 5,000 g/mol to about 15.000 g/mol, such as in the range of from 15,000 g/mol to about 350,000 g/mol, a molecular weight in the range of from 5,000 g/mol to for example a molecular weight in the range of from 15,000 about 10,000 g/mol, for example a molecular weight in the g/mol to about 300,000 g/mol, such as a molecular weight range of from 10,000 g/mol to about 1,000,000 g/mol, such in the range of from 15,000 g/mol to about 250,000 g/mol, as a molecular weight in the range of from 10,000 g/mol to for example a molecular weight in the range of from 15,000 about 900,000 g/mol, for example a molecular weight in g/mol to about 200,000 g/mol, such as a molecular weight the range of from 10,000 g/mol to about 800,000 g/mol, in the range of from 15,000 g/mol to about 100,000 g/mol, such as a molecular weight in the range of from 10,000 for example a molecular weight in the range of from 15,000 g/mol to about 900,000 g/mol, for example a molecular g/mol to about 80,000 g/mol, such as a molecular weight in weight in the range of from 10,000 g/mol to about 800,000 the range of from 15,000 g/mol to about 60,000 g/mol, for g/mol. Such as a molecular weight in the range of from example a molecular weight in the range of from 15,000 10,000 g/mol to about 750,000 g/mol, for example a g/mol to about 50,000 g/mol, such as a molecular weight in molecular weight in the range of from 10,000 g/mol to the range of from 15,000 g/mol to about 40,000 g/mol, for about 700,000 g/mol, such as a molecular weight in the example a molecular weight in the range of from 15,000 range of from 10,000 g/mol to about 1270,000 g/mol, for g/mol to about 35.000 g/mol, such as a molecular weight in example a molecular weight in the range of from 10,000 the range of from 15,000 g/mol to about 30,000 g/mol, for g/mol to about 600,000 g/mol, such as a molecular weight example a molecular weight in the range of from 15,000 in the range of from 10,000 g/mol to about 550,000 g/mol, g/mol to about 25.000 g/mol, such as a molecular weight in for example a molecular weight in the range of from 10,000 the range of from 15,000 g/mol to about 20,000 g/mol, for g/mol to about 500,000 g/mol, such as a molecular weight example a molecular weight in the range of from 20,000 in the range of from 10,000 g/mol to about 450,000 g/mol, g/mol to about 1,000,000 g/mol, such as a molecular for example a molecular weight in the range of from 10,000 weight in the range of from 20,000 g/mol to about 900,000 g/mol to about 400,000 g/mol, such as a molecular weight g/mol, for example a molecular weight in the range of from in the range of from 10,000 g/mol to about 350,000 g/mol, 20,000 g/mol to about 800,000 g/mol, such as a molecular for example a molecular weight in the range of from 10,000 weight in the range of from 20,000 g/mol to about 900,000 g/mol to about 300,000 g/mol, such as a molecular weight g/mol, for example a molecular weight in the range of from in the range of from 10,000 g/mol to about 250,000 g/mol, 20,000 g/mol to about 800,000 g/mol, such as a molecular for example a molecular weight in the range of from 10,000 weight in the range of from 20,000 g/mol to about 750,000 g/mol to about 200,000 g/mol, such as a molecular weight g/mol, for example a molecular weight in the range of from in the range of from 10,000 g/mol to about 100,000 g/mol, 20,000 g/mol to about 700,000 g/mol, such as a molecular for example a molecular weight in the range of from 10,000 weight in the range of from 20,000 g/mol to about 1270, g/mol to about 80,000 g/mol, such as a molecular weight in 000 g/mol, for example a molecular weight in the range of the range of from 10,000 g/mol to about 60,000 g/mol, for from 20,000 g/mol to about 600,000 g/mol, such as a example a molecular weight in the range of from 10,000 molecular weight in the range of from 20,000 g/mol to g/mol to about 50,000 g/mol, such as a molecular weight in about 550,000 g/mol, for example a molecular weight in the range of from 10,000 g/mol to about 40,000 g/mol, for the range of from 20,000 g/mol to about 500,000 g/mol, example a molecular weight in the range of from 10,000 such as a molecular weight in the range of from 20,000 g/mol to about 35.000 g/mol, such as a molecular weight in g/mol to about 450,000 g/mol, for example a molecular the range of from 10,000 g/mol to about 30,000 g/mol, for weight in the range of from 20,000 g/mol to about 400,000 example a molecular weight in the range of from 10,000 g/mol. Such as a molecular weight in the range of from g/mol to about 25.000 g/mol, such as a molecular weight in 20,000 g/mol to about 350,000 g/mol, for example a the range of from 10,000 g/mol to about 20,000 g/mol, for molecular weight in the range of from 20,000 g/mol to example a molecular weight in the range of from 10,000 about 300,000 g/mol, such as a molecular weight in the g/mol to about 15.000 g/mol, such as a molecular weight in range of from 20,000 g/mol to about 250,000 g/mol, for the range of from 15,000 g/mol to about 1,000,000 g/mol, example a molecular weight in the range of from 20,000 such as a molecular weight in the range of from 15,000 g/mol to about 200,000 g/mol, such as a molecular weight g/mol to about 900,000 g/mol, for example a molecular in the range of from 20,000 g/mol to about 100,000 g/mol, weight in the range of from 15,000 g/mol to about 800,000 for example a molecular weight in the range of from 20,000 g/mol. Such as a molecular weight in the range of from g/mol to about 80,000 g/mol, such as a molecular weight in 15,000 g/mol to about 900,000 g/mol, for example a the range of from 20,000 g/mol to about 60,000 g/mol, for molecular weight in the range of from 15,000 g/mol to example a molecular weight in the range of from 20,000 about 800,000 g/mol, such as a molecular weight in the g/mol to about 50,000 g/mol, such as a molecular weight in range of from 15,000 g/mol to about 750,000 g/mol, for the range of from 20,000 g/mol to about 40,000 g/mol, for example a molecular weight in the range of from 15,000 example a molecular weight in the range of from 20,000 g/mol to about 700,000 g/mol, such as a molecular weight g/mol to about 35.000 g/mol, such as a molecular weight in in the range of from 15,000 g/mol to about 1270,000 g/mol, the range of from 20,000 g/mol to about 30,000 g/mol, for US 2009/O 143280 A1 Jun. 4, 2009 19

example a molecular weight in the range of from 20,000 g/mol to about 200,000 g/mol, such as a molecular weight g/mol to about 25.000 g/mol, such as a molecular weight in in the range of from 30,000 g/mol to about 100,000 g/mol, the range of from 25,000 g/mol to about 1,000,000 g/mol, for example a molecular weight in the range of from 30,000 such as a molecular weight in the range of from 25,000 g/mol to about 80,000 g/mol, such as a molecular weight in g/mol to about 900,000 g/mol, for example a molecular the range of from 30,000 g/mol to about 60,000 g/mol, for weight in the range of from 25,000 g/mol to about 800,000 example a molecular weight in the range of from 30,000 g/mol. Such as a molecular weight in the range of from g/mol to about 50,000 g/mol, such as a molecular weight in 25,000 g/mol to about 900,000 g/mol, for example a the range of from 30,000 g/mol to about 40,000 g/mol, for molecular weight in the range of from 25,000 g/mol to example a molecular weight in the range of from 30,000 about 800,000 g/mol, such as a molecular weight in the g/mol to about 35.000 g/mol, such as a molecular weight in range of from 25,000 g/mol to about 750,000 g/mol, for the range of from 40,000 g/mol to about 1,000,000 g/mol, example a molecular weight in the range of from 25,000 such as a molecular weight in the range of from 40,000 g/mol to about 700,000 g/mol, such as a molecular weight g/mol to about 900,000 g/mol, for example a molecular in the range of from 25,000 g/mol to about 1270,000 g/mol, weight in the range of from 40,000 g/mol to about 800,000 for example a molecular weight in the range of from 25,000 g/mol. Such as a molecular weight in the range of from g/mol to about 600,000 g/mol, such as a molecular weight 40,000 g/mol to about 900,000 g/mol, for example a in the range of from 25,000 g/mol to about 550,000 g/mol, molecular weight in the range of from 40,000 g/mol to for example a molecular weight in the range of from 25,000 about 800,000 g/mol, such as a molecular weight in the g/mol to about 500,000 g/mol, such as a molecular weight range of from 40,000 g/mol to about 750,000 g/mol, for in the range of from 25,000 g/mol to about 450,000 g/mol, example a molecular weight in the range of from 40,000 for example a molecular weight in the range of from 25,000 g/mol to about 700,000 g/mol, such as a molecular weight g/mol to about 400,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 1270,000 g/mol, in the range of from 25,000 g/mol to about 350,000 g/mol, for example a molecular weight in the range of from 40,000 for example a molecular weight in the range of from 25,000 g/mol to about 600,000 g/mol, such as a molecular weight g/mol to about 300,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 550,000 g/mol, in the range of from 25,000 g/mol to about 250,000 g/mol, for example a molecular weight in the range of from 40,000 for example a molecular weight in the range of from 25,000 g/mol to about 500,000 g/mol, such as a molecular weight g/mol to about 200,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 450,000 g/mol, in the range of from 25,000 g/mol to about 100,000 g/mol, for example amolecular weight in the range of from 40,000 for example a molecular weight in the range of from 25,000 g/mol to about 400,000 g/mol, such as a molecular weight g/mol to about 80,000 g/mol, such as a molecular weight in in the range of from 40,000 g/mol to about 350,000 g/mol, the range of from 25,000 g/mol to about 60,000 g/mol, for for example a molecular weight in the range of from 40,000 example a molecular weight in the range of from 25,000 g/mol to about 300,000 g/mol, such as a molecular weight g/mol to about 50,000 g/mol, such as a molecular weight in in the range of from 40,000 g/mol to about 250,000 g/mol, the range of from 25,000 g/mol to about 40,000 g/mol, for for example a molecular weight in the range of from 40,000 example a molecular weight in the range of from 25,000 g/mol to about 200,000 g/mol, such as a molecular weight g/mol to about 35.000 g/mol, such as a molecular weight in in the range of from 40,000 g/mol to about 100,000 g/mol, the range of from 25,000 g/mol to about 30,000 g/mol, for for example a molecular weight in the range of from 40,000 example a molecular weight in the range of from 30,000 g/mol to about 80,000 g/mol, such as a molecular weight in g/mol to about 1,000,000 g/mol, such as a molecular the range of from 40,000 g/mol to about 60,000 g/mol, for weight in the range of from 30,000 g/mol to about 900,000 example a molecular weight in the range of from 40,000 g/mol, for example a molecular weight in the range of from g/mol to about 50,000 g/mol, such as a molecular weight in 30,000 g/mol to about 800,000 g/mol, such as a molecular the range of from 50,000 g/mol to about 1,000,000 g/mol, weight in the range of from 30,000 g/mol to about 900,000 such as a molecular weight in the range of from 50,000 g/mol, for example a molecular weight in the range of from g/mol to about 900,000 g/mol, for example a molecular 30,000 g/mol to about 800,000 g/mol, such as a molecular weight in the range of from 50,000 g/mol to about 800,000 weight in the range of from 30,000 g/mol to about 750,000 g/mol. Such as a molecular weight in the range of from g/mol, for example a molecular weight in the range of from 50,000 g/mol to about 900,000 g/mol, for example a 30,000 g/mol to about 700,000 g/mol, such as a molecular molecular weight in the range of from 50,000 g/mol to weight in the range of from 30,000 g/mol to about 1270, about 800,000 g/mol, such as a molecular weight in the 000 g/mol, for example a molecular weight in the range of range of from 50,000 g/mol to about 750,000 g/mol, for from 30,000 g/mol to about 600,000 g/mol, such as a example a molecular weight in the range of from 50,000 molecular weight in the range of from 30,000 g/mol to g/mol to about 700,000 g/mol, such as a molecular weight about 550,000 g/mol, for example a molecular weight in in the range of from 50,000 g/mol to about 1270,000 g/mol, the range of from 30,000 g/mol to about 500,000 g/mol, for example a molecular weight in the range of from 50,000 such as a molecular weight in the range of from 30,000 g/mol to about 600,000 g/mol, such as a molecular weight g/mol to about 450,000 g/mol, for example a molecular in the range of from 50,000 g/mol to about 550,000 g/mol, weight in the range of from 30,000 g/mol to about 400,000 for example a molecular weight in the range of from 50,000 g/mol. Such as a molecular weight in the range of from g/mol to about 500,000 g/mol, such as a molecular weight 30,000 g/mol to about 350,000 g/mol, for example a in the range of from 50,000 g/mol to about 450,000 g/mol, molecular weight in the range of from 30,000 g/mol to for example a molecular weight in the range of from 50,000 about 300,000 g/mol, such as a molecular weight in the g/mol to about 400,000 g/mol, such as a molecular weight range of from 30,000 g/mol to about 250,000 g/mol, for in the range of from 50,000 g/mol to about 350,000 g/mol, example a molecular weight in the range of from 30,000 for example a molecular weight in the range of from 50,000 US 2009/O 143280 A1 Jun. 4, 2009 20

g/mol to about 300,000 g/mol, such as a molecular weight about 200,000 g/mol, such as a molecular weight in the in the range of from 50,000 g/mol to about 250,000 g/mol, range of from 200,000 g/mol to about 300,000 g/mol, for for example a molecular weight in the range of from 50,000 example a molecular weight in the range of from 300,000 g/mol to about 200,000 g/mol, such as a molecular weight g/mol to about 400,000 g/mol, such as a molecular weight in the range of from 50,000 g/mol to about 100,000 g/mol, in the range of from 400,000 g/mol to about 500,000 g/mol, for example a molecular weight in the range of from 50,000 for example a molecular weight in the range of from 500, g/mol to about 80,000 g/mol, such as a molecular weight in 000 g/mol to about 600,000 g/mol, such as a molecular the range of from 50,000 g/mol to about 60,000 g/mol, for weight in the range of from 700,000 g/mol to about 800, example a molecular weight in the range of from 75,000 000 g/mol, for example a molecular weight in the range of g/mol to about 1,000,000 g/mol, such as a molecular from 800,000 g/mol to about 900,000 g/mol, such as a weight in the range of from 75,000 g/mol to about 900,000 molecular weight in the range of from 900,000 g/mol to g/mol, for example a molecular weight in the range of from about 1,000,000 g/mol. 75,000 g/mol to about 800,000 g/mol, such as a molecular 0454) 135. The bioactive agent according to item 2, weight in the range of from 75,000 g/mol to about 900,000 wherein the polysaccharide comprises a structural compo g/mol, for example a molecular weight in the range of from nent selected from the group of components consisting of 75,000 g/mol to about 800,000 g/mol, such as a molecular 0455 (1-3)-alpha-D-glucan: weight in the range of from 75,000 g/mol to about 750,000 0456 (1-3)-alpha-D-glucan with (1-6)-beta branching: g/mol, for example a molecular weight in the range of from 0457 (1-3)-alpha-D-glucan with (1-6)-alpha branch 75,000 g/mol to about 700,000 g/mol, such as a molecular 1ng weight in the range of from 75,000 g/mol to about 1270, 0458 (1-3)-alpha-D-glucan with (1-4)-beta branching; 000 g/mol, for example a molecular weight in the range of 0459 (1-3)-alpha-D-glucan with (1-4)-alpha branch from 75,000 g/mol to about 600,000 g/mol, such as a 1ng molecular weight in the range of from 75,000 g/mol to 0460) (1-3)-beta-D-glucan: about 550,000 g/mol, for example a molecular weight in 0461) (1-3)-beta-D-glucan with (1-6)-beta branching: the range of from 75,000 g/mol to about 500,000 g/mol, 0462 (1-3)-beta-D-glucan with (1-6)-alpha branching; such as a molecular weight in the range of from 75,000 0463 (1-3)-beta-D-glucan with (1-4)-beta branching: g/mol to about 450,000 g/mol, for example a molecular 0464 (1-3)-beta-D-glucan with (1-4)-alpha branching; weight in the range of from 75,000 g/mol to about 400,000 0465 (1-4)-alpha-D-glucan: g/mol, such as a molecular weight in the range of from 0466 (1-4)-alpha-D-glucan with (1-6)-beta branching: 75,000 g/mol to about 350,000 g/mol, for example a 0467 (1-4)-alpha-D-glucan with (1-6)-alpha branch molecular weight in the range of from 75,000 g/mol to ing: about 300,000 g/mol, such as a molecular weight in the 0468 (1-4)-alpha-D-glucan with (1-4)-beta branching; range of from 75,000 g/mol to about 250,000 g/mol, for 0469 (1-4)-alpha-D-glucan with (1-4)-alpha branch example a molecular weight in the range of from 75,000 ing: g/mol to about 200,000 g/mol, such as a molecular weight 0470 (1-4)-beta-D-glucan: in the range of from 75,000 g/mol to about 100,000 g/mol, (1-4)-beta-D-glucan with (1-6)-beta branching: for example a molecular weight in the range of from 75,000 0471) g/mol to about 80,000 g/mol, a molecular weight in the 0472 (1-4)-beta-D-glucan with (1-6)-alpha branching; range of from 100,000 g/mol to about 1,000,000 g/mol, 0473 (1-4)-beta-D-glucan with (1-4)-beta branching; such as a molecular weight in the range of from 100,000 0474) (1-4)-beta-D-glucan with (1-4)-alpha branching; g/mol to about 900,000 g/mol, for example a molecular 0475 (1-6)-beta-D-glucan: weight in the range of from 100,000 g/mol to about 800, 0476 (1-6)-beta-D-glucan with (1-6)-beta branching: 000 g/mol. Such as a molecular weight in the range of from 0477 (1-6)-beta-D-glucan with (1-6)-alpha branching; 100,000 g/mol to about 900,000 g/mol, for example a 0478 (1-6)-beta-D-glucan with (1-4)-beta branching: molecular weight in the range of from 100,000 g/mol to 0479 (1-6)-beta-D-glucan with (1-4)-alpha branching; about 800,000 g/mol, such as a molecular weight in the 0480 (1-6)-alpha-D-glucan: range of from 100,000 g/mol to about 750,000 g/mol, for 0481 (1-6)-alpha-D-glucan with (1-6)-beta branching; example a molecular weight in the range of from 100,000 0482 (1-6)-alpha-D-glucan with (1-6)-alpha branch g/mol to about 700,000 g/mol, such as a molecular weight ing: in the range of from 100,000 g/mol to about 1270,000 g/mol, for example a molecular weight in the range of from 0483) (1-6)-alpha-D-glucan with (1-4)-beta branching; 100,000 g/mol to about 600,000 g/mol, such as a molecular 0484 (1-6)-alpha-D-glucan with (1-4)-alpha branch weight in the range of from 100,000 g/mol to about 550, ing: 000 g/mol, for example a molecular weight in the range of 0485 136. The bioactive agent according to item 2, from 100,000 g/mol to about 500,000 g/mol, such as a wherein the polysaccharide comprises a structural compo molecular weight in the range of from 100,000 g/mol to nent comprising (1-3)-alpha-D-glucan. about 450,000 g/mol, for example a molecular weight in 0486 137. The bioactive agent according to item 2, the range of from 100,000 g/mol to about 400,000 g/mol, wherein the polysaccharide comprises a structural compo such as a molecular weight in the range of from 100,000 nent comprising (1-3)-alpha-D-glucan with (1-6)-beta g/mol to about 350,000 g/mol, for example a molecular branching. weight in the range of from 100,000 g/mol to about 300, 0487. 138. The bioactive agent according to item 2, 000 g/mol. Such as a molecular weight in the range of from wherein the polysaccharide comprises a structural compo 100,000 g/mol to about 250,000 g/mol, for example a nent comprising (1-3)-alpha-D-glucan with (1-6)-alpha molecular weight in the range of from 100,000 g/mol to branching. US 2009/O 143280 A1 Jun. 4, 2009

0488 139. The bioactive agent according to item 2, 0504 155. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-3)-alpha-D-glucan with (1-4)-beta nent comprising (1-4)-beta-D-glucan with (1-4)-alpha branching. branching. 0489. 140. The bioactive agent according to item 2, 0505 156. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-3)-alpha-D-glucan with (1-4)-alpha nent comprising (1-6)-beta-D-glucan. branching. 0506 157. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo 0490 141. The bioactive agent according to item 2, nent comprising (1-6)-beta-D-glucan with (1-6)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-beta-D-glucan. 0507 158. The bioactive agent according to item 2, 0491. 142. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-beta-D-glucan with (1-6)-alpha nent comprising (1-3)-beta-D-glucan with (1-6)-beta branching. branching. 0508 159. The bioactive agent according to item 2, 0492) 143. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-beta-D-glucan with (1-4)-beta nent comprising (1-3)-beta-D-glucan with (1-6)-alpha branching. branching. 0509 160. The bioactive agent according to item 2, 0493. 144. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-beta-D-glucan with (1-4)-alpha nent comprising (1-3)-beta-D-glucan with (1-4)-beta branching. branching. 0510) 161. The bioactive agent according to item 2, 0494. 145. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-alpha-D-glucan. nent comprising (1-3)-beta-D-glucan with (1-4)-alpha 0511 162. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0495. 146. The bioactive agent according to item 2, nent comprising (1-6)-alpha-D-glucan with (1-6)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-4)-alpha-D-glucan. 0512 163. The bioactive agent according to item 2, 0496 147. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-alpha-D-glucan with (1-6)-alpha nent comprising (1-4)-alpha-D-glucan with (1-6)-beta branching. branching. 0513. 164. The bioactive agent according to item 2, 0497 148. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-alpha-D-glucan with (1-4)-beta nent comprising (1-4)-alpha-D-glucan with (1-6)-alpha branching. branching. 0514) 165. The bioactive agent according to item 2, 0498. 149. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-6)-alpha-D-glucan with (1-4)-alpha nent comprising (1-4)-alpha-D-glucan with (1-4)-beta branching. branching. 0515, 166. The bioactive agent according to item 2, 0499 150. The bioactive agent according to item 2, wherein the polysaccharide backbone comprises a plural wherein the polysaccharide comprises a structural compo ity of monosaccharide units linked by a chemical bond nent comprising (1-4)-alpha-D-glucan with (1-4)-alpha selected from the group consisting of (1-6)-beta bonds, branching. (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta bonds, 0500 151. The bioactive agent according to item 2, (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha wherein the polysaccharide comprises a structural compo bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-al nent comprising (1-4)-beta-D-glucan. pha bonds, (1-4)-alpha bonds and (1-6)-alpha bonds. 0501 152. The bioactive agent according to item 2, 0516 167. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide backbone comprises a plural nent comprising (1-4)-beta-D-glucan with (1-6)-beta ity of monosaccharide units linked by (1-6)-beta bonds. branching. 0517 168. The bioactive agent according to item 2, 0502. 153. The bioactive agent according to item 2, wherein the polysaccharide backbone comprises a plural wherein the polysaccharide comprises a structural compo ity of monosaccharide units linked by (1-4)-beta bonds. nent comprising (1-4)-beta-D-glucan with (1-6)-alpha 0518) 169. The bioactive agent according to item 2, branching. wherein the polysaccharide backbone comprises a plural 0503 154. The bioactive agent according to item 2, ity of monosaccharide units linked by (1-3)-beta bonds. wherein the polysaccharide comprises a structural compo 0519 170. The bioactive agent according to item 2, nent comprising (1-4)-beta-D-glucan with (1-4)-beta wherein the polysaccharide backbone comprises a plural branching. ity of monosaccharide units linked by (1-2)-beta bonds. US 2009/O 143280 A1 Jun. 4, 2009 22

0520 171. The bioactive agent according to item 2, 0536 187. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by (1-1)-beta bonds. prise a plurality of monosaccharide units linked by 1-al 0521 172. The bioactive agent according to item 2, pha-1-beta bonds. wherein the polysaccharide backbone comprises a plural 0537) 188. The bioactive agent according to any of items ity of monosaccharide units linked by 1-beta-1-alpha 166 to 178, wherein the polysaccharide side chains com bonds. prise a plurality of monosaccharide units linked by (1-2)- 0522 173. The bioactive agent according to item 2, alpha bonds. wherein the polysaccharide backbone comprises a plural 0538 189. The bioactive agent according to any of items ity of monosaccharide units linked by 1-alpha-1-alpha 166 to 178, wherein the polysaccharide side chains com bonds. prise a plurality of monosaccharide units linked by (1-3)- 0523) 174. The bioactive agent according to item 2, alpha bonds. wherein the polysaccharide backbone comprises a plural 0539) 190. The bioactive agent according to any of items ity of monosaccharide units linked by 1-alpha-1-beta 166 to 178, wherein the polysaccharide side chains com bonds. prise a plurality of monosaccharide units linked by (1-4)- 0524 175. The bioactive agent according to item 2, alpha bonds. wherein the polysaccharide backbone comprises a plural 0540 191. The bioactive agent according to any of items ity of monosaccharide units linked by (1-2)-alphabonds. 166 to 178, wherein the polysaccharide side chains com 0525 176. The bioactive agent according to item 2, prise a plurality of monosaccharide units linked by (1-6)- wherein the polysaccharide backbone comprises a plural alpha bonds. ity of monosaccharide units linked by (1-3)-alpha bonds. 0541) 192. The bioactive agent according to any of items 2 0526 177. The bioactive agent according to item 2, to 191, wherein the polysaccharide is a heteropolymer wherein the polysaccharide backbone comprises a plural comprising two or more different monosaccharides in the ity of monosaccharide units linked by (1-4)-alphabonds. main chain, Such as 3 different monosaccharides in the 0527, 178. The bioactive agent according to item 2, main chain, for example 4 different monosaccharides in the wherein the polysaccharide backbone comprises a plural main chain, Such as 5 different monosaccharides in the ity of monosaccharide units linked by (1-6)-alpha bonds. main chain, for example 6 different monosaccharides in the 0528 179. The bioactive agent according to any of items main chain. 166 to 178, wherein the polysaccharide further comprises (0542) 193. The bioactive agent according to item 192, side chains comprising a plurality of monosaccharides wherein the polysaccharide further comprises two or more Selected from the group consisting of (1-6)-beta bonds, different monosaccharides in the side chains, such as 3 (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta bonds, different monosaccharides in the side chains, for example (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha 4 different monosaccharides in the side chains, such as 5 bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-al different monosaccharides in the side chains, for example pha bonds, (1-4)-alpha bonds and (1-6)-alpha bonds. 6 different monosaccharides in the side chains. 0529) 180. The bioactive agent according to any of items 0543) 194. The bioactive agent according to any of items 7, 166 to 178, wherein the polysaccharide side chains com 38 and 69, wherein the ratio R=a/b between a) the number prise a plurality of monosaccharide units linked by (1-6)- of glucose monosaccharides and b) the number of further beta bonds. monosaccharides is about 0.0001, for example about 0530 181. The bioactive agent according to any of items 0.0005, such as about 0.001, for example about 0.005, such 166 to 178, wherein the polysaccharide side chains com as about 0.01, for example about 0.05, such as about 0.1, prise a plurality of monosaccharide units linked by (1-4)- for example about 0.2, such as about 0.3, for example about beta bonds. 0.4, such as about 0.5, for example about 0.6, such as about 0.7, for example about 0.8, such as about 0.9, for example 0531 182. The bioactive agent according to any of items about 1; such as from 1:10000 to 1, such as from 2:10000 166 to 178, wherein the polysaccharide side chains com to 1; for example from 4:10000 to 1; such as from 10:10000 prise a plurality of monosaccharide units linked by (1-3)- to 1; for example from 20:10000 to 1; such as from beta bonds. 40:10000 to 1; for example from 80:10000 to 1; such as 0532 183. The bioactive agent according to any of items from 100:10000 to 1; for example from 100:10000 to 1: 166 to 178, wherein the polysaccharide side chains com such as from 200:10000 to 1; for example from 250:10000 prise a plurality of monosaccharide units linked by (1-2)- to 1; such as from 400:10000 to 1; for example from 500: beta bonds. 10000 to 1; such as from 1000:10000 to 1; for example 0533 184. The bioactive agent according to any of items from 2000:10000 to 1; such as from 2500:10000 to 1; for 166 to 178, wherein the polysaccharide side chains com example from 3000:10000 to 1; such as from 4000:10000 prise a plurality of monosaccharide units linked by (1-1)- to 1; for example from 5000:10000 to 1; such as from beta bonds. 6000:10000 to 1; for example from 7000:10000 to 1; such 0534 185. The bioactive agent according to any of items as from 7500:10000 to 1; for example from 8000:10000 to 166 to 178, wherein the polysaccharide side chains com 1; such as from 9000:10000 to 1; for example from 9500: prise a plurality of monosaccharide units linked by 1-beta 10000 to 1, such as from 1:10000 to 5:10000; for example 1-alpha bonds. from 5:10000 to 20:10000, such as from 20:10000 to 100: 0535, 186. The bioactive agent according to any of items 10000; for example from 100:10000 to 500:10000; such as 166 to 178, wherein the polysaccharide side chains com from 500:10000 to 1000:10000; for example from 1000: prise a plurality of monosaccharide units linked by 1-al 10000 to 2000:10000; such as from 2000:10000 to 3000: pha-1-alpha bonds. 10000; for example from 3000:10000 to 4000:10000; such US 2009/O 143280 A1 Jun. 4, 2009 23

as from 4000:10000 to 5000:10000; for example from example from 1000:10000 to 2000:10000; such as from 5000:10000 to 6000:10000; such as from 6000:10000 to 2000:10000 to 3000:10000; for example from 3000:10000 7000:10000; for example from 7000:10000 to to 4000:10000; such as from 4000:10000 to 5000:10000; 8000:10000; such as from 8000:10000 to 9000:10000. for example from 5000:10000 to 6000:10000; such as from 0544 195. The bioactive agent according to any of items 7, 6000:10000 to 7000:10000; for example from 7000:10000 38 and 69, wherein the ratio R=b/a between a) the number to 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of further 0546) 197. The bioactive agent according to any of items 7, monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=b/a between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of glucu as about 0.01, for example about 0.05, such as about 0.1, ronic acid monosaccharides is about 0.0001, for example for example about 0.2, such as about 0.3, for example about about 0.0005, such as about 0.001, for example about 0.4, such as about 0.5, for example about 0.6, such as about 0.005, such as about 0.01, for example about 0.05, such as 0.7, for example about 0.8, such as about 0.9, for example about 0.1, for example about 0.2, such as about 0.3, for about 1; for example from 1:10000 to 1, such as from example about 0.4, such as about 0.5, for example about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.6, such as about 0.7, for example about 0.8, such as about 10:10000 to 1; for example from 20:10000 to 1; such as 0.9, for example about 1; for example from 1:10000 to 1, from 40:10000 to 1; for example from 80:10000 to 1; such such as from 2:10000 to 1; for example from 4:10000 to 1: as from 100:10000 to 1; for example from 100:10000 to 1: such as from 10:10000 to 1; for example from 20:10000 to such as from 200:10000 to 1; for example from 250:10000 1; such as from 40:10000 to 1; for example from 80:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; such as from 100:10000 to 1; for example from 100: 10000 to 1; such as from 1000:10000 to 1; for example 10000 to 1; such as from 200:10000 to 1; for example from from 2000:10000 to 1; such as from 2500:10000 to 1; for 250:10000 to 1; such as from 400:10000 to 1; for example example from 3000:10000 to 1; such as from 4000:10000 from 500:10000 to 1; such as from 1000:10000 to 1; for to 1; for example from 5000:10000 to 1; such as from example from 2000:10000 to 1; such as from 2500:10000 6000:10000 to 1; for example from 7000:10000 to 1; such to 1; for example from 3000:10000 to 1; such as from as from 7500:10000 to 1; for example from 8000:10000 to 4000:10000 to 1; for example from 5000:10000 to 1; such 1; such as from 9000:10000 to 1; for example from 9500: as from 6000:10000 to 1; for example from 7000:10000 to 10000 to 1; such as from 1:10000 to 5:10000; for example 1; such as from 7500:10000 to 1; for example from 8000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 1; such as from 9000:10000 to 1; for example 10000; for example from 100:10000 to 500:10000; such as from 9500:10000 to 1; such as from 1:10000 to 5:10000; from 500:10000 to 1000:10000; for example from 1000: for example from 5:10000 to 20:10000, such as from 10000 to 2000:10000; such as from 2000:10000 to 3000: 20:10000 to 100:10000; for example from 100:10000 to 10000; for example from 3000:10000 to 4000:10000; such 500:10000; such as from 500: 10000 to 1000:10000; for as from 4000:10000 to 5000:10000; for example from example from 1000:10000 to 2000:10000; such as from 5000:10000 to 6000:10000; such as from 6000:10000 to 2000:10000 to 3000:10000; for example from 3000:10000 7000:10000; for example from 7000:10000 to to 4000:10000; such as from 4000:10000 to 5000:10000; 8000:10000; such as from 8000:10000 to 9000:10000. for example from 5000:10000 to 6000:10000; such as from 0545) 196. The bioactive agent according to any of items 7, 6000:10000 to 7000:10000; for example from 7000:10000 38 and 69, wherein the ratio R=a/b between a) the number to 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of glucu 0547 198. The bioactive agent according to any of items 7, ronic acid monosaccharides is about 0.0001, for example 38 and 69, wherein the ratio R=a/b between a) the number about 0.0005, such as about 0.001, for example about of glucose monosaccharides and b) the number of galac 0.005, such as about 0.01, for example about 0.05, such as tose monosaccharides is about 0.0001, for example about about 0.1, for example about 0.2, such as about 0.3, for 0.0005, such as about 0.001, for example about 0.005, such example about 0.4, such as about 0.5, for example about as about 0.01, for example about 0.05, such as about 0.1, 0.6, such as about 0.7, for example about 0.8, such as about for example about 0.2, such as about 0.3, for example about 0.9, for example about 1; for example from 1:10000 to 1, 0.4, such as about 0.5, for example about 0.6, such as about such as from 2:10000 to 1; for example from 4:10000 to 1: 0.7, for example about 0.8, such as about 0.9, for example such as from 10:10000 to 1; for example from 20:10000 to about 1; for example from 1:10000 to 1, such as from 1; such as from 40:10000 to 1; for example from 80:10000 2:10000 to 1; for example from 4:10000 to 1; such as from to 1; such as from 100:10000 to 1; for example from 100: 10:10000 to 1; for example from 20:10000 to 1; such as 10000 to 1; such as from 200:10000 to 1; for example from from 40:10000 to 1; for example from 80:10000 to 1; such 250:10000 to 1; such as from 400:10000 to 1; for example as from 100:10000 to 1; for example from 100:10000 to 1: from 500:10000 to 1; such as from 1000:10000 to 1; for such as from 200:10000 to 1; for example from 250:10000 example from 2000:10000 to 1; such as from 2500:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; for example from 3000:10000 to 1; such as from 10000 to 1; such as from 1000:10000 to 1; for example 4000:10000 to 1; for example from 5000:10000 to 1; such from 2000:10000 to 1; such as from 2500:10000 to 1; for as from 6000:10000 to 1; for example from 7000:10000 to example from 3000:10000 to 1; such as from 4000:10000 1; such as from 7500:10000 to 1; for example from 8000: to 1; for example from 5000:10000 to 1; such as from 10000 to 1; such as from 9000:10000 to 1; for example 6000:10000 to 1; for example from 7000:10000 to 1; such from 9500: 10000 to 1; such as from 1:10000 to 5:10000; as from 7500:10000 to 1; for example from 8000:10000 to for example from 5:10000 to 20:10000, such as from 1; such as from 9000:10000 to 1; for example from 9500: 20:10000 to 100: 10000; for example from 100:10000 to 10000 to 1; such as from 1:10000 to 5:10000; for example 500:10000; such as from 500: 10000 to 1000:10000; for from 5:10000 to 20:10000, such as from 20:10000 to 100: US 2009/O 143280 A1 Jun. 4, 2009 24

10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0548) 199. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=b/a between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of galac 0550 201. The bioactive agent according to any of items 7, tose monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=b/a between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of mannose as about 0.01, for example about 0.05, such as about 0.1, monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such 0.4, such as about 0.5, for example about 0.6, such as about as about 0.01, for example about 0.05, such as about 0.1, 0.7, for example about 0.8, such as about 0.9, for example for example about 0.2, such as about 0.3, for example about about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for to 1; such as from 400:10000 to 1; for example from 500: example from 3000:10000 to 1; such as from 4000:10000 10000 to 1; such as from 1000:10000 to 1; for example to 1; for example from 5000:10000 to 1; such as from from 2000:10000 to 1; such as from 2500:10000 to 1; for 6000:10000 to 1; for example from 7000:10000 to 1; such example from 3000:10000 to 1; such as from 4000:10000 as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such 10000 to 1; such as from 1:10000 to 5:10000; for example as from 7500:10000 to 1; for example from 8000:10000 to from 5:10000 to 20:10000, such as from 20:10000 to 100: 1; such as from 9000:10000 to 1; for example from 9500: 10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0549. 200. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=a/b between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of mannose 0551 202. The bioactive agent according to any of items 7, monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=a/b between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of arabi as about 0.01, for example about 0.05, such as about 0.1, nose monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such 0.4, such as about 0.5, for example about 0.6, such as about as about 0.01, for example about 0.05, such as about 0.1, 0.7, for example about 0.8, such as about 0.9, for example for example about 0.2, such as about 0.3, for example about about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for to 1; such as from 400:10000 to 1; for example from 500: example from 3000:10000 to 1; such as from 4000:10000 10000 to 1; such as from 1000:10000 to 1; for example to 1; for example from 5000:10000 to 1; such as from from 2000:10000 to 1; such as from 2500:10000 to 1; for 6000:10000 to 1; for example from 7000:10000 to 1; such example from 3000:10000 to 1; such as from 4000:10000 as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such US 2009/O 143280 A1 Jun. 4, 2009 25

as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such 10000 to 1; such as from 1:10000 to 5:10000; for example as from 7500:10000 to 1; for example from 8000:10000 to from 5:10000 to 20:10000, such as from 20:10000 to 100: 1; such as from 9000:10000 to 1; for example from 9500: 10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0552 203. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=b/a between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of arabi 0554 205. The bioactive agent according to any of items 7, nose monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=b/a between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of Xylose as about 0.01, for example about 0.05, such as about 0.1, monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such 0.4, such as about 0.5, for example about 0.6, such as about as about 0.01, for example about 0.05, such as about 0.1, 0.7, for example about 0.8, such as about 0.9, for example for example about 0.2, such as about 0.3, for example about about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for to 1; such as from 400:10000 to 1; for example from 500: example from 3000:10000 to 1; such as from 4000:10000 10000 to 1; such as from 1000:10000 to 1; for example to 1; for example from 5000:10000 to 1; such as from from 2000:10000 to 1; such as from 2500:10000 to 1; for 6000:10000 to 1; for example from 7000:10000 to 1; such example from 3000:10000 to 1; such as from 4000:10000 as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such 10000 to 1; such as from 1:10000 to 5:10000; for example as from 7500:10000 to 1; for example from 8000:10000 to from 5:10000 to 20:10000, such as from 20:10000 to 100: 1; such as from 9000:10000 to 1; for example from 9500: 10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0553 204. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=a/b between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of Xylose 0555 206. The bioactive agent according to item 2, monosaccharides is about 0.0001, for example about wherein the polysaccharide comprises a structural compo 0.0005, such as about 0.001, for example about 0.005, such nent in the backbone comprising beta-1,2-linked D-man as about 0.01, for example about 0.05, such as about 0.1, nopyranosyl residues and a structural component in the for example about 0.2, such as about 0.3, for example about side chains comprising beta-D-glucopyranosyl-3-O-beta 0.4, such as about 0.5, for example about 0.6, such as about D-glucopyranosyl residues. 0.7, for example about 0.8, such as about 0.9, for example about 1; for example from 1:10000 to 1, such as from 0556. 207. The bioactive agent according to item 2, 2:10000 to 1; for example from 4:10000 to 1; such as from wherein the polysaccharide is a complex comprising a 10:10000 to 1; for example from 20:10000 to 1; such as (1,4)-alpha-D-glucan and a (1,6)-beta glucan. from 40:10000 to 1; for example from 80:10000 to 1; such 0557. 208. The bioactive agent according to item 2, as from 100:10000 to 1; for example from 100:10000 to 1: wherein the polysaccharide is a complex comprising a such as from 200:10000 to 1; for example from 250:10000 (1,4)-alpha-D-glucan and a (1,6)-alpha glucan. to 1; such as from 400:10000 to 1; for example from 500: 0558. 209. The bioactive agent according to any of the 10000 to 1; such as from 1000:10000 to 1; for example above items 1 to 208, wherein said bioactive agent is pro from 2000:10000 to 1; such as from 2500:10000 to 1; for duced by liquid cultivation of a Basidiomycete cell example from 3000:10000 to 1; such as from 4000:10000 selected from the group consisting of cells belonging to the US 2009/O 143280 A1 Jun. 4, 2009 26

Subclasses of Agaricomycetidae, Exobasidiomycetidae, 0575 226. The bioactive agent according to item 216, Tremellomycetidae and Ustilaginomycetidae. wherein Basidiomycete cell is selected from the family of 0559) 210. The bioactive agent according to item 209, Hemigasteraceae. wherein the Basidiomycete cell is selected form the sub 0576 227. The bioactive agent according to item 216, class of Agaricomycetidae. wherein Basidiomycete cell is selected from the family of 0560 211. The bioactive agent according to item 209, Hydnangiaceae. wherein the Basidiomycete cell is selected form the sub 0577. 228. The bioactive agent according to item 216, class of Exobasidiomycetidae. wherein Basidiomycete cell is selected from the family of 0561. 212. The bioactive agent according to item 209, Lycoperdaceae. wherein the Basidiomycete cell is selected form the sub 0578 229. The bioactive agent according to item 216, class of Tremellomyceditae. wherein Basidiomycete cell is selected from the family of 0562. 213. The bioactive agent according to item 209, Marasmiaceae. wherein the Basidiomycete cell is selected form the sub 0579. 230. The bioactive agent according to item 216, class of Ustilaginomycetidae. wherein Basidiomycete cell is selected from the family of 0563. 214. The bioactive agent according to item 1 to 208, Mesopheliaceae. wherein said bioactive agent is produced by liquid cultiva 0580 231. The bioactive agent according to item 216, tion of a Basidiomycete cell selected from the group con wherein Basidiomycete cell is selected from the family of sisting of cells belonging to the orders of Agaricales, Bole Mycenastraceae. tales, Cantheralles, Ceratobasidiales, Dacrymycetales, 0581 232. The bioactive agent according to item 216, Hymenochaetales, Phallales, Polyporales, Poriales, Rus wherein Basidiomycete cell is selected from the family of Sulales, Thelphorales, Auriculariales, Christianseniales, Niaceae. Cystofilobasidiales, Filobasidiales, Tremellaleles, 0582) 233. The bioactive agent according to item 216, Tulasenellales and Urocystales. wherein Basidiomycete cell is selected from the family of 0564) 215. The bioactive agent according to item 214, Nidulariaceae. wherein the Basidiomycete cell is selected from the order 0583. 234. The bioactive agent according to item 216, of Agaricales. wherein Basidiomycete cell is selected from the family of 0565 216. The bioactive agent according to item 215, Phelloriniaceae. wherein said Basidiomycete cell belongs to a family 0584) 235. The bioactive agent according to item 216, selected from the group consisting of Agaricaceae, Bolbi wherein Basidiomycete cell is selected from the family of tiaceae, Broomeiaceae, Clavariaceae, Coprinaceae, Corti Pleurotaceae. nariaceae, Entolomataceae, Fistulinaceae, Gigasper 0585 236. The bioactive agent according to item 216, maceae, Hemigasteraceae, Hydnangiaceae, wherein Basidiomycete cell is selected from the family of Lycoperdaceae, Marasmiaceae, Mesopheliaceae, Myce Pluteaceae. nastraceae, Niaceae, Nidulariaceae, Phelloriniaceae, Pleu 0586. 237. The bioactive agent according to item 216, rotaceae, Pluteaceae, Pterulaceae, Schizophyllaceae, Stro wherein Basidiomycete cell is selected from the family of matocyphaceae, Strophariaceae, Tricholomataceae, Pterulaceae. Tulostomataceae. Typhulaceae and Xerulaceae. 0587. 238. The bioactive agent according to item 216, 0566 217. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Schizophyllaceae. Agaricaceae. 0588 239. The bioactive agent according to item 216, 0567 218. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Stromatocyphaceae. Bolbitiaceae. 0589 240. The bioactive agent according to item 216, 0568. 219. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Strophariaceae. Broomeiaceae. 0590 241. The bioactive agent according to item 216, 0569. 220. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Tricholomataceae. Clavariaceae. 0591 242. The bioactive agent according to item 216, 0570) 221. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Tulostomataceae. Coprinaceae. 0592 243. The bioactive agent according to item 216, 0571) 222. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Typhulaceae. Cortinariaceae. 0593. 244. The bioactive agent according to item 216, 0572 223. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Xerulaceae. Entolomataceae. 0594. 245. The bioactive agent according to item 214, 0573 224. The bioactive agent according to item 216, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Polyporales. Fistulinaceae. 0595 246. The bioactive agent according to item 245, 0574) 225. The bioactive agent according to item 216, wherein said Basidiomycete cell belongs to a family wherein Basidiomycete cell is selected from the family of selected from the group consisting of Albatrellaceae, Athe Gigaspermaceae. liaceae, Boreostereaceae, Corticiaceae, Cyphellaceae, US 2009/O 143280 A1 Jun. 4, 2009 27

Cystostereaceae, Epitheliaceae, Fomitopsidaceae, Gano 0615. 266. The bioactive agent according to item 246, dermataceae, Gloeophyllaceae, Grammotheleaceae, wherein Basidiomycete cell is selected from the family of Hapalopillaceae, Hyphodermataceae, Meripilaceae, Mer Sparassidaceae. uliaceae, Phanerochaetaceae, Podoscyphaceae, Polypora 0616 267. The bioactive agent according to item 246, ceae, Sistotremataceae, Sparassidaceae, Steccherinaceae, wherein Basidiomycete cell is selected from the family of Tubulicrinaceae and Xenasmataceae. Steccherinaceae. 0596 247. The bioactive agent according to item 246, 0617) 268. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Albatrellaceae. Tubulicrinaceae. 0597 248. The bioactive agent according to item 246, 0618. 269. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Atheliaceae. Xenasmataceae. 0598 249. The bioactive agent according to item 246, 0619 270. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Boreostereaceae. of Boletales. 0599 250. The bioactive agent according to item 246, 0620) 271. The bioactive agent according to item 270, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Corticiaceae. selected from the group consisting of Boletaceae, Boleti 0600 251. The bioactive agent according to item 246, nellaceae, Coniophoraceae, Diplocystaceae, Gasterel wherein Basidiomycete cell is selected from the family of laceae, Gastrosporiaceae, Gomphidiaceae, Gyroporaceae, Cyphellaceae. Hygrophoropsidaceae, Hymenogasteraceae, Leucogas 0601. 252. The bioactive agent according to item 246, traceae, Melanogastraceae, Octavianiaceae, Octaviani wherein Basidiomycete cell is selected from the family of naceae, Paxillaceae, Protogastraceae, Rhizopogonaceae, Cystostereaceae. Sclerodermataceae and Suillaceae. 0602 253. The bioactive agent according to item 246, 0621. 272. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Epitheliaceae. Boletaceae. 0603 254. The bioactive agent according to item 246, 0622 273. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Fomitopsidaceae. Boletinellaceae. 0604) 255. The bioactive agent according to item 246, 0623, 274. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Ganodermataceae. Coniophoraceae. 0605 256. The bioactive agent according to item 246, 0624, 275. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Gloeophyllaceae. Diplocystaceae. 0606. 257. The bioactive agent according to item 246, 0625 276. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Grammotheleaceae. Gasterellaceae. 0607 258. The bioactive agent according to item 246, 0626 277. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hapalopillaceae. Gastrosporiaceae. 0608) 259. The bioactive agent according to item 246, 0627 278. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hyphodermataceae. Gomphidiaceae. 0609. 260. The bioactive agent according to item 246, 0628 279. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Meripilaceae. Gyroporaceae. 0610 261. The bioactive agent according to item 246, 0629 280. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Meruliaceae. Hygrophoropsidaceae. 0611) 262. The bioactive agent according to item 246, 0630) 281. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Phanerochaetaceae. Hymenogasteraceae. 0612 263. The bioactive agent according to item 246, 0631 282. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Podoscyphaceae. Leucogastraceae. 0613 264. The bioactive agent according to item 246, 0632 283. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Polyporaceae. Melanogastraceae. 0614, 265. The bioactive agent according to item 246, 0633 284. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Sistotremataceae. Octavianiaceae. US 2009/O 143280 A1 Jun. 4, 2009 28

0634. 285. The bioactive agent according to item 271, 0654) 305. The bioactive agent according to item 303, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Octavianinaceae. Dacrymycetaceae. 0635 286. The bioactive agent according to item 271, 0655 306. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Paxillaceae. of Hymenochaetales. 0636 287. The bioactive agent according to item 271, 0656 307. The bioactive agent according to item 306, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Protogastraceae. selected from the group consisting of Asterostromataceae, 0637 288. The bioactive agent according to item 271, Hymenochaetaceae and Schizoporaceae. wherein Basidiomycete cell is selected from the family of 0657. 308. The bioactive agent according to item 307, Rhizopogonaceae. wherein Basidiomycete cell is selected from the family of 0638 289. The bioactive agent according to item 271, Asterostromataceae. wherein Basidiomycete cell is selected from the family of 0658 309. The bioactive agent according to item 307, Sclerodermataceae. wherein Basidiomycete cell is selected from the family of 0639. 290. The bioactive agent according to item 271, Hymenochaetaceae. wherein Basidiomycete cell is selected from the family of 0659) 310. The bioactive agent according to item 307, Suillaceae. wherein Basidiomycete cell is selected from the family of 0640 291. The bioactive agent according to item 214, Schizoporaceae. wherein the Basidiomycete cell is selected from the order of Cantheralles. 0660 311. The bioactive agent according to item 214, 0641) 292. The bioactive agent according to item 291, wherein the Basidiomycete cell is selected from the order wherein said Basidiomycete cell belongs to a family of Phallales. Selected from the group consisting of Aphelariaceae, Bot 0661 312. The bioactive agent according to item 311, ryobasidiaceae, Cantharellaceae, Clavulinaceae, and Hyd wherein said Basidiomycete cell belongs to a family aCCaC. selected from the group consisting of Geastraceae, Gom 0642 293. The bioactive agent according to item 271, phaceae, Hysterangiaceae, Phallaceae and Ramariaceae. wherein Basidiomycete cell is selected from the family of 0662. 313. The bioactive agent according to item 312, Aphelariaceae. wherein Basidiomycete cell is selected from the family of 0643 294. The bioactive agent according to item 271, Geastraceae. wherein Basidiomycete cell is selected from the family of 0663 314. The bioactive agent according to item 312, Botryobasidiaceae. wherein Basidiomycete cell is selected from the family of 0644 295. The bioactive agent according to item 271, Gomphaceae. wherein Basidiomycete cell is selected from the family of 0664 3.15. The bioactive agent according to item 312, Cantharellaceae. wherein Basidiomycete cell is selected from the family of 0645 296. The bioactive agent according to item 271, Hysterangiaceae. wherein Basidiomycete cell is selected from the family of 0665 316. The bioactive agent according to item 312, Clavulinaceae. wherein Basidiomycete cell is selected from the family of 0646 297. The bioactive agent according to item 271, Phallaceae. wherein Basidiomycete cell is selected from the family of 0.666 317. The bioactive agent according to item 312, Hydnaceae. wherein Basidiomycete cell is selected from the family of 0647. 298. The bioactive agent according to item 214, Ramariaceae. wherein the Basidiomycete cell is selected from the order 0667 318. The bioactive agent according to item 214, of Ceratobasidiales. wherein the Basidiomycete cell is selected from the order 0648. 299. The bioactive agent according to item 298, of Poriales. wherein said Basidiomycete cell belongs to a family 0668) 319. The bioactive agent according to item 318, Selected from the group consisting of Ceratobasidiaceae wherein said Basidiomycete cell belongs to a family of and Oliveoniaceae. Polyporaceae. 0649) 300. The bioactive agent according to item 299, 0669 320. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Ceratobasidiaceae. of Russulales. 0650) 301. The bioactive agent according to item 299, 0670 321. The bioactive agent according to item 320, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Oliveoniaceae. selected from the group consisting of Auriscalpiaceae, 0651 302. The bioactive agent according to item 214, Bondarzewiaceae, Echinodontiaceae, Hericiaceae, Hybo wherein the Basidiomycete cell is selected from the order gasteraceae, Lachnocladiaceae, Peniophoraceae, Phanero of Dacrymycetales. chaetaceae, Russulaceae, Stephanosporaceae and 0652 303. The bioactive agent according to item 302, Stereaceae. wherein said Basidiomycete cell belongs to a family 0671 322. The bioactive agent according to item 321, Selected from the group consisting of Cerinomycetaceae wherein Basidiomycete cell is selected from the family of and Dacrymycetaceae. Auriscalpiaceae. 0653. 304. The bioactive agent according to item 303, 0672 323. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Cerinomycetaceae. Bondarzewiaceae. US 2009/O 143280 A1 Jun. 4, 2009 29

0673 324. The bioactive agent according to item 321, 0694 345. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Echinodontiaceae. of Tremellales. 0674) 325. The bioactive agent according to item 321, 0695 346. The bioactive agent according to item 345, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Hericiaceae. selected from the group consisting of Aporpiaceae, Cuni 0675 326. The bioactive agent according to item 321, culitremaceae, Exidiaceae, Hyaloriaceae, Phragmoxenidi wherein Basidiomycete cell is selected from the family of aceae, Rhynchogastremataceae, Sirobasidiaceae, SyZy Hybogasteraceae. gosporaceae, Tetragoniomycetaceae, Tremellaceae and 0676 327. The bioactive agent according to item 321, Tremellodendropsidaceae. wherein Basidiomycete cell is selected from the family of 0696 347. The bioactive agent according to item 346, Lachnocladiaceae. wherein Basidiomycete cell is selected from the family of 0677 328. The bioactive agent according to item 321, Aporpiaceae. wherein Basidiomycete cell is selected from the family of 0697 348. The bioactive agent according to item 346, Peniophoraceae. wherein Basidiomycete cell is selected from the family of 0678 329. The bioactive agent according to item 321, Cuniculitremaceae. wherein Basidiomycete cell is selected from the family of 0698 349. The bioactive agent according to item 346, Phanerochaetaceae. wherein Basidiomycete cell is selected from the family of 0679) 330. The bioactive agent according to item 321, Exidiaceae. wherein Basidiomycete cell is selected from the family of 0699 350. The bioactive agent according to item 346, Russulaceae. wherein Basidiomycete cell is selected from the family of 0680 331. The bioactive agent according to item 321, Hyaloriaceae. wherein Basidiomycete cell is selected from the family of 0700 351. The bioactive agent according to item 346, Stephanosporaceae. wherein Basidiomycete cell is selected from the family of 0681 332. The bioactive agent according to item 321, Phragmoxenidiaceae. wherein Basidiomycete cell is selected from the family of 0701 352. The bioactive agent according to item 346, Stereaceae. wherein Basidiomycete cell is selected from the family of 0682 333. The bioactive agent according to item 214, Rhynchogastremataceae. wherein the Basidiomycete cell is selected from the order (0702 353. The bioactive agent according to item 346, of Thelophorales. wherein Basidiomycete cell is selected from the family of 0683 334. The bioactive agent according to item 333, Sirobasidiaceae. wherein said Basidiomycete cell belongs to a family 0703 354. The bioactive agent according to item 346, Selected from the group consisting of Bankeraceae and wherein Basidiomycete cell is selected from the family of Thelephoraceae. Syzygosporaceae. 0684 335. The bioactive agent according to item 334, 0704 355. The bioactive agent according to item 346, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Bankeraceae. Tetragoniomycetaceae. 0685 336. The bioactive agent according to item 334, 0705 356. The bioactive agent according to item 346, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Thelephoraceae. Tremellaceae. 0686 337. The bioactive agent according to item 214, 0706 357. The bioactive agent according to item 346, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Auriculariales. Tremellodendropsidaceae. 0687 338. The bioactive agent according to item 337, 0707 358. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Auriculariaceae. of Tulasenellales. 0688 339. The bioactive agent according to item 214, (0708 359. The bioactive agent according to item 358, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Christianseniales. Tulasnellaceae. 0689 340. The bioactive agent according to item 339, 0709 360. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Christianseniaceae. of Urocystales. 0690 341. The bioactive agent according to item 214, 0710) 361. The bioactive agent according to item 360, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Cystofilobasidiales. Urocystaceae. 0691 342. The bioactive agent according to item 341, 0711 362. The bioactive agent according to item 217, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a genus Cystofilobasidiaceae. selected from the group consisting of Agaricus, Amanita, 0692 343. The bioactive agent according to item 214, Amylolepiota, Araneosa, Artymenium, Attamyces, Barche wherein the Basidiomycete cell is selected from the order ria, Cauloglossum, Chainoderma, Chamaenyces, Chito of Filobasidiales. nia, Chitoniella, Chitonis, Chlorolepiota, Chlorophyllum, 0693) 344. The bioactive agent according to item 343, Chlorosperma, Chlorospora, Clarkeinda, Clavogaster, wherein Basidiomycete cell is selected from the family of Coccobotrys, Crucispora, Cystoagaricus, Cystolepiota, Filobasidiaceae. Drosella, Endolepiotula, Fungus, Fusispora, Gasterellop US 2009/O 143280 A1 Jun. 4, 2009 30

sis, Glaucospora, Gymnogaster, Gyrophragmium, Heine 0728 379. The bioactive agent according to item 362, mannomyces, Herculea, Hiatulopsis, Holocotylon, wherein Basidiomycete cell is selected from the genus of Horakia, Hymenagaricus, Hypogaea, Hypophyllum, Lepi Chlorospora. dotus, Lepiotella, Lepiotula, Leucoagaricus, Leucobolbi 0729) 380. The bioactive agent according to item 362, tius, Leucocoprinus, Longia, Longula, Macrolepiota, wherein Basidiomycete cell is selected from the genus of Mastocephalus, Melanophylium, Metraria, Metrodia, Clarkeinda. Micropsalliota, Montagnea, Montagnites, Morobia, 0730 381. The bioactive agent according to item 362, Myces, Neosecotium, Notholepiota, Panaeolopsis, wherein Basidiomycete cell is selected from the genus of Phaeopholiota, Phlebonema, Phyllogaster, Podaxis, Poly Clavogaster. plocium, Pseudoauricularia, Pulverolepiota, Rickella, 0731 382. The bioactive agent according to item 362, Rugosospora, Schinzinia, Schulzeria, Schweinitzia, Seco wherein Basidiomycete cell is selected from the genus of tium, Sericeomyces, Singerina, Smithiogaster; Smithiomy Coccobotrys. ces, Stellifera, Termiticola, Verrucospora, Volvigerum, Vol 0732 383. The bioactive agent according to item 362, volepiota and Xanthagaricus. wherein Basidiomycete cell is selected from the genus of 0712 363. The bioactive agent according to item 362, Crucispora. wherein Basidiomycete cell is selected from the genus of 0733 384. The bioactive agent according to item 362, Agaricus. wherein Basidiomycete cell is selected from the genus of 0713 364. The bioactive agent according to item 362, Cystoagaricus. wherein Basidiomycete cell is selected from the genus of 0734 385. The bioactive agent according to item 362, Amanita. wherein Basidiomycete cell is selected from the genus of 0714 365. The bioactive agent according to item 362, Cystolepiota. wherein Basidiomycete cell is selected from the genus of 0735. 386. The bioactive agent according to item 362, Amylolepiota. wherein Basidiomycete cell is selected from the genus of 0715 366. The bioactive agent according to item 362, Drosella. wherein Basidiomycete cell is selected from the genus of 0736. 387. The bioactive agent according to item 362, Araneosa. wherein Basidiomycete cell is selected from the genus of 0716 367. The bioactive agent according to item 362, Endolepiotula. wherein Basidiomycete cell is selected from the genus of 0737 388. The bioactive agent according to item 362, Artymenium. wherein Basidiomycete cell is selected from the genus of 0717 368. The bioactive agent according to item 362, Fungus. wherein Basidiomycete cell is selected from the genus of 0738 389. The bioactive agent according to item 362, Attamyces. wherein Basidiomycete cell is selected from the genus of 0718 369. The bioactive agent according to item 362, Fusispora. wherein Basidiomycete cell is selected from the genus of (0739 390. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of Barcheria. Gasterellopsis. 0719. 370. The bioactive agent according to item 362, 0740. 391. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cauloglossum. Glaucospora. 0720 371. The bioactive agent according to item 362, 0741 392. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chainoderma. Gymnogaster: 0721 372. The bioactive agent according to item 362, 0742 393. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chamaenyces. Gyrophragmium. 0722 373. The bioactive agent according to item 362, 0743) 394. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chitonia. Heinemannomyces. 0723 374. The bioactive agent according to item 362, 0744 395. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chitoniella. Herculea. 0724 375. The bioactive agent according to item 362, 0745 396. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chitonis. Hiatulopsis. 0725 376. The bioactive agent according to item 362, 0746. 397. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chlorolepiota. Holocotylon. 0726) 377. The bioactive agent according to item 362, 0747 398. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chlorophyllum. Horakia. 0727 378. The bioactive agent according to item 362, 0748 399. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chlorosperma. Hymenagaricus. US 2009/O 143280 A1 Jun. 4, 2009

0749 400. The bioactive agent according to item 362, 0770 421. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypogaea. Notholepiota. 0750 401. The bioactive agent according to item 362, 0771 422. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypophyllum. Panaeolopsis. 0751 402. The bioactive agent according to item 362, 0772 423. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepidotus. Phaeopholiota. 0752 403. The bioactive agent according to item 362, 0773) 424. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepiotella. Phlebonema. 0753. 404. The bioactive agent according to item 362, 0774 425. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepiotula. Phyllogaster: 0754 405. The bioactive agent according to item 362, 0775 426. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucoagaricus. Podaxis. 0755 406. The bioactive agent according to item 362, 0776 427. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucobolbitius. Polyplocium. 0756 407. The bioactive agent according to item 362, 0777 428. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucocoprinus. Pseudoauricularia. 0757 408. The bioactive agent according to item 362, 0778 429. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of LOngia. Pulverolepiota. 0758 409. The bioactive agent according to item 362, (0779 430. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Longula. Rickella. 0759 410. The bioactive agent according to item 362, 0780. 431. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Macrolepiota. RugOSOspora. 0760 411. The bioactive agent according to item 362, 0781 432. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mastocephalus. Schinzinia. 0761 412. The bioactive agent according to item 362, 0782) 433. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Melanophyllum. Schulzeria. 0762. 413. The bioactive agent according to item 362, 0783) 434. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Metraria. Schweinitzia. 0763 414. The bioactive agent according to item 362, 0784 435. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Metrodia. Secotium. 0764 415. The bioactive agent according to item 362, 0785 436. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Micropsalliota. Sericeomyces. 0765) 416. The bioactive agent according to item 362, 0786 437. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Montagnea. Singerina. 0766 417. The bioactive agent according to item 362, 0787 438. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Montagnites. Smithiogaster. 0767 418. The bioactive agent according to item 362, 0788) 439. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Morobia. Smithiomyces. 0768 419. The bioactive agent according to item 362, 0789 440. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myces. Stellifera. 0769 420. The bioactive agent according to item 362, 0790 441. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of NeoSecotium. Termiticola. US 2009/O 143280 A1 Jun. 4, 2009 32

0791) 442. The bioactive agent according to item 362, 0808 459. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Verrucospora. Cyclocybe. 0792 443. The bioactive agent according to item 362, 0809 460. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Volvigerum. Cyclopus. 0793 444. The bioactive agent according to item 362, 0810) 461. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Volvolepiota. Cyphellopus. 0794. 445. The bioactive agent according to item 362, 08.11 462. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xanthagaricus. Cyttarophyllopsis. 0795. 446. The bioactive agent according to item 218, 0812 463. The bioactive agent according to item 446, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Acetabularia, Agro Cyttarophyllum. cybe, Agrogaster, Alnicola, Anellaria, Bolbitius, Bulla, 0813 464. The bioactive agent according to item 446, Campanularius, Chalymnota, Conocybe, Copelandia, wherein Basidiomycete cell is selected from the genus of Coprimarius, Cyclocybe, Cyclopus, Cyphellopus, Cyttaro Galerella. phyllopsis, Cyttarophyllum, Galerella, Galeropsis, Gas 0814. 465. The bioactive agent according to item 446, trocybe, Gymnoglossum, Hebelona, Hebelomatis, Hvlo wherein Basidiomycete cell is selected from the genus of phila, Myxocybe, Naucoria, Panaeolina, Panaeolus, Galeropsis. Pholiotella, Pholiotina, Picromyces, Pluteolus, Psammo 0815) 466. The bioactive agent according to item 446, myces, Pseudoconocybe, Pseudodeconica, Ptychella, wherein Basidiomycete cell is selected from the genus of Raddetes, Roumeguerites, Sarcoloma, Setchelliogaster; Gastrocybe. Togaria, Tubariella, Tubariopsis, Tvmpanella and 0816 467. The bioactive agent according to item 446, Wielandomyces. wherein Basidiomycete cell is selected from the genus of 0796 447. The bioactive agent according to item 446, Gymnoglossum. wherein Basidiomycete cell is selected from the genus of 0817. 468. The bioactive agent according to item 446, Acetabularia. wherein Basidiomycete cell is selected from the genus of 0797. 448. The bioactive agent according to item 446, Hebelona. wherein Basidiomycete cell is selected from the genus of 0818 469. The bioactive agent according to item 446, Agrocybe. wherein Basidiomycete cell is selected from the genus of 0798. 449. The bioactive agent according to item 446, Hebelomatis. wherein Basidiomycete cell is selected from the genus of 0819 470. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of Agrogaster: Hylophila. 0799 450. The bioactive agent according to item 446, 0820 471. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Alnicola. Myxocybe. 0800 451. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of 0821 472. The bioactive agent according to item 446, Anellaria. wherein Basidiomycete cell is selected from the genus of Naucoria. 0801 452. The bioactive agent according to item 446, 0822 473. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bolbitius. Panaeolina. 0802) 453. The bioactive agent according to item 446, 0823 474. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bulla. Panaeolus. 0803 454. The bioactive agent according to item 446, 0824. 475. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Campanularius. Pholiotella. 0804 455. The bioactive agent according to item 446, 0825 476. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chalymnota. Pholiotina. 0805 456. The bioactive agent according to item 446, 0826 477. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Conocybe. Picromyces. 0806 457. The bioactive agent according to item 446, 0827 478. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Copelandia. Pluteolus. 0807 458. The bioactive agent according to item 446, 0828 479. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprimarius. Psammomyces. US 2009/O 143280 A1 Jun. 4, 2009

0829 480. The bioactive agent according to item 446, 0849 500. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoconocybe. Macrotyphula. 0830 481. The bioactive agent according to item 446, 0850. 501. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudodeconica. Manina. 0831 482. The bioactive agent according to item 446, 0851 502. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ptychella. Multiclavula. 0832 483. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of 0852 503. The bioactive agent according to item 493, Raddetes. wherein Basidiomycete cell is selected from the genus of 0833 484. The bioactive agent according to item 446, Podostrombium. wherein Basidiomycete cell is selected from the genus of 0853) 504. The bioactive agent according to item 493, Roumeguerites. wherein Basidiomycete cell is selected from the genus of 0834 485. The bioactive agent according to item 446, Ramaria. wherein Basidiomycete cell is selected from the genus of 0854 505. The bioactive agent according to item 493, Sarcoloma. wherein Basidiomycete cell is selected from the genus of 0835 486. The bioactive agent according to item 446, Ramariopsis. wherein Basidiomycete cell is selected from the genus of 0855 506. The bioactive agent according to item 493, Setchelliogaster. wherein Basidiomycete cell is selected from the genus of 0836) 487. The bioactive agent according to item 446, Scytinopogon. wherein Basidiomycete cell is selected from the genus of 0856) 507. The bioactive agent according to item 493, Togaria. wherein Basidiomycete cell is selected from the genus of 0837 488. The bioactive agent according to item 446, Setigeroclavula. wherein Basidiomycete cell is selected from the genus of 0857 508. The bioactive agent according to item 493, Tubariella. wherein Basidiomycete cell is selected from the genus of 0838 489. The bioactive agent according to item 446, Stichoclavaria. wherein Basidiomycete cell is selected from the genus of 0858 509. The bioactive agent according to item 221, Tubariopsis. wherein said Basidiomycete cell belongs to a genus 0839 490. The bioactive agent according to item 446, selected from the group consisting of Annularius, Asty wherein Basidiomycete cell is selected from the genus of lospora, Coprinellus, Coprinopsis, Coprinus, Copri Timpanella. nusella, Cortiniopsis, Drosophila, Ephemerocybe, Gas 0840 491. The bioactive agent according to item 446, teroagaricoides, Glyptospora, Gymnochilus, Homophron, wherein Basidiomycete cell is selected from the genus of Hypholomopsis, Lacrymaria, Lentispora, Macrometriula, Wielandomyces. Onchopus, Palaeocybe, Pannucia, Parasola, Pluteopsis, 0841 492. The bioactive agent according to item 219, Psalliotina, Psammocoparius, Psathyra, Psathyrella, wherein Basidiomycete cell is selected from the genus of Pselliophora, Pseudocoprinus, Psilocybe, Rhacophyllus, Broomeia. Xerocoprinus and Zerovaenyces. 0842) 493. The bioactive agent according to item 220, 0859 510. The bioactive agent according to item 509, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Capitoclavaria, Cla Annularius. varia, Clavulinopsis, Cornicularia, Donkella, Holoc 0860 511. The bioactive agent according to item 509, Oryne, Macrotyphula, Manina, Multiclavula, Podostrom wherein Basidiomycete cell is selected from the genus of bium, Ramaria, Ramariopsis, Scytinopogon, Astylospora. Setigeroclavula and Stichoclavaria. 0843. 494. The bioactive agent according to item 493, 0861 512. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Capitoclavaria. Coprinellus. 0844. 495. The bioactive agent according to item 493, 0862 513. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clavaria. Coprinopsis. 0845 496. The bioactive agent according to item 493, 0863 514. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clavulinopsis. Coprinus. 0846 497. The bioactive agent according to item 493, 0864) 515. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cornicularia. Coprinusella. 0847 498. The bioactive agent according to item 493, 0865 516. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Donkella. Cortiniopsis. 0848 499. The bioactive agent according to item 493, 0866 517. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Holocoryne. Drosophila. US 2009/O 143280 A1 Jun. 4, 2009 34

0867. 518. The bioactive agent according to item 509, 0888 539. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ephemerocybe. Rhacophyllus. 0868 519. The bioactive agent according to item 509, 0889 540. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gasteroagaricoides. Xerocoprinus. 0869 520. The bioactive agent according to item 509, 0890. 541. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Glyptospora. Zerovaemyces. 0870) 521. The bioactive agent according to item 509, 0891 542. The bioactive agent according to item 222, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Gymnochilus. selected from the group consisting of Agmocybe, Anamika, 0871 522. The bioactive agent according to item 509, Aroramyces, Astrosporina, Bulbopodium, Calathinus, wherein Basidiomycete cell is selected from the genus of Cereicium, Chromocyphella, Clypeus, Cortinarius, Crepi Homophron. dotus, Cribbea, Cuphocybe, Cyanicium, Cymbella, 0872 523. The bioactive agent according to item 509, Cyphellathelia, Cystocybe, Dermocybe, Descolea, Doch wherein Basidiomycete cell is selected from the genus of miopus, Epicorticium, Episphaeria, Flammulaster, Floc Hypholomopsis. culina, Fulvidula, Galera, Galerina, Galerula, Gomphos, 0873. 524. The bioactive agent according to item 509, Gymnopilus, Hebelomina, Horakomyces, Hydrocybe, wherein Basidiomycete cell is selected from the genus of Hydrocybium, Hydrotelamonia, Hygramaricium, Lacrymaria. Hygromyxacium, Inocibium, Inocybe, Inocybella, Ino 0874) 525. The bioactive agent according to item 509, loma, Kjeldsenia, Leucocortinarius, Leucopus, Locellina, wherein Basidiomycete cell is selected from the genus of Mackintoshia, Marasmiopsis, Melanomphalia, Meli Lentispora. derma, Mycolevis, Myxacium, Myxopholis, Nanstelo 0875 526. The bioactive agent according to item 509, cephala, Octojuga, Pellidiscus, Phaeocarpus, Phaeocolly wherein Basidiomycete cell is selected from the genus of bia, Phaeocyphella, Phaeogalera, Phaeoglabrotricha, Macrometrula. Phaeomarasmius, Phaeosolenia, Phialocybe, Phleg 0876 527. The bioactive agent according to item 509, macium, Pholidotopsis, Pleurotellus, PseudodesCollea, wherein Basidiomycete cell is selected from the genus of Pseudogymnopilus, Pyrrhoglossum, Quercella, Ramicola, Onchopus. Rapacea, Raphanozon, Rozites, Sericeocybe, Simocybe, 0877 528. The bioactive agent according to item 509, Sphaerotrachys, Squamaphlegma, Stagnicola, Stephano wherein Basidiomycete cell is selected from the genus of pus, Telamonia, Thaxterogaster; Tremellastrum, Tremel Palaeocybe. lopsis, Tubaria, Velomycena and Weinzettlia. 0878) 529. The bioactive agent according to item 509, 0892 543. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pannucia. Agmocybe. 0879 530. The bioactive agent according to item 509, 0893 544. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parasola. Anamika. 0880. 531. The bioactive agent according to item 509, 0894 545. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pluteopsis. Aroramyces. 0881. 532. The bioactive agent according to item 509, 0895 546. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psalliotina. Astrosporina. 0882 533. The bioactive agent according to item 509, 0896 547. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psammocoparius. Bulbopodium. 0883 534. The bioactive agent according to item 509, 0897 548. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psathyra. Calathinus. 0884. 535. The bioactive agent according to item 509, 0898 549. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psathyrella. Cereicium. 0885 536. The bioactive agent according to item 509, (0899 550. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pselliophora. Chromocyphella. 0886 537. The bioactive agent according to item 509, 0900 551. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudocoprinus. Clypeus. 0887 538. The bioactive agent according to item 509, 0901) 552. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psilocybe. Cortinarius. US 2009/O 143280 A1 Jun. 4, 2009

0902 553. The bioactive agent according to item 542, 0923 574. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crepidotus. Horakomyces. 0903 554. The bioactive agent according to item 542, 0924 575. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cribbea. Hydrocybe. 0904. 555. The bioactive agent according to item 542, 0925 576. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cuphocybe. Hydrocybium. 0905 556. The bioactive agent according to item 542, 0926 577. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyanicium. Hydrotelamonia. 0906 557. The bioactive agent according to item 542, 0927. 578. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cymbella. Hygramaricium. (0907 558. The bioactive agent according to item 542, 0928 579. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellathelia. Hygromyxacium. 0908 559. The bioactive agent according to item 542, 0929. 580. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystocybe. Inocibium. (0909 560. The bioactive agent according to item 542, 0930) 581. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dermocybe. Inocybe. 0910 561. The bioactive agent according to item 542, 0931 582. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Descolea. Inocybella. 0911 562. The bioactive agent according to item 542, 0932 583. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dochimiopus. Inoloma. 0912 563. The bioactive agent according to item 542, 0933 584. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epicorticium. Kjeldsenia. 0913 564. The bioactive agent according to item 542, 0934 585. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Episphaeria. Leucocortinarius. 0914 565. The bioactive agent according to item 542, 0935 586. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammulaster: Leucopus. 0915 566. The bioactive agent according to item 542, 0936 587. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flocculina. Locellina. 0916 567. The bioactive agent according to item 542, 0937) 588. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fulvidula. Mackintoshia. 0917 568. The bioactive agent according to item 542, 0938 589. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galera. Marasmiopsis. 0918. 569. The bioactive agent according to item 542, 0939 590. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galerina. Melanomphalia. (0919. 570. The bioactive agent according to item 542, 0940 591. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galerula. Meliderma. 0920) 571. The bioactive agent according to item 542, 0941 592. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gomphos. Mycolevis. 0921 572. The bioactive agent according to item 542, 0942. 593. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gymnopilus. Myxacium. 0922 573. The bioactive agent according to item 542, 0943 594. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hebelomina. Myxopholis. US 2009/O 143280 A1 Jun. 4, 2009 36

0944 595. The bioactive agent according to item 542, 0965 616. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nanstelocephala. Rozites. 0945. 596. The bioactive agent according to item 542, 0966 617. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Octojuga. Sericeocybe. 0946 597. The bioactive agent according to item 542, 0967 618. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pellidiscus. Simocybe. 0947 598. The bioactive agent according to item 542, 0968 619. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocarpus. Sphaerotrachys. 0948 599. The bioactive agent according to item 542, 0969 620. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocollybia. Squamaphlegma. 0949 600. The bioactive agent according to item 542, 0970) 621. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocyphella. Stagnicola. 0950 601. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of 0971 622. The bioactive agent according to item 542, Phaeogalera. wherein Basidiomycete cell is selected from the genus of 0951 602. The bioactive agent according to item 542, Stephanopus. wherein Basidiomycete cell is selected from the genus of 0972 623. The bioactive agent according to item 542, Phaeoglabrotricha. wherein Basidiomycete cell is selected from the genus of 0952 603. The bioactive agent according to item 542, Telamonia. wherein Basidiomycete cell is selected from the genus of 0973 624. The bioactive agent according to item 542, Phaeomarasmius. wherein Basidiomycete cell is selected from the genus of 0953. 604. The bioactive agent according to item 542, Thaxterogaster. wherein Basidiomycete cell is selected from the genus of 0974 625. The bioactive agent according to item 542, Phaeosolenia. wherein Basidiomycete cell is selected from the genus of 0954 605. The bioactive agent according to item 542, Tremellastrum. wherein Basidiomycete cell is selected from the genus of 0975 626. The bioactive agent according to item 542, Phialocybe. wherein Basidiomycete cell is selected from the genus of 0955 606. The bioactive agent according to item 542, Tremellopsis. wherein Basidiomycete cell is selected from the genus of 0976 627. The bioactive agent according to item 542, Phlegmacium. wherein Basidiomycete cell is selected from the genus of 0956 607. The bioactive agent according to item 542, Tubaria. wherein Basidiomycete cell is selected from the genus of 0977. 628. The bioactive agent according to item 542, Pholidotopsis. wherein Basidiomycete cell is selected from the genus of 0957 608. The bioactive agent according to item 542, Velomycena. wherein Basidiomycete cell is selected from the genus of 0978) 629. The bioactive agent according to item 542, Pleurotellus. wherein Basidiomycete cell is selected from the genus of 0958 609. The bioactive agent according to item 542, Weinzettlia. wherein Basidiomycete cell is selected from the genus of 0979 630. The bioactive agent according to item 223, PseudodesCollea. wherein said Basidiomycete cell belongs to a genus 0959 610. The bioactive agent according to item 542, selected from the group consisting of Alboleptonia, Areni wherein Basidiomycete cell is selected from the genus of cola, Calliderma, Claudopus, Clitopiloidea, Clitopilopsis, Pseudogymnopilus. Clitopilus, Eccilia, Entoloma, Fibropilus, Hexaiuga, Hir 0960 611. The bioactive agent according to item 542, neola, Inocephalus, Inopilus, Lanolea, Latzinaea, Lepto wherein Basidiomycete cell is selected from the genus of nia, Leptoniella, Nigropogon, Nolanea, Omphaliopsis, Pyrrhoglossum. Orcella, Paraeccilia, Paraleptonia, Paxillopsis, Pouza 0961 612. The bioactive agent according to item 542, rella, Pouzaromyces, Rhodocybe, Rhodocybella, Rhodo wherein Basidiomycete cell is selected from the genus of gaster, Rhodophana, Rhodophyllus, Richoniella and Tri Quercella. chopilus. 0962. 613. The bioactive agent according to item 542, 0980 631. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ramicola. Alboleptonia. 0963 614. The bioactive agent according to item 542, 0981 632. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rapacea. Arenicola. 0964 615. The bioactive agent according to item 542, 0982) 633. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Raphanozon. Calliderma. US 2009/O 143280 A1 Jun. 4, 2009 37

0983 634. The bioactive agent according to item 630, 1004 655. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Claudopus. Paxillopsis. 0984 635. The bioactive agent according to item 630, 1005 656. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clitopiloidea. Pouzarella. 0985 636. The bioactive agent according to item 630, 1006 657. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clitopilopsis. Pouzaromyces. 0986 637. The bioactive agent according to item 630, 1007 658. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clitopilus. Rhodocybe. 0987. 638. The bioactive agent according to item 630, 1008 659. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Eccilia. Rhodocybella. 0988 639. The bioactive agent according to item 630, 1009 660. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Entoloma. Rhodogaster: 0989 640. The bioactive agent according to item 630, 1010) 661. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fibropilus. Rhodophana. 0990) 641. The bioactive agent according to item 630, 1011 662. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hexajuga. Rhodophyllus. 0991) 642. The bioactive agent according to item 630, 1012) 663. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hirneola. Richoniella. 0992) 643. The bioactive agent according to item 630, 1013 664. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Inocephalus. Trichopilus. 0993 644. The bioactive agent according to item 630, 1014 665. The bioactive agent according to item 224, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Inopilus. selected from the group consisting of Agarico-carnis, 0994) 645. The bioactive agent according to item 630, Buglossus, Confistulina, Fistulina, Hypodrys and Pseud wherein Basidiomycete cell is selected from the genus of ofistulina. Lanolea. 1015 666. The bioactive agent according to item 665, 0995 646. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agarico-carnis. Latzinaea. 1016 667. The bioactive agent according to item 665, 0996 647. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Buglossus. Leptonia. 1017 668. The bioactive agent according to item 665, 0997 648. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Confistulina. Leptoniella. 1018) 669. The bioactive agent according to item 665, 0998 649. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fistulina. Nigropogon. 1019 670. The bioactive agent according to item 665, 0999 650. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypodrys. Nolanea. 1020 671. The bioactive agent according to item 665, 1000 651. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudofistulina. Omphaliopsis. 1021 672. The bioactive agent according to item 225, 1001 652. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gigasperma. Orcella. 1022 673. The bioactive agent according to item 226, 1002 653. The bioactive agent according to item 630, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemigaster. Paraeccilia. 1023 674. The bioactive agent according to item 227, 1003 654. The bioactive agent according to item 630, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Hydmangium, Lac Paraleptonia. caria, Maccagnia, Podohydmangium and Russuliopsis. US 2009/O 143280 A1 Jun. 4, 2009

1024 675. The bioactive agent according to item 674, 1042 693. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hydnangium. Capillaria. 1025 676. The bioactive agent according to item 674, 1043 694. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laccaria. Catastoma. 1026 677. The bioactive agent according to item 674, 1044 695. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Maccagnia. Cerophora. 1027. 678. The bioactive agent according to item 674, 1045 696. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Podohydmangium. Disciseda. 1028 679. The bioactive agent according to item 674, 1046 697. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Russuliopsis. Enteromyxa. 1029 680. The bioactive agent according to item 228, 1047 698. The bioactive agent according to item 680, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Abstoma, Acuto Eriosphaera. capilitium, Arachnion, Arachniopsis, Bovista, Bovistaria, 1048 699. The bioactive agent according to item 680, Bovistella, Bovistina, Calbovista, Calvatia, Calvatiella, wherein Basidiomycete cell is selected from the genus of Calvatiopsis, Capillaria, Catastoma, Cerophora, Dis Gastropilla. ciseda, Enteromyxa, Eriosphaera, Gastropilla, Globaria, 1049 700. The bioactive agent according to item 680, Glyptoderma, Handkea, Hippoperdon, Hypoblema, Japo wherein Basidiomycete cell is selected from the genus of nogaster; Langermannia, Lanopila, Lasiosphaera, Globaria. Lycogalopsis, Lycoperdon, Lycoperdopsis, Morganella, 1050 701. The bioactive agent according to item 680, Omallycus, Piemycus, Piesmycus, Pila, Priapus, Pseudoly wherein Basidiomycete cell is selected from the genus of Coperdon, Sackea, Scoleciocarpus, Sufa, Utraria and Vas Glyptoderma. cellum. 1051 702. The bioactive agent according to item 680, 1030) 681. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Handkea. Abstoma. 1031 682. The bioactive agent according to item 680, 1052 703. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Acutocapillitium. Hippoperdon. 1032 683. The bioactive agent according to item 680, 1053 704. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arachnion. Hypoblema. 1033 684. The bioactive agent according to item 680, 1054 705. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arachniopsis. Japonogaster: 1034 685. The bioactive agent according to item 680, 1055. 706. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bovista. Langermannia. 1035 686. The bioactive agent according to item 680, 1056 707. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bovistaria. Lanopila. 1036 687. The bioactive agent according to item 680, 1057 708. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bovistella. Lasiosphaera. 1037 688. The bioactive agent according to item 680, 1058 709. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bovistina. Lycogalopsis. 1038. 689. The bioactive agent according to item 680, 1059 710. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calbovista. Lycoperdon. 1039 690. The bioactive agent according to item 680, 1060 711. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calvatia. Lycoperaopsis. 1040 691. The bioactive agent according to item 680, 1061 712. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calvatiella. Morganella. 1041 692. The bioactive agent according to item 680, 1062 713. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calvatiopsis. Omallycus. US 2009/O 143280 A1 Jun. 4, 2009 39

1063 714. The bioactive agent according to item 680, 1076 727. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Piemycus. Androsaceus. 1064 715. The bioactive agent according to item 680, 1077 728. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pies mycus. Anthracophyllum. 1078 729. The bioactive agent according to item 724, 1065 716. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aphotistus. Pila. 1079 730. The bioactive agent according to item 724, 1066 717. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aphyllotus. Priapus. 1080) 731. The bioactive agent according to item 724, 1067 718. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Armillaria. Pseudolycoperdon. 1081 732. The bioactive agent according to item 724, 1068 719. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Armillariella. Sackea. 1082 733. The bioactive agent according to item 724, 1069 720. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Baeospora. Scoleciocarpus. 1083) 734. The bioactive agent according to item 724, 1070 721. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Baumanniella. Sufa. 1084) 735. The bioactive agent according to item 724, 1071 722. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calathella. Utraria. 1085. 736. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of 1072 723. The bioactive agent according to item 680, Campanella. wherein Basidiomycete cell is selected from the genus of Vascellum. 1086 737. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of 1073 724. The bioactive agent according to item 229, Cephaloscypha. wherein said Basidiomycete cell belongs to a genus Selected from the group consisting of Amyloflagellula, 1087 738. The bioactive agent according to item 724, Anastrophella, Androsaceus, Anthracophyllum, Aphotis wherein Basidiomycete cell is selected from the genus of tus, Aphyllotus, Armillaria, Armilariella, Baeospora, Chaetocalathus. Baumanniella, Calathella, Campanella, Cephaloscypha, 1088 739. The bioactive agent according to item 724, Chaetocalathus, Chamaeceras, Collybidium, Colly biop wherein Basidiomycete cell is selected from the genus of sis, Coprinopsis, Cymatella, Cymatellopsis, Cyphellopsis, Chamaeceras. Cyptotrama, Dactylosporina, Deigloria, Discocyphella, 1089 740. The bioactive agent according to item 724, Eoagaricus, Epicnaphus, Favolaschia, Fissolimbus, wherein Basidiomycete cell is selected from the genus of Flagelloscypha, Flammulina, Galeromycena, Gerronema, Collybidium. Glabrocyphella, Gloiocephala, Heliomyces, Hispidoca 1090 741. The bioactive agent according to item 724, lyptella, Hologloea, Hormonitaria, Hymenoconidium, wherein Basidiomycete cell is selected from the genus of Hymenogloea, Hymenomarasmius, Lachnella, Laschia, Colly biopsis. Lecanocybe, Lentinula, Libellus, Macrocystidia, Macro 1091 742. The bioactive agent according to item 724, cystis, Manuripia, Marasniellus, Marasmius, Meris wherein Basidiomycete cell is selected from the genus of modes, Micromphale, Monodelphus, Mucidula, Mycetinis, Coprinopsis. Mycomedusa, Myxocollybia, Nochascypha, Omphalotus, 1092 743. The bioactive agent according to item 724, Oudemansia, Oudemansiella, Phaeocyphellopsis, Phae wherein Basidiomycete cell is selected from the genus of Odepas, Phaeolimacium, Physalacria, Plagiotus, Poly Cymatella. marasmius, Polymyces, Poroauricula, Porolaschia, Proto 1093 744. The bioactive agent according to item 724, marasinius, Pseudodasyscypha, Pseudotyphula, wherein Basidiomycete cell is selected from the genus of Pterospora, Rhizomorpha, Rhodocolybia, Scorteus, Setu Cymatellopsis. lipes, Shitaker, Skepperiella, Stipitocyphella, Strobilurus, 1094) 745. The bioactive agent according to item 724, Stromatocyphella, Sympodia, Tephrophana, Tetrapyrgos, wherein Basidiomycete cell is selected from the genus of Vanromburghia, Xerula and Xerulina. Cyphellopsis. 1074. 725. The bioactive agent according to item 724, 1095 746. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amyloflagellula. Cyptotrama. 1075 726. The bioactive agent according to item 724, 1096 747. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Anastrophella. Dactylosporina. US 2009/O 143280 A1 Jun. 4, 2009 40

1097 748. The bioactive agent according to item 724, 1118 769. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Deigloria. Lecanocybe. 1098 749. The bioactive agent according to item 724, 1119 770. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Discocyphella. Lentinula. 1099 750. The bioactive agent according to item 724, 1120) 771. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Eoagaricus. Libellus. 1100 751. The bioactive agent according to item 724, 1121 772. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epicnaphus. Macrocystidia. 1101) 752. The bioactive agent according to item 724, 1122 773. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Favolaschia. Macrocystis. 1102 753. The bioactive agent according to item 724, 1123 774. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fissolimbus. Manuripia. 1103 754. The bioactive agent according to item 724, 1124 775. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flagelloscypha. Marasmiellus. 1104) 755. The bioactive agent according to item 724, 1125 776. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammulina. Marasmius. 1105 756. The bioactive agent according to item 724, 1126 777. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galeromycena. Merismodes. 1106 757. The bioactive agent according to item 724, 1127 778. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gerronema. Micromphale. 1107 758. The bioactive agent according to item 724, 1128 779. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Glabrocyphella. Monodelphus. 1108 759. The bioactive agent according to item 724, 1129 780. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gloiocephala. Mucidula. 1109 760. The bioactive agent according to item 724, 1130 781. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heliomyces. Mycetinis. 1110 761. The bioactive agent according to item 724, 1131 782. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hispidocalyptella. Mycomedusa. 1111 762. The bioactive agent according to item 724, 1132 783. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hologloea. Myxocolybia. 1112 763. The bioactive agent according to item 724, 1133 784. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hormonitaria. Nochascypha. 1113 764. The bioactive agent according to item 724, 1134 785. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hymenoconidium. Omphalotus. 1114 765. The bioactive agent according to item 724, 1135 786. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hymenogloea. Oudemansia. 1115 766. The bioactive agent according to item 724, 1136 787. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hymenomarasmius. Oudemansiella. 1116 767. The bioactive agent according to item 724, 1137 788. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lachnella. Phaeocyphellopsis. 1117 768. The bioactive agent according to item 724, 1138 789. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laschia. Phaeodepas. US 2009/O 143280 A1 Jun. 4, 2009

1139 790. The bioactive agent according to item 724, 1160 811. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeolimacium. Tephrophana. 1140 791. The bioactive agent according to item 724, 1161 812. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Physalacria. Tetrapyrgos. 1141 792. The bioactive agent according to item 724, 1162 813. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Plagiotus. Vanromburghia. 1142 793. The bioactive agent according to item 724, 1163 814. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Polymarasmius. Xerula. 1143 794. The bioactive agent according to item 724, 1164 815. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Polymyces. Xerulina. 1144. 795. The bioactive agent according to item 724, 1165) 816. The bioactive agent according to item 230, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Poroauricula. selected from the group consisting of Andebbia, Cas 1145 796. The bioactive agent according to item 724, toreum, Gummiglobus, Gummivena, Inoderma, Malaic wherein Basidiomycete cell is selected from the genus of zukia, Mesophelia, Nothocastoreum and Potoromyces. Porolaschia. 1166 817. The bioactive agent according to item 816, 1146 797. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Andebbia. Protomarasmius. 1167 818. The bioactive agent according to item 816, 1147 798. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Castoreum. Pseudodasyscypha. 1168 819. The bioactive agent according to item 816, 1148 799. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gummiglobus. Pseudotyphula. 1169 820. The bioactive agent according to item 816, 1149 800. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gummivena. Pterospora. 1170 821. The bioactive agent according to item 816, 1150 801. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Inoderma. Rhizomorpha. 1171 822. The bioactive agent according to item 816, 1151 802. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Malajczukia. Rhodocollybia. 1172 823. The bioactive agent according to item 816, 1152 803. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mesophelia. Scorteus. 1173 824. The bioactive agent according to item 816, 1153 804. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothocastoreum. Setulipes. 1174 825. The bioactive agent according to item 816, 1154) 805. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Potoromyces. Shitaker. 1175 826. The bioactive agent according to item 231, 1155) 806. The bioactive agent according to item 724, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Endonevrum, Myce Skepperiella. nastrum and Pachyderma. 1156 807. The bioactive agent according to item 724, 1176 827. The bioactive agent according to item 826, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stipitocyphella. Endonevrum. 1157 808. The bioactive agent according to item 724, 1177 828. The bioactive agent according to item 826, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Strobilurus. Mycenastrum. 1158. 809. The bioactive agent according to item 724, 1178. 829. The bioactive agent according to item 826, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stromatocyphella. Pachyderma. 1159 810. The bioactive agent according to item 724, 1179 830. The bioactive agent according to item 232, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sympodia. Nia. US 2009/O 143280 A1 Jun. 4, 2009 42

1180 831. The bioactive agent according to item 233, 1199 850. The bioactive agent according to item 849, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Crucibulum, Acanthocystis. Cyathia, Cyathodes, Cyathus, Granularia, Mycocalia, 1200 851. The bioactive agent according to item 849, Nidula, Nidularia and Peziza. wherein Basidiomycete cell is selected from the genus of 1181 832. The bioactive agent according to item 831, Agaricochaete. wherein Basidiomycete cell is selected from the genus of 1201 852. The bioactive agent according to item 849, Crucibulum. wherein Basidiomycete cell is selected from the genus of 1182) 833. The bioactive agent according to item 831, Crepidopus. wherein Basidiomycete cell is selected from the genus of 1202) 853. The bioactive agent according to item 849, Cyathia. wherein Basidiomycete cell is selected from the genus of 1183 834. The bioactive agent according to item 831, Cyclopleurotus. wherein Basidiomycete cell is selected from the genus of Cyathodes. 1203 854. The bioactive agent according to item 849, 1184 835. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gelona. Cyathus. 1204 855. The bioactive agent according to item 849, 1185 836. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Geopetalum. Granularia. 1205 856. The bioactive agent according to item 849, 1186 837. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hohenbuehelia. Mycocalia. 1206 857. The bioactive agent according to item 849, 1187 838. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentodiopsis. Nidula. 1207 858. The bioactive agent according to item 849, 1188) 839. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pleurotus. Nidularia. 1208 859. The bioactive agent according to item 849, 1189 840. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pterophyllus. Peziza. 1209 860. The bioactive agent according to item 849, 1190 841. The bioactive agent according to item 234, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Scleroma. Selected from the group consisting of Areolaria, Battarre 1210 861. The bioactive agent according to item 236, Opsis, Cyphelomyces, Dictyocephalos, Phellorinia, Whet wherein said Basidiomycete cell belongs to a genus stonia and Xylopodium. selected from the group consisting of Agaricus, Amanita, 1191 842. The bioactive agent according to item 841, Amanitaria, Amanitella, Amanitina, Amanitopsis, Amar wherein Basidiomycete cell is selected from the genus of rendia, Amidella, Amplariella, Annularia, Ariella, Aspi Areolaria. della, Boletium, Chamaeota, Gilbertia, Hyporrhodius, 1192 843. The bioactive agent according to item 841, Lepidella, Leucomyces, Limacella, Myxoderma, Pluteus, wherein Basidiomycete cell is selected from the genus of Pseudofarinaceus, Rhodosporus, Termitosphaera, Torren Battarreopsis. dia, Vaginaria, Vaginarius, Vaginata, Venenarius, Volva, 1193 844. The bioactive agent according to item 841, Volvaria, Volvariella, Volvariopsis, Volvarius, Volvella, wherein Basidiomycete cell is selected from the genus of Cyphellomyces. Volvoamanita and Volvoboletus. 1194 845. The bioactive agent according to item 841, 1211 862. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyocephalos. Agaricus. 1212 863. The bioactive agent according to item 861, 1195 846. The bioactive agent according to item 841, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amanita. Phelorinia. 1196 847. The bioactive agent according to item 841, 1213 864. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Whetstonia. Amanitaria. 1197 848. The bioactive agent according to item 841, 1214 865. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xylopodium. Amanitella. 1198 849. The bioactive agent according to item 235, 1215 866. The bioactive agent according to item 861, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Acanthocystis, Amanitina. Agaricochaete, Crepidopus, Cyclopleurotus, Gelona, 1216 867. The bioactive agent according to item 861, Geopetalum, Hohenbuehelia, Lentodiopsis, Pleurotus, wherein Basidiomycete cell is selected from the genus of Pterophyllus and Scieroma. Amanitopsis. US 2009/O 143280 A1 Jun. 4, 2009

1217 868. The bioactive agent according to item 861, 1238 889. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amarrendia. Vaginata. 1218 869. The bioactive agent according to item 861, 1239 890. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amidella. Venenarius. 1219 870. The bioactive agent according to item 861, 1240 891. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amplariella. Volva. 1220) 871. The bioactive agent according to item 861, 1241 892. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Annularia. Volvaria. 1221. 872. The bioactive agent according to item 861, 1242 893. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ariella. Volvariella. 1222 873. The bioactive agent according to item 861, 1243 894. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aspidella. Volvariopsis. 1223 874. The bioactive agent according to item 861, 1244 895. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Boletium. Volvarius. 1224 875. The bioactive agent according to item 861, 1245) 896. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chamaeota. Wolvella. 1225 876. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of 1246 897. The bioactive agent according to item 861, Gilbertia. wherein Basidiomycete cell is selected from the genus of 1226 877. The bioactive agent according to item 861, Volvoamanita. wherein Basidiomycete cell is selected from the genus of 1247 898. The bioactive agent according to item 861, Hyporrhodius. wherein Basidiomycete cell is selected from the genus of 1227 878. The bioactive agent according to item 861, Volvoboletus. wherein Basidiomycete cell is selected from the genus of 1248 899. The bioactive agent according to item 237, Lepidella. wherein said Basidiomycete cell belongs to a genus 1228 879. The bioactive agent according to item 861, selected from the group consisting of Actiniceps, Allan wherein Basidiomycete cell is selected from the genus of tula, Ceratella, Deflexula, Dimorphocystis, Parapteruli Leucomyces. cium, Penicillaria, Phaeopterula, Pterula and Pterulicium. 1229 880. The bioactive agent according to item 861, 1249 900. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Limacella. Actiniceps. 1230 881. The bioactive agent according to item 861, 1250 901. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxoderma. Allantula. 1231 882. The bioactive agent according to item 861, 1251 902. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pluteus. Ceratella. 1232) 883. The bioactive agent according to item 861, 1252 903. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudofarinaceus. Deflexula. 1233 884. The bioactive agent according to item 861, 1253 904. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodosporus. Dimorphocystis. 1234 885. The bioactive agent according to item 861, 1254 905. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Termitosphaera. Parapterulicium. 1235. 886. The bioactive agent according to item 861, 1255 906. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Torrendia. Penicillaria. 1236 887. The bioactive agent according to item 861, 1256 907. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Vaginaria. Phaeopterula. 1237 888. The bioactive agent according to item 861, 1257. 908. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Vaginarius. Pterula. US 2009/O 143280 A1 Jun. 4, 2009 44

1258 909. The bioactive agent according to item 899, Deconica, Delitescor; Derminus, Dryophila, Flammopsis, wherein Basidiomycete cell is selected from the genus of Flammula, Galeropsina, Geophila, Gymnocybe, Hemi Pterulicium. pholiota, Hypholoma, Hypodendrum, Kuehneromyces, Le 1259, 910. The bioactive agent according to item 238, Ratia, Lerationyces, Melanotus, Mythicomyces, Nemato wherein said Basidiomycete cell belongs to a genus loma, Nemecomyces, Nivatogastrium, Pachylepyrium, Selected from the group consisting of Apus, Auriculariop Phaeonematoloma, Pholiota, Pleuroflammula, Psilocybe, sis, Cytidiella, Ditiola, Flabellaria, Henningsomyces, Ryssospora, Stropharia, Stropholoma, Visculus and Wer Hyponevris, Petrona, Phaeoschizophyllum, Porotheleum, COC. Rectipilus, Rhipidium, Scaphophoeum, Schizonia, Schizo 1278 929. The bioactive agent according to item 928, phyllum and Solenia. wherein Basidiomycete cell is selected from the genus of 1260 911. The bioactive agent according to item 910, Cytophyllopsis. wherein Basidiomycete cell is selected from the genus of 1279 930. The bioactive agent according to item 928, Apus. wherein Basidiomycete cell is selected from the genus of 1261) 912. The bioactive agent according to item 910, Deconica. wherein Basidiomycete cell is selected from the genus of 1280 931. The bioactive agent according to item 928, Auriculariopsis. wherein Basidiomycete cell is selected from the genus of 1262. 913. The bioactive agent according to item 910, Delitescor: wherein Basidiomycete cell is selected from the genus of Cytidiella. 1281 932. The bioactive agent according to item 928, 1263) 914. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Derminus. Ditiola. 1282 933. The bioactive agent according to item 928, 1264 915. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dryophila. Flabellaria. 1283 934. The bioactive agent according to item 928, 1265. 916. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammopsis. Henningsomyces. 1284 935. The bioactive agent according to item 928, 1266) 917. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammula. Hyponevris. 1285 936. The bioactive agent according to item 928, 1267 918. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galeropsina. Petrona. 1286 937. The bioactive agent according to item 928, 1268 919. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Geophila. Phaeoschizophyllum. 1287 938. The bioactive agent according to item 928, 1269) 920. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gymnocybe. Porotheleum. 1288 939. The bioactive agent according to item 928, 1270 921. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemipholiota. Rectipilus. 1271 922. The bioactive agent according to item 910, 1289 940. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhipidium. Hypholoma. 1272 923. The bioactive agent according to item 910, 1290 941. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scaphophoeun. Hypodendrum. 1273 924. The bioactive agent according to item 910, 1291 942. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Schizonia. Kuehneromyces. 1274. 925. The bioactive agent according to item 910, 1292 943. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Schizophyllum. Le-Ratia. 1275 926. The bioactive agent according to item 910, 1293 944. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Solenia. Lerationnyces. 1276 927. The bioactive agent according to item 239, 1294. 945. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stromatoscypha. Melanotus. 1277) 928. The bioactive agent according to item 240, 1295 946. The bioactive agent according to item 928, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Cytophyllopsis, Mythicomyces. US 2009/O 143280 A1 Jun. 4, 2009 45

1296 947. The bioactive agent9. according9. to item 928, Hygrocybe,ygrocy Hygrophorus,ygrop Hygrotrama,g HypsiDSi ZygllS, wherein Basidiomycete cell is selected from the genus of Infundibulicybe, Insiticia, Jacobia, Lactocolybia, Nematoloma. Lampteromyces, Leiopoda, Lepista, Leptoglossum, Lepto 1297 948. The bioactive agent according to item 928, myces, Leptotus, Leucoinocybe, Leucopaxillus, Leucopho wherein Basidiomycete cell is selected from the genus of liota, Lichenomphalia, Limacinus, Linacium, Linopo Nemecomyces. dium, Lulesia, Lyophyllopsis, Lyophyllum, Macrocybe, 1298 949. The bioactive agent according to item 928, Maireina, Mastoleucomyces, Megacolybia, Megatricho wherein Basidiomycete cell is selected from the genus of loma, Melaleuca, Melanoleuca, Metulocyphella, Micro Nivatogastrium. collybia, Microcollybia, Mniopetalum, Moniliophthora, 1299 950. The bioactive agent according to item 928, Monomyces, Mycena, Mycenella, Mycenoporella, wherein Basidiomycete cell is selected from the genus of Mycenopsis, Mycenula, Mycoalvinia, Myxomphalia, Pachylepvrium.Vlepy Nematoctonus, Neoclitocybe,y Neohygrocybe,ygrocy Neohygro'g 1300 951. The bioactive agent according to item 928, phorus, Neonothopanus, Nothoclavulina, Nothopanus, wherein Basidiomycete cell is selected from the genus of Nyctalis, Omphalia, Omphalia, Omphaliaster, Ompha Phaeonematoloma. lina, Omphalius, Omphalopsis, Ossicaulis, Palaeo 1301 952. The bioactive agent according to item 928, cephala, Panellus, Paralepista, Peglerochaete, Pegleromy wherein Basidiomycete cell is selected from the genus of ces, Perona, Phaeolepiota, Phaeomycena, Phaeotellus, Pholiota. Phalomia, Phlebomarasmius, Phlebomycena, Phlebo 1302 953. The bioactive agent according to item 928, phora, Phyllotopsis, Phyllotremella, Phyllotus, Physocys wherein Basidiomycete cell is selected from the genus of tidium, Phytoconis, Pleurella, Pleurocollybia, Pleurocy Pleuroflammula. bella, Pleuromycenula, Pleurotopsis, Podabrella, 1303) 954. The bioactive agent according to item 928, Poromycena, Popoloma, Prunulus, Psammospora, wherein Basidiomycete cell is selected from the genus of Pseudoarmillariella, Pseudobaeospora, Pseudoclitocybe, Psilocybe. Pseudohiatula, Pseudohygrocybe, Pseudohygrophorus, 1304. 955. The bioactive agent according to item 928, Pseudolyophyllum, Pseudomycena, Pseudoomphalina, wherein Basidiomycete cell is selected from the genus of Rajapa, Resinomycena, Resupinatus, Retocybe, Ryssospora. Rhodocyphella, Rhodopaxillus, Rhodotus, Rickenella, 1305 956. The bioactive agent according to item 928, E. R.artitella, St.artites, S.C.CeS, whereinStropharia. Basidiomycete cell is selected from the genus of Scytinotopsis,ubeolarius, Rugosomyces,Scytinotus, Semiomphalina,Sarcomyxa, Sclerostilbum, Singerella, 1306 957. The bioactive agent according to item 928, Singerocybe, Sinotermitomyces, Sphaerocephalus, Squa wherein Basidiomycete cell is selected from the genus of manita, Stachyomphalina, Stanglomyces, Stereopodium, Stropholoma. Stigmatolemma, Tectella, Tephrocybe, Termitomyces, Tilachlidiopsis, Tilotus, Tomentifolium, Tricholoma, Tri 1307) 958. The bioactive agent according to item 928, cholomella, Tricholomopsis, Tricholosporum, Trigonipes, wherein Basidiomycete cell is selected from the genus of Trogia, Ugola, Urceolus, Urospora, Urosporellina, Valen Visculus. tinia, Xeromphalina and Zephirea. 1308 959. The bioactive agent according to item 928, 1310 961. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Weraroa. Aeruginospora. 1309 960. The bioactive agent according to item 241, wherein said Basidiomycete cell belongs to a genus 1311 962. The bioactive agent according to item 960, Selected from the group consisting of Aeruginospora, wherein Basidiomycete cell is selected from the genus of Amparolina, Ampulloclitocybe, Arrhenia, Arthrosporella, Amparolina. Asproinocybe, Aspropaxillus, Asterophora, Asterotrichum, 1312 963. The bioactive agent according to item 960, Asterotus, Austroclitocybe, Austroomphaliaster, Bactrobo wherein Basidiomycete cell is selected from the genus of letus, Basidopus, Bertrandia, Bertrandiella, Biannularia, Ampulloclitocybe. Boehmia, Botrydina, Caesposus, Callistodermatium, Cal 1313 964. The bioactive agent according to item 960, listosporium, Calocybe, Calyptella, Camarophyllopsis, wherein Basidiomycete cell is selected from the genus of Camarophyllus, Campanophyllum, Cantharellopsis, Ampulloclitocybe. Cantharellula, Cantharocybe, Catathelasma, Catatrama, 1314 965. The bioactive agent according to item 960, Caulorhiza, Cellypha, Chemonophyllum, Chromosera, wherein Basidiomycete cell is selected from the genus of Chrysobostrychodes, Chrysomphalina, Clavicybe, Arrhenia. ClavOmphalia, Clitocybe, Clitocybula, Collopus, Colly- 1315 966. The bioactive agent according to item 960, bia, Conchomyces, Coolia, Coriscium, Corniola, Corru- wherein Basidiomycete cell is selected from the genus of garia, Cortinellus, Crinipellis, Cuphophyllus, Cynema, Arthrosporella. Cyphellocalathus, Cystoderma, Cystodermella, Decapita- 1316 967. The bioactive agent according to item 960, tus, Delicatula, Dendrocolybia, Dennisionyces, Dermo- wherein Basidiomycete cell is selected from the genus of loma, Dictyolus, Dictyopanus, Dictyoploca, Dissoderma, Asproinocybe. Echinosporella, Eomycenella, Fayodia, Filoboletus, Fla- 1317. 968. The bioactive agent according to item 960, bellimycena, Floccularia, Galactopus, Gamundia, Geo- wherein Basidiomycete cell is selected from the genus of tus, Gerhardtia, Gliophorus, Glutinaster, Godfrinia, Gym- Aspropaxillus. nopus, Gyroflexus, Gyrophila, Haasiella, Heimiomyces, 1318 969. The bioactive agent according to item 960, Helotium, Hemimycena, Heterosporula, Hiatula, Hodo- wherein Basidiomycete cell is selected from the genus of philus, Humidicultis, Hydrophorus, Hydropus, Hygroaster, Asterophora. US 2009/O 143280 A1 Jun. 4, 2009 46

1319 970. The bioactive agent according to item 960, 1340 991. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterotrichum. Cantharocybe. 1320. 971. The bioactive agent according to item 960, 1341 992. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterotus. Catathelasma. 1321 972. The bioactive agent according to item 960, 1342 993. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austroclitocybe. Catatrama. 1322 973. The bioactive agent according to item 960, 1343 994. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austroomphaliaster: Caulorhiza. 1323 974. The bioactive agent according to item 960, 1344. 995. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bactroboletus. Cellypha. 1324 975. The bioactive agent according to item 960, 1345 996. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Basidopus. Chemonophyllum. 1325 976. The bioactive agent according to item 960, 1346 997. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bertrandia. Chromosera. 1326 977. The bioactive agent according to item 960, 1347 998. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bertrandiella. Chrysobostrychodes. 1327 978. The bioactive agent according to item 960, 1348 999. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Biannularia. Chrysomphalina. 1328 979. The bioactive agent according to item 960, 1349 1000. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Boehmia. Clavicybe. 1329 980. The bioactive agent according to item 960, 1350 1001. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Botrydina. ClavOmphalia. 1330 981. The bioactive agent according to item 960, 1351 1002. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of CaespOsus. Clitocybe. 1331 982. The bioactive agent according to item 960, 1352 1003. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Callistodermatium. Clitocybula. 1332 983. The bioactive agent according to item 960, 1353 1004. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Callistosporium. Collopus. 1333 984. The bioactive agent according to item 960, 1354 1005. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calocybe. Collybia. 1334. 985. The bioactive agent according to item 960, 1355 1006. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calyptella. Conchomyces. 1335 986. The bioactive agent according to item 960, 1356 1007. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Camarophyllopsis. Coolia. 1336 987. The bioactive agent according to item 960, 1357 1008. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Camarophyllus. Coriscium. 1337 988. The bioactive agent according to item 960, 1358 1009. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Campanophyllum. Corniola. 1338 989. The bioactive agent according to item 960, 1359 1010. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cantharellopsis. Corrugaria. 1339 990. The bioactive agent according to item 960, 1360 1011. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cantharellula. Cortinellus. US 2009/O 143280 A1 Jun. 4, 2009 47

1361) 1012. The bioactive agent according to item 960, 1382) 1033. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crinipellis. Galactopus. 1362) 1013. The bioactive agent according to item 960, 1383. 1034. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cuphophyllus. Gamundia. 1363 1014. The bioactive agent according to item 960, 1384 1035. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cynema. Geotus. 1364) 1015. The bioactive agent according to item 960, 1385 1036. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellocalathus. Gerhardtia. 1365 1016. The bioactive agent according to item 960, 1386 1037. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystoderma. Gliophorus. 1366 1017. The bioactive agent according to item 960, 1387 1038. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystodermella. Glutinaster. 1367 1018. The bioactive agent according to item 960, 1388 1039. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Decapitatus. Godfrinia. 1368 1019. The bioactive agent according to item 960, 1389 1040. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Delicatula. Gymnopus. 1369 1020. The bioactive agent according to item 960, 1390 1041. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrocollybia. Gyroflexus. 1370 1021. The bioactive agent according to item 960, 1391 1042. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dennisionyces. Gyrophila. 1371 1022. The bioactive agent according to item 960, 1392) 1043. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dermoloma. Haasiella. 1372 1023. The bioactive agent according to item 960, 1393) 1044. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyolus. Heimiomyces. 1373 1024. The bioactive agent according to item 960, 1394 1045. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyopanus. Helotium. 1374 1025. The bioactive agent according to item 960, 1395 1046. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyoploca. Hemimycena. 1375 1026. The bioactive agent according to item 960, 1396 1047. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dissoderma. Heterosporula. 1376. 1027. The bioactive agent according to item 960, 1397 1048. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Echinosporella. Hiatula. 1377 1028. The bioactive agent according to item 960, 1398. 1049. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Eomycenella. Hodophilus. 1378 1029. The bioactive agent according to item 960, 1399) 1050. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fayodia. Humidicultis. 1379 1030. The bioactive agent according to item 960, 1400 1051. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Filoboletus. Hydrophorus. 1380 1031. The bioactive agent according to item 960, 1401 1052. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flabellimycena. Hydropus. 1381 1032. The bioactive agent according to item 960, 1402 1053. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Floccularia. Hygroaster: US 2009/O 143280 A1 Jun. 4, 2009 48

1403) 1054. The bioactive agent according to item 960, 1424 1075. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrocybe. Lyophyllopsis. 1404 1055. The bioactive agent according to item 960, 1425 1076. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrophorus. Lyophyllum. 1405 1056. The bioactive agent according to item 960, 1426 1077. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrotrama. Macrocybe. 1406 1057. The bioactive agent according to item 960, 1427 1078. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypsizygus. Maireina. 1407 1058. The bioactive agent according to item 960, 1428. 1079. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Infindibulicybe. Mastoleucomyces. 1408 1059. The bioactive agent according to item 960, 1429) 1080. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Insiticia. Megacolybia. 1409 1060. The bioactive agent according to item 960, 1430 1081. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Jacobia. Megatricholoma. 1410 1061. The bioactive agent according to item 960, 1431. 1082. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lactocolybia. Melaleuca. 1411 1062. The bioactive agent according to item 960, 1432) 1083. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lampteromyces. Melanoleuca. 1412 1063. The bioactive agent according to item 960, 1433 1084. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leiopoda. Metulocyphella. 1413 1064. The bioactive agent according to item 960, 1434 1085. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepista. Microcollybia. 1414 1065. The bioactive agent according to item 960, 1435 1086. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptoglossum. Mniopetalum. 1415 1066. The bioactive agent according to item 960, 1436. 1087. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptotus. Moniliophthora. 1416 1067. The bioactive agent according to item 960, 1437 1088. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucoinocybe. Monomyces. 1417 1068. The bioactive agent according to item 960, 1438) 1089. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucopaxillus. Mycena. 1418) 1069. The bioactive agent according to item 960, 1439 1090. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucopholiota. Mycenella. 1419 1070. The bioactive agent according to item 960, 1440 1091. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lichenomphalia. Mycenoporella. 1420 1071. The bioactive agent according to item 960, 1441 1092. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Limacinus. Mycenopsis. 1421 1072. The bioactive agent according to item 960, 1442 1093. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Linacium. Mycenula. 1422 1073. The bioactive agent according to item 960, 1443) 1094. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Linopodium. Mycoalvinia. 1423 1074. The bioactive agent according to item 960, 1444 1095. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lulesia. Myxomphalia. US 2009/O 143280 A1 Jun. 4, 2009 49

1445 1096. The bioactive agent according to item 960, 1466 1117. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nematoctonus. Phaeomycena. 1446 1097. The bioactive agent according to item 960, 1467. 1118. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neoclitocybe. Phaeotellus. 1447 1098. The bioactive agent according to item 960, 1468 1119. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neohygrocybe. Phalomia. 1448 1099. The bioactive agent according to item 960, 1469 1120. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neohygrophorus. Phlebomarasmius. 1449 1100. The bioactive agent according to item 960, 1470. 1121. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neonothopanus. Phlebomycena. 1450 1101. The bioactive agent according to item 960, 1471) 1122. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothoclavulina. Phlebophora. 1451 1102. The bioactive agent according to item 960, 1472) 1123. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothopanus. Phyllotopsis. 1452 1103. The bioactive agent according to item 960, 1473) 1124. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nyctalis. Phyllotremella. 1453) 1104. The bioactive agent according to item 960, 1474 1125. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalia. Phyllotus. 1454. 1105. The bioactive agent according to item 960, 1475) 1126. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphaliaster: Physocystidium. 1455 1106. The bioactive agent according to item 960, 1476) 1127. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalina. Phytoconis. 1456 1107. The bioactive agent according to item 960, 1477 1128. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalius. Pleurella. 1457 1108. The bioactive agent according to item 960, 1478 1129. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalopsis. Pleurocolybia. 1458) 1109. The bioactive agent according to item 960, 1479 1130. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ossicaulis. Pleurocybella. 1459 1110. The bioactive agent according to item 960, 1480) 1131. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Palaeocephala. Pleuromycenula. 1460 1111. The bioactive agent according to item 960, 1481 1132. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Panellus. Pleurotopsis. 1461) 1112. The bioactive agent according to item 960, 1482) 1133. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Paralepista. Podabrella. 1462 1113. The bioactive agent according to item 960, 1483 1134. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Peglerochaete. Poromycena. 1463. 1114. The bioactive agent according to item 960, 1484 1135. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pegleromyces. Porpoloma. 1464. 1115. The bioactive agent according to item 960, 1485) 1136. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Perona. Prunulus. 1465) 1116. The bioactive agent according to item 960, 1486 1137. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeolepiota. Psammospora. US 2009/O 143280 A1 Jun. 4, 2009 50

1487 1138. The bioactive agent according to item 960, 1508 1159. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoarmillariella. Rubeolarius. 1488 1139. The bioactive agent according to item 960, 1509 1160. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudobaeospora. Rugosomyces. 1489 1140. The bioactive agent according to item 960, 1510) 1161. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoclitocybe. Sarcomyxa. 1490) 1141. The bioactive agent according to item 960, 1511 1162. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohiatula. Sclerostilbum. 1491) 1142. The bioactive agent according to item 960, 1512 1163. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohygrocybe. Scytinotopsis. 1492 1143. The bioactive agent according to item 960, 1513 1164. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohygrophorus. Scytinotus. 1493) 1144. The bioactive agent according to item 960, 1514) 1165. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudolyophyllum. Semiomphalina. 1494. 1145. The bioactive agent according to item 960, 1515 1166. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudomycena. Singerella. 1495) 1146. The bioactive agent according to item 960, 1516 1167. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoomphalina. Singerocybe. 1496 1147. The bioactive agent according to item 960, 1517 1168. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rajapa. Sinotermitomyces. 1497 1148. The bioactive agent according to item 960, 1518 1169. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resinomycena. Sphaerocephalus. 1498. 1149. The bioactive agent according to item 960, 1519 1170. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resupinatus. Squamanita. 1499. 1150. The bioactive agent according to item 960, 1520 1171. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Retocybe. StachyOmphalina. 1500 1151. The bioactive agent according to item 960, 1521 1172. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodocyphella. Stanglomyces. 1501 1152. The bioactive agent according to item 960, 1522 1173. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodopaxillus. Stereopodium. 1502) 1153. The bioactive agent according to item 960, 1523) 1174. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodotus. Stigmatolemma. 1503 1154. The bioactive agent according to item 960, 1524. 1175. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rickenella. Tectella. 1504. 1155. The bioactive agent according to item 960, 1525) 1176. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rimbachia. Tephrocybe. 1505 1156. The bioactive agent according to item 960, 1526 1177. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ripartitella. Termitomyces. 1506 1157. The bioactive agent according to item 960, 1527 1178. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ripartites. Tilachlidiopsis. 1507 1158. The bioactive agent according to item 960, 1528 1179. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Roridomyces. Tilotus. US 2009/O 143280 A1 Jun. 4, 2009

1529 1180. The bioactive agent according to item 960, 1549 1200. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tomentifolium. Oueletia. 1530 1181. The bioactive agent according to item 960, 1550 1201. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholoma. Schizostoma. 1531 1182. The bioactive agent according to item 960, 1551 1202. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholomella. Sphaericeps. 1532) 1183. The bioactive agent according to item 960, 1552 1203. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholomopsis. Tulasnodea. 1533 1184. The bioactive agent according to item 960, 1553) 1204. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholosporum. Tulostoma. 1534 1185. The bioactive agent according to item 960, 1554 1205. The bioactive agent according to item 243, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Trigonipes. selected from the group consisting of Apiosporium, 1535 1186. The bioactive agent according to item 960, Astoma, Bronicola, Cnazonaria, Coccopleum, Dacry wherein Basidiomycete cell is selected from the genus of opsella, Gliocoryne, Lutypha, Phacorhiza, Pistillaria, Pis Trogia. tillina, Scleromitra, Sclerotiomyces, Sclerotium, 1536 1187. The bioactive agent according to item 960, Sphaerula, Tiphula and Xylochoeras. wherein Basidiomycete cell is selected from the genus of 1555 1206. The bioactive agent according to item 1205, Ugola. wherein Basidiomycete cell is selected from the genus of 1537 1188. The bioactive agent according to item 960, Apiosporium. wherein Basidiomycete cell is selected from the genus of 1556 1207. The bioactive agent according to item 1205, Urceolus. wherein Basidiomycete cell is selected from the genus of Astoma. 1538 1189. The bioactive agent according to item 960, 1557 1208. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urospora. Bromicolla. 1539 1190. The bioactive agent according to item 960, 1558) 1209. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urosporellina. Cnazonaria. 1540 1191. The bioactive agent according to item 960, 1559 1210. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Valentinia. Coccopleum. 1541 1192. The bioactive agent according to item 960, 1560 1211. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xeromphalina. Dacryopsella. 1542) 1193. The bioactive agent according to item 960, 1561 1212. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Zephirea. Gliocoryne. 1543) 1194. The bioactive agent according to item 242, 1562. 1213. The bioactive agent according to item 1205, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Battarraeastrum, Lutypha. Battarrea, Battarreoides, Chlamydopus, Dendromyces, 1563) 1214. The bioactive agent according to item 1205, Oueletia, Schizostoma, Sphaericeps, Tulasnodea and wherein Basidiomycete cell is selected from the genus of Tulostoma. Phacorhiza. 1544 1195. The bioactive agent according to item 1195, 1564. 1215. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Battarraeastrum. Pistillaria. 1545) 1196. The bioactive agent according to item 1195, 1565. 1216. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Battarrea. Pistillina. 1546 1197. The bioactive agent according to item 1195, 1566 1217. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Battarreoides. Scleromitra. 1547 1198. The bioactive agent according to item 1195, 1567. 1218. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chlamydopus. Sclerotiomyces. 1548 1199. The bioactive agent according to item 1195, 1568 1219. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendromyces. Sclerotium. US 2009/O 143280 A1 Jun. 4, 2009 52

1569 1220. The bioactive agent according to item 1205, 1586 1237. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sphaerula. Athelidium. 1570 1221. The bioactive agent according to item 1205, 1587. 1238. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tiphula. Atheliopsis. 1571 1222. The bioactive agent according to item 1205, 1588 1239. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xylochoeras. Butlerelfia. 1572 1223. The bioactive agent according to item 244, 1589 1240. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhizomarasmius. ByssocOrticium. 1573) 1224. The bioactive agent according to item 247, 1590 1241. The bioactive agent according to item 1231, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Albatrellopsis, Byssocristella. Albatrellus, Jahnoporus, Ovinus, Polyporoletus and Scuti 1591 1242. The bioactive agent according to item 1231, ger. wherein Basidiomycete cell is selected from the genus of 1574 1225. The bioactive agent according to item 1225, Byssoporia. wherein Basidiomycete cell is selected from the genus of 1592) 1243. The bioactive agent according to item 1231, Albatrellopsis. wherein Basidiomycete cell is selected from the genus of 1575) 1226. The bioactive agent according to item 1225, Caerulicium. wherein Basidiomycete cell is selected from the genus of 1593) 1244. The bioactive agent according to item 1231, Albatrellus. wherein Basidiomycete cell is selected from the genus of 1576. 1227. The bioactive agent according to item 1225, Cora. wherein Basidiomycete cell is selected from the genus of 1594) 1245. The bioactive agent according to item 1231, Jahnoporus. wherein Basidiomycete cell is selected from the genus of 1577 1228. The bioactive agent according to item 1225, Coraemyces. wherein Basidiomycete cell is selected from the genus of 1595 1246. The bioactive agent according to item 1231, Ovinus. wherein Basidiomycete cell is selected from the genus of 1578 1229. The bioactive agent according to item 1225, Corella. wherein Basidiomycete cell is selected from the genus of 1596 1247. The bioactive agent according to item 1231, Polyporoletus. wherein Basidiomycete cell is selected from the genus of 1579 1230. The bioactive agent according to item 1225, Cristinia. wherein Basidiomycete cell is selected from the genus of 1597 1248. The bioactive agent according to item 1231, Scutiger. wherein Basidiomycete cell is selected from the genus of 1580 1231. The bioactive agent according to item 248, Dacryobasidium. wherein said Basidiomycete cell belongs to a genus Selected from the group consisting of Amphinema, Amy 1598 1249. The bioactive agent according to item 1231, loathelia, Amylocorticium, Athelia, Athelicium, Athe wherein Basidiomycete cell is selected from the genus of lidium, Atheliopsis, Butlerelfia, ByssocOrticium, Byssocris Dichonema. tella, Byssoporia, Caerulicium, Cora, Coraemyces, 1599 1250. The bioactive agent according to item 1231, Corella, Cristinia, Dacryobasidium, Dichonema, Dicty wherein Basidiomycete cell is selected from the genus of onema, Dictyonematomyces, Digitatispora, Diplonema, Dictyonema. Fibulomyces, Fibulorhizoctonia, Gyrolophium, Hypoch 1600 1251. The bioactive agent according to item 1231, nella, Hypochniciellum, Irpicodon, Laudatea, Leptosporo wherein Basidiomycete cell is selected from the genus of myces, Lobulicium, Luellia, Meizericium, Mycostigma, Dictyonematomyces. Piloderma, Plicatura, Plicaturopsis, Rhipidonema, Rhipi 1601 1252. The bioactive agent according to item 1231, donematomyces, Rhizonema, Taeniospora, Tomentellop wherein Basidiomycete cell is selected from the genus of sis, Tvlosperma, Tvlospora and Wainiocora. Digitatispora. 1581 1232. The bioactive agent according to item 1231, 1602 1253. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amphinema. Diplonema. 1582 1233. The bioactive agent according to item 1231, 1603) 1254. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amyloathelia. Fibulomyces. 1583) 1234. The bioactive agent according to item 1231, 1604 1255. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amylocorticium. Fibulorhizoctonia. 1584 1235. The bioactive agent according to item 1231, 1605 1256. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Athelia. Gyrolophium. 1585 1236. The bioactive agent according to item 1231, 1606 1257. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Athelicium. Hypochnella. US 2009/O 143280 A1 Jun. 4, 2009

1607 1258. The bioactive agent according to item 1231, 1627 1278. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypochniciellum. Boreostereum. 1608 1259. The bioactive agent according to item 1231, 1628 1279. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Irpicodon. Chaetocarpus. 1609 1260. The bioactive agent according to item 1231, 1629 1280. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laudatea. Chaetodermella. 1610 1261. The bioactive agent according to item 1231, 1630 1281. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amphinema, Amyloathelia, Amylocorticium, Athelia, Lep Columnocystis. tosporomyces. 1631) 1282. The bioactive agent according to item 1277, 1611 1262. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grandinioides. Lobulicium. 1612 1263. The bioactive agent according to item 1231, 1632 1283. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Luellia. Hirneola. 1613 1264. The bioactive agent according to item 1231, 1633 1284. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Meizericium. Mycobonia. 1614 1265. The bioactive agent according to item 1231, 1634 1285. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Mycostigma. Mycothele. 1615 1266. The bioactive agent according to item 1231, 1635 1286. The bioactive agent according to item 1277, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Piloderma. Veluticeps. 1616) 1267. The bioactive agent according to item 1231, 1636) 1287. The bioactive agent according to item 250, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Plicatura. selected from the group consisting Acantholichen, Aleuro 1617. 1268. The bioactive agent according to item 1231, corticium, Allosphaerium, Ambivina, Amylobasidium, wherein Basidiomycete cell is selected from the genus of Auricula, Bryochysium, Corticirama, Corticium, Plicaturopsis. Cyanobasidium, Cytidia, Dendrocorticium, Dendrodon 1618 1269. The bioactive agent according to item 1231, tia, Dendrophysellum, Dendrothele, Dextrinodontia, Hem wherein Basidiomycete cell is selected from the genus of mesomyces, Laeticorticium, Laetisaria, Leptocorticium, Rhipidonema. Licrostroma, Limonomyces, Lindtneria, Lomatia, Loma tina, Lyomyces, Matula, Melzerodontia, Merulicium, 1619 1270. The bioactive agent according to item 1231, Moniliopsis, Mutatoderma, Mycinema, Mycolindtneria, wherein Basidiomycete cell is selected from the genus of Necator, Nothocorticium, Papyrodiscus, Phaeophlebia, Rhipidonematomyces. Pulcherricium, Punctularia, Rhizoctonia, Ripexicium, 1620 1271. The bioactive agent according to item 1231, Thanatophytum and Vuilleminia. wherein Basidiomycete cell is selected from the genus of 1637. 1288. The bioactive agent according to item 1287, Rhizonema. wherein Basidiomycete cell is selected from the genus of 1621) 1272. The bioactive agent according to item 1231, Acantholichen. wherein Basidiomycete cell is selected from the genus of Taeniospora. 1638 1289. The bioactive agent according to item 1287, 1622 1273. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aleurocorticium. Tomentellopsis. 1639 1290. The bioactive agent according to item 1287, 1623) 1274. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Allosphaerium. Tvlosperma. 1640 1291. The bioactive agent according to item 1287, 1624 1275. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ambivina. Tvlospora. 1641) 1292. The bioactive agent according to item 1287, 1625 1276. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amylobasidium. Wainiocora. 1642 1293. The bioactive agent according to item 1287, 1626 1277. The bioactive agent according to item 249, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Auricula. Selected from the group consisting Boreostereum, Chaeto 1643) 1294. The bioactive agent according to item 1287, carpus, Chaetodermella, Columnocystis, Grandinioides, wherein Basidiomycete cell is selected from the genus of Hirneola, Mycobonia, Mycothele and Veluticeps. Bryochysium. US 2009/O 143280 A1 Jun. 4, 2009 54

1644 1295. The bioactive agent according to item 1287, 1665. 1316. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corticirama. Merulicium. 1645 1296. The bioactive agent according to item 1287, 1666 1317. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corticium. Moniliopsis. 1646 1297. The bioactive agent according to item 1287, 1667 1318. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyanobasidium. Mutatoderma. 1647 1298. The bioactive agent according to item 1287, 1668 1319. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cytidia. Mycinema. 1648 1299. The bioactive agent according to item 1287, 1669 1320. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrocorticium. Mycolindtneria. 1649 1300. The bioactive agent according to item 1287, 1670 1321. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrodontia. Necator. 1650 1301. The bioactive agent according to item 1287, 1671) 1322. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrophysellum. Nothocorticium. 1651) 1302. The bioactive agent according to item 1287, 1672) 1323. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrothele. Papyrodiscus. 1652 1303. The bioactive agent according to item 1287, 1673 1324. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dextrinodontia. Phaeophlebia. 1653) 1304. The bioactive agent according to item 1287, 1674 1325. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemmesomyces. Pulcherricium. 1654 1305. The bioactive agent according to item 1287, 1675) 1326. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laeticorticium. Punctularia. 1655 1306. The bioactive agent according to item 1287, 1676. 1327. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetisaria. Rhizoctonia. 1656 1307. The bioactive agent according to item 1287, 1677 1328. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptocorticium. Ripexicium. 1678 1329. The bioactive agent according to item 1287, 1657 1308. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Thanatophytum. Licrostroma. 1679. 1330. The bioactive agent according to item 1287, 1658 1309. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Vuilleminia. Limonomyces. 1680 1331. The bioactive agent according to item 251, 1659 1310. The bioactive agent according to item 1287, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Adustomyces, Lindtneria. Asterocyphella, Catilla, Cyphella, Dendrocyphella, Fla 1660. 1311. The bioactive agent according to item 1287, vophlebia, Globulicium, Gloeocorticium, Halocyphina, wherein Basidiomycete cell is selected from the genus of Hyphoradulum, Incrustocalyptella, Limnoperdon, Oxy Lomatia. dontia, Phaeoporotheleum, Pseudolagarobasidium, Radu 1661 1312. The bioactive agent according to item 1287, lodon, Radulomyces, Rhodoarrhenia, Sarcodontia, Seti wherein Basidiomycete cell is selected from the genus of cyphella, Sphaerobasidioscypha, Thujacorticium, Lomatina. Wiesnerina, and Woldmaria. 1662. 1313. The bioactive agent according to item 1287, 1681 1332. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lyomyces. Adustomyces. 1663 1314. The bioactive agent according to item 1287, 1682. 1333. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Matula. Asterocyphella. 1664 1315. The bioactive agent according to item 1287, 1683) 1334. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Meizerodontia. Catilla. US 2009/O 143280 A1 Jun. 4, 2009

1684 1335. The bioactive agent according to item 1331, 1705 1356. The bioactive agent according to item 252, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Cyphella. selected from the group consisting of Cericium, Crustomy 1685 1336. The bioactive agent according to item 1331, ces, Cystidiodontia, Cystostereum, Dentocorticium, Par wherein Basidiomycete cell is selected from the genus of vobasidium, Physodontia and Pteridomyces. Dendrocyphella. 1706 1357. The bioactive agent according to item 1356, 1686 1337. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cericium. Flavophlebia. 1707 1358. The bioactive agent according to item 1356, 1687 1338. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crustomyces. Globulicium. 1708 1359. The bioactive agent according to item 1356, 1688 1339. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystidiodontia. Gloeocorticium. 1709 1360. The bioactive agent according to item 1356, 1689 1340. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystostereum. Halocyphina. 1710 1361. The bioactive agent according to item 1356, 1690 1341. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dentocorticium. Hyphoradulum. 1711 1362. The bioactive agent according to item 1356, 1691. 1342. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parvobasidium. Incrustocalyptella. 1712 1363. The bioactive agent according to item 1356, 1692) 1343. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Physodontia. Limnoperdon. 1713 1364. The bioactive agent according to item 1356, 1693 1344. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pteridomyces. Oxydontia. 1714 1365. The bioactive agent according to item 253, 1694 1345. The bioactive agent according to item 1331, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Epithele, Epithellop Phaeoporotheleum. sis and Skeletohydmum. 1695) 1346. The bioactive agent according to item 1331, 1715 1366. The bioactive agent according to item 1365, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudolagarobasidium. Epithele. 1716 1367. The bioactive agent according to item 1365, 1696 1347. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epitheliopsis. Radulodon. 1717 1368. The bioactive agent according to item 1365, 1697 1348. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Skeletohydnum. Radulomyces. 1718 1369. The bioactive agent according to item 254, 1698 1349. The bioactive agent according to item 1331, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Agaricon, Agarico Rhodoarrhenia. pulpa, Agarico-suber, Agaricum, Agaricus, Amylocystis, 1699) 1350. The bioactive agent according to item 1331, Anomoporia, Auriporia, Buglossoporus, Daedalea, Donk wherein Basidiomycete cell is selected from the genus of ioporia, Fomitopsis, Gilbertsonia, Hemidiscia, Laricifo Sarcodontia. mes, Osteina, Parmastomyces, Phaeodaedalea, Pilato 1700 1351. The bioactive agent according to item 1331, porus, Piptoporus, Placoderma, Podoporia, Postia, wherein Basidiomycete cell is selected from the genus of Rhodofomes, Spelaeomyces, Spongiporus, Strangulidium, Seticyphella. Striglia, Ungularia, Wolfiporia and Xvlostroma. 1701 1352. The bioactive agent according to item 1331, 1719 1370. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sphaerobasidioscypha. Agaricon. 1702) 1353. The bioactive agent according to item 1331, 1720. 1371. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Thujacorticium. Agarico-pulpa. 1703) 1354. The bioactive agent according to item 1331, 1721 1372. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Wiesnerina. Agarico-suber: 1704 1355. The bioactive agent according to item 1331, 1722. 1373. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Woldmaria. Agaricum. US 2009/O 143280 A1 Jun. 4, 2009 56

1723 1374. The bioactive agent according to item 1369, 1744 1395. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agaricus. Spongiporus. 1724. 1375. The bioactive agent according to item 1369, 1745 1396. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amylocystis. Strangulidium. 1725 1376. The bioactive agent according to item 1369, 1746 1397. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Anomoporia. Striglia. 1726 1377. The bioactive agent according to item 1369, 1747 1398. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Auriporia. Ungularia. 1727 1378. The bioactive agent according to item 1369, 1748 1399. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Buglossoporus. Wolfporia. 1728 1379. The bioactive agent according to item 1369, 1749 1400. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Daedalea. Xylostroma. 1729 1380. The bioactive agent according to item 1369, 1750 1401. The bioactive agent according to item 255, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Donkioporia. selected from the group consisting of Amauroderma, Den 1730 1381. The bioactive agent according to item 1369, drophagus, Elfvingia, Friesia, Ganoderma, Haddowia, wherein Basidiomycete cell is selected from the genus of Humphreya, Lazulinospora, Magoderna, Thermophy Fomitopsis. matospora, Tomophagus, Trachyderma and Whitfordia. 1731. 1382. The bioactive agent according to item 1369, 1751. 1402. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gilbertsonia. Amauroderma. 1732) 1383. The bioactive agent according to item 1369, 1752) 1403. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemidiscia. Dendrophagus. 1733 1384. The bioactive agent according to item 1369, 1753) 1404. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laricifomes. Elfvingia. 1734 1385. The bioactive agent according to item 1369, 1754. 1405. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Osteina. Friesia. 1735. 1386. The bioactive agent according to item 1369, 1755 1406. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parmastomyces. Ganoderma. 1736 1387. The bioactive agent according to item 1369, 1756) 1407. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeodaedalea. Haddowia. 1737 1388. The bioactive agent according to item 1369, 1757 1408. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pilatoporus. Humphreya. 1738 1389. The bioactive agent according to item 1369, 1758 1409. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Piptoporus. Lazulinospora. 1739 1390. The bioactive agent according to item 1369, 1759 1410. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Placoderma. Magoderna. 1740. 1391. The bioactive agent according to item 1369, 1760. 1411. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Podoporia. Thermophymatospora. 1741 1392. The bioactive agent according to item 1369, 1761) 1412. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Postia. Tomophagus. 1742) 1393. The bioactive agent according to item 1369, 1762. 1413. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodofomes. Trachyderma. 1743 1394. The bioactive agent according to item 1369, 1763. 1414. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Spelaeomyces. Whitfordia. US 2009/O 143280 A1 Jun. 4, 2009

1764. 1415. The bioactive agent according to item 256, 1782) 1433. The bioactive agent according to item 1431, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Anisomyces, Cerato Bjerkandera. phora, Gloeophyllum, Griseoporia, Lenzitina, Phaeocori 1783. 1434. The bioactive agent according to item 1431, Olellus, Reisneria, Serda and Sesia. wherein Basidiomycete cell is selected from the genus of 1765. 1416. The bioactive agent according to item 1415, Ceraporus. wherein Basidiomycete cell is selected from the genus of 1784. 1435. The bioactive agent according to item 1431, Anisomyces. wherein Basidiomycete cell is selected from the genus of 1766 1417. The bioactive agent according to item 1415, Ceriporia. wherein Basidiomycete cell is selected from the genus of 1785 1436. The bioactive agent according to item 1431, Ceratophora. wherein Basidiomycete cell is selected from the genus 1767 1418. The bioactive agent according to item 1415, CeripOriopsis. wherein Basidiomycete cell is selected from the genus of 1786) 1437. The bioactive agent according to item 1431, Gloeophyllum. wherein Basidiomycete cell is selected from the genus of 1768. 1419. The bioactive agent according to item 1415, Climacocystis. wherein Basidiomycete cell is selected from the genus of 1787 1438. The bioactive agent according to item 1431, Griseoporia. wherein Basidiomycete cell is selected from the genus of 1769. 1420. The bioactive agent according to item 1415, Gelatoporia. wherein Basidiomycete cell is selected from the genus of 1788 1439. The bioactive agent according to item 1431, Lenzitina. wherein Basidiomycete cell is selected from the genus of 1770 1421. The bioactive agent according to item 1415, Hapalopilus. wherein Basidiomycete cell is selected from the genus of 1789 1440. The bioactive agent according to item 1431, Phaeocoriolellus. wherein Basidiomycete cell is selected from the genus of 1771. 1422. The bioactive agent according to item 1415, Irpiciporus. wherein Basidiomycete cell is selected from the genus of 1790 1441. The bioactive agent according to item 1431, Reisneria. wherein Basidiomycete cell is selected from the genus of Ischnoderma. 1772 1423. The bioactive agent according to item 1415, 1791. 1442. The bioactive agent according to item 1431, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Serda. Leptoporus. 1773 1424. The bioactive agent according to item 1415, 1792) 1443. The bioactive agent according to item 1431, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sesia. Myriadoporus. 1774 1425. The bioactive agent according to item 257, wherein said Basidiomycete cell belongs to a genus 1793. 1444. The bioactive agent according to item 1431, Selected from the group consisting of Grammothele, wherein Basidiomycete cell is selected from the genus of Hymenogramme, Porogramme, Theleporus and Tinctopo Porpomyces. 1794) 1445. The bioactive agent according to item 1431, C. wherein Basidiomycete cell is selected from the genus of 1775. 1426. The bioactive agent according to item 1425, Pouzaroporia. wherein Basidiomycete cell is selected from the genus of 1795. 1446. The bioactive agent according to item 1431, Grammothele. wherein Basidiomycete cell is selected from the genus of 1776) 1427. The bioactive agent according to item 1425, Sarcoporia. wherein Basidiomycete cell is selected from the genus of 1796) 1447. The bioactive agent according to item 1431, Hymenogramme. wherein Basidiomycete cell is selected from the genus of 1777 1428. The bioactive agent according to item 1425, Sonion. wherein Basidiomycete cell is selected from the genus of 1797] 1448. The bioactive agent according to item 1431, Porogramme. wherein Basidiomycete cell is selected from the genus of 1778. 1429. The bioactive agent according to item 1425, Spongipellis. wherein Basidiomycete cell is selected from the genus of 1798. 1449. The bioactive agent according to item 259, Theleporus. wherein said Basidiomycete cell belongs to a genus 1779. 1430. The bioactive agent according to item 1425, selected from the group consisting of Aegerita, Aegeritina, wherein Basidiomycete cell is selected from the genus of Aegeritopsis, Amaurohydnum, Amauromyces, Athelo Tinctoporia. derma, Brevicellicium, Bulbillomyces, Cerocorticium, 1780 1431. The bioactive agent according to item 258, Chrysoderma, Conohypha, Coronicium, Crocysporium, wherein said Basidiomycete cell belongs to a genus Cyanodontia, Dermosporium, Elaphocephala, Galzinia, Selected from the group consisting of Aurantiporus, Bjer Gloeohypochnicium, Hydnellum, Hyphoderma, Hyph kandera, Ceraporus, Ceriporia, CeripOriopsis, Climaco Odontiastra, Hyphodontiella, Hypochnicium, Intextomy cystis, Gelatoporia, Hapalopilus, Irpiciporus, Ischno ces, Kneifia, Kneifiella, Lyomyces, Metulodontia, Neok derma, Leptoporus, Myriadoporus, Porpomyces, neifia, Nodotia, Odontiopsis, Pirex, Pycnodon, Pouzaroporia, Sarcoporia, Sonion and Spongipellis. Subulicium, Subulicystidium, Uncobasidium and Xylodon. 1781. 1432. The bioactive agent according to item 1431, 1799. 1450. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aurantiporus. Aegerita. US 2009/O 143280 A1 Jun. 4, 2009

1800 1451. The bioactive agent according to item 1449, 1821 1472. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aegeritina. Hypochnicium. 1801. 1452. The bioactive agent according to item 1449, 1822, 1473. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aegeritopsis. Intextomyces. 1802 1453. The bioactive agent according to item 1449, 1823 1474. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amaurohydmum. Kneifia. 1803) 1454. The bioactive agent according to item 1449, 1824 1475. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amauromyces. Kneifiella. 1804 1455. The bioactive agent according to item 1449, 1825 1476. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Atheloderma. LyOmyces. 1805 1456. The bioactive agent according to item 1449, 1826 1477. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Brevicellicium. Metulodontia. 1806 1457. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of 1827 1478. The bioactive agent according to item 1449, Bulbillomyces. wherein Basidiomycete cell is selected from the genus of 1807 1458. The bioactive agent according to item 1449, Neokneifia. wherein Basidiomycete cell is selected from the genus of 1828. 1479. The bioactive agent according to item 1449, Cerocorticium. wherein Basidiomycete cell is selected from the genus of 1808 1459. The bioactive agent according to item 1449, Nodotia. wherein Basidiomycete cell is selected from the genus of 1829. 1480. The bioactive agent according to item 1449, Chrysoderma. wherein Basidiomycete cell is selected from the genus of 1809. 1460. The bioactive agent according to item 1449, Odontiopsis. wherein Basidiomycete cell is selected from the genus of 1830. 1481. The bioactive agent according to item 1449, Conohypha. wherein Basidiomycete cell is selected from the genus of 1810 1461. The bioactive agent according to item 1449, Pirex. wherein Basidiomycete cell is selected from the genus of 1831 1482. The bioactive agent according to item 1449, Coronicium. wherein Basidiomycete cell is selected from the genus of 1811 1462. The bioactive agent according to item 1449, Pycnodon. wherein Basidiomycete cell is selected from the genus of 1832) 1483. The bioactive agent according to item 1449, Crocysporium. wherein Basidiomycete cell is selected from the genus of 1812 1463. The bioactive agent according to item 1449, Subulicium. wherein Basidiomycete cell is selected from the genus of 1833. 1484. The bioactive agent according to item 1449, Cyanodontia. wherein Basidiomycete cell is selected from the genus of 1813. 1464. The bioactive agent according to item 1449, Subulicystidium. wherein Basidiomycete cell is selected from the genus of 1834 1485. The bioactive agent according to item 1449, Dermosporium. wherein Basidiomycete cell is selected from the genus of 1814 1465. The bioactive agent according to item 1449, Uncobasidium. wherein Basidiomycete cell is selected from the genus of 1835. 1486. The bioactive agent according to item 1449, Elaphocephala. wherein Basidiomycete cell is selected from the genus of 1815 1466. The bioactive agent according to item 1449, Xylodon. wherein Basidiomycete cell is selected from the genus of 1836) 1487. The bioactive agent according to item 260, Galzinia. wherein said Basidiomycete cell belongs to a genus 1816) 1467. The bioactive agent according to item 1449, selected from the group consisting of Abortiporus, wherein Basidiomycete cell is selected from the genus of Antrodia, Bornetina, Cartilosoma, Cautinia, Cladoden Gloeohypochnicium. dron, Cladomeris, Coriolellus, Diacanthodes, Flabellopi 1817 1468. The bioactive agent according to item 1449, lus, Grifola, Henningsia, Heteroporus, Hydnopolyporus, wherein Basidiomycete cell is selected from the genus of Irpicium, Leucofomes, Loweomyces, Meripilus, Merisma, Hydnellum. Physisporinus, Polypilus and Rigidoporus. 1818 1469. The bioactive agent according to item 1449, 1837 1488. The bioactive agent according to item 1487, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hyphoderma. Abortiporus. 1819. 1470. The bioactive agent according to item 1449, 1838 1489. The bioactive agent according to item 1487, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hyphodontiastra. Antrodia. 1820 1471. The bioactive agent according to item 1449, 1839. 1490. The bioactive agent according to item 1487, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hyphodontiella. Bornetina. US 2009/O 143280 A1 Jun. 4, 2009 59

1840 1491. The bioactive agent according to item 1487, Himantia, Jacksonomyces, Meruliopsis, Merulius, Mycoa wherein Basidiomycete cell is selected from the genus of cia, Mycoaciella, Phlebia, Resinicium, Ricnophora, Cartilosoma. Scopuloides, Skvortzovia and Trabecularia. 1841 1492. The bioactive agent according to item 1487, 1860 1511. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cautinia. Acia. 1842) 1493. The bioactive agent according to item 1487, 1861) 1512. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladodendron. Byssomerulius. 1843) 1494. The bioactive agent according to item 1487, 1862. 1513. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladomeris. Caloporia. 1844. 1495. The bioactive agent according to item 1487, 1863. 1514. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolellus. Caloporus. 1845 1496. The bioactive agent according to item 1487, 1864. 1515. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Diacanthodes. Castanoporus. 1846) 1497. The bioactive agent according to item 1487, 1865. 1516. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flabellopilus. Ceraceohydmum. 1847 1498. The bioactive agent according to item 1487, 1866. 1517. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grifola. Ceraceomerulius. 1848. 1499. The bioactive agent according to item 1487, 1867. 1518. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Henningsia. Chondrostereum. 1849 1500. The bioactive agent according to item 1487, 1868. 1519. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heteroporus. Climacodon. 1850 1501. The bioactive agent according to item 1487, 1869 1520. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hydnopolyporus. Columnodontia. 1851 1502. The bioactive agent according to item 1487, wherein Basidiomycete cell is selected from the genus of 1870 1521. The bioactive agent according to item 1510, Irpicium. wherein Basidiomycete cell is selected from the genus of 1852 1503. The bioactive agent according to item 1487, Crustoderma. wherein Basidiomycete cell is selected from the genus of 1871 1522. The bioactive agent according to item 1510, Leucofomes. wherein Basidiomycete cell is selected from the genus of 1853 1504. The bioactive agent according to item 1487, Cylindrobasidium. wherein Basidiomycete cell is selected from the genus of 1872 1523. The bioactive agent according to item 1510, Loweomyces. wherein Basidiomycete cell is selected from the genus of 1854 1505. The bioactive agent according to item 1487, Dacryobolus. wherein Basidiomycete cell is selected from the genus of 1873 1524. The bioactive agent according to item 1510, Meripilus. wherein Basidiomycete cell is selected from the genus of 1855 1506. The bioactive agent according to item 1487, Donkia. wherein Basidiomycete cell is selected from the genus of 1874 1525. The bioactive agent according to item 1510, Merisma. wherein Basidiomycete cell is selected from the genus of 1856 1507. The bioactive agent according to item 1487, Gloeocystidium. wherein Basidiomycete cell is selected from the genus of 1875 1526. The bioactive agent according to item 1510, Physisporinus. wherein Basidiomycete cell is selected from the genus of 1857 1508. The bioactive agent according to item 1487, Gloeoporus. wherein Basidiomycete cell is selected from the genus of 1876) 1527. The bioactive agent according to item 1510, Polypilus. wherein Basidiomycete cell is selected from the genus of 1858. 1509. The bioactive agent according to item 1487, Gloeostereum. wherein Basidiomycete cell is selected from the genus of 1877 1528. The bioactive agent according to item 1510, Rigidoporus. wherein Basidiomycete cell is selected from the genus of 1859 1510. The bioactive agent according to item 261, Himantia. wherein said Basidiomycete cell belongs to a genus 1878 1529. The bioactive agent according to item 1510, Selected from the group consisting of Acia, Byssomerulius, wherein Basidiomycete cell is selected from the genus of Caloporia, Caloporus, Castanoporus, Ceraceohydmum, Jacksonomyces. Ceraceomerulius, Chondrostereum, Climacodon, Colum 1879. 1530. The bioactive agent according to item 1510, nodontia, Crustoderma, Cylindrobasidium, Dacryobolus, wherein Basidiomycete cell is selected from the genus of Donkia, Gloeocystidium, Gloeoporus, Gloeostereum, Meruliopsis. US 2009/O 143280 A1 Jun. 4, 2009 60

1880 1531. The bioactive agent according to item 1510, 1899 1550. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Merulius. Hjortstamia. 1881 1532. The bioactive agent according to item 1510, 1900 1551. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycoacia. Hydnophlebia. 1882 1533. The bioactive agent according to item 1510, 1901 1552. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycoaciella. Hyphodermella. 1883. 1534. The bioactive agent according to item 1510, 1902 1553. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phlebia. Hyphodermopsis. 1884 1535. The bioactive agent according to item 1510, 1903 1554. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resinicium. Licentia. 1885 1536. The bioactive agent according to item 1510, 1904 1555. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ricnophora. Lloydella. 1886 1537. The bioactive agent according to item 1510, 1905 1556. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scopuloides. Lopharia. 1887 1538. The bioactive agent according to item 1510, 1906 1557. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Skvortzovia. Membranicium. 1888 1539. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of 1907 1558. The bioactive agent according to item 1540, Trabecularia. wherein Basidiomycete cell is selected from the genus of Odonticium. 1889. 1540. The bioactive agent according to item 262, wherein said Basidiomycete cell belongs to a genus 1908 1559. The bioactive agent according to item 1540, Selected from the group consisting of Australicium, Bot wherein Basidiomycete cell is selected from the genus of rvodontia, Candelabrochaete, Ceraceomyces, Corticium, Phanerochaete. Efibula, Erythricium, Grandiniella, Gyrophanopsis, 1909 1560. The bioactive agent according to item 1540, Hjortstamia, Hydnophlebia, Hyphodermella, Hyphoder wherein Basidiomycete cell is selected from the genus of mopsis, Licentia, Lloydella, Lopharia, Membranicium, Phlebiopsis. Odonticium, Phanerochaete, Phlebiopsis, Porostereum, 1910 1561. The bioactive agent according to item 1540, Terana, Thwaitesiella and Xerocarpus. wherein Basidiomycete cell is selected from the genus of 1890 1541. The bioactive agent according to item 1540, Porostereun. wherein Basidiomycete cell is selected from the genus of 1911 1562. The bioactive agent according to item 1540, Australicium. wherein Basidiomycete cell is selected from the genus of 1891. 1542. The bioactive agent according to item 1540, Terana. wherein Basidiomycete cell is selected from the genus of 1912 1563. The bioactive agent according to item 1540, Botryodontia. wherein Basidiomycete cell is selected from the genus of 1892 1543. The bioactive agent according to item 1540, Thwaitesiella. wherein Basidiomycete cell is selected from the genus of 1913 1564. The bioactive agent according to item 1540, Candelabrochaete. wherein Basidiomycete cell is selected from the genus of 1893 1544. The bioactive agent according to item 1540, Xerocarpus. wherein Basidiomycete cell is selected from the genus of 1914 1565. The bioactive agent according to item 263, Ceraceomyces. wherein said Basidiomycete cell belongs to a genus 1894) 1545. The bioactive agent according to item 1540, selected from the group consisting of Actinostroma, wherein Basidiomycete cell is selected from the genus of Aquascypha, Beccaria, Beccariella, Bresadolina, Caripia, Corticium. Cladoderris, Coralloderma, Cotylidia, Craterella, Cyma 1895 1546. The bioactive agent according to item 1540, toderma, Cyphellostereum, Granulobasidium, Infla wherein Basidiomycete cell is selected from the genus of tostereum, Podoscypha, Pseudolasiobolus, Stereogloeo Efibula. cystidium, Stereophyllum and Stereopsis. 1896 1547. The bioactive agent according to item 1540, 1915 1566. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Erythricium. Actinostroma. 1897 1548. The bioactive agent according to item 1540, 1916) 1567. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grandiniella. Aquascypha. 1898. 1549. The bioactive agent according to item 1540, 1917. 1568. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gyrophanopsis. Beccaria. US 2009/O 143280 A1 Jun. 4, 2009

1918 1569. The bioactive agent according to item 1565, Grammotheliopsis, Hansenia, Haploporus, Heliocybe, wherein Basidiomycete cell is selected from the genus of Hexagonia, Hirschioporus, Hornodermoporus, Incrusto Beccariella. poria, Laccocephalum, Laetifomes, Laetiporus, Lasio 1919. 1570. The bioactive agent according to item 1565, chlaena, Lentinopanus, Lentinus, Lentodiellum, Lento wherein Basidiomycete cell is selected from the genus of dium, Lentus, Lenzites, Leptopora, Leptoporellus, Bresadolina. Leptotrimitus, Leucolenzites, Leucoporus, Lignosus, 1920 1571. The bioactive agent according to item 1565, Lithopolyporales, Loweporus, Macrohyporia, Macropo wherein Basidiomycete cell is selected from the genus of ria, Megasporoporia, Melanoporella, Melanoporia, Mel Caripia. anopus, Merulioporia, Microporellus, Microporus, Molli 1921 1572. The bioactive agent according to item 1565, Carpus, Mycelithe, Navisporus, Neolentinus, wherein Basidiomycete cell is selected from the genus of Neolentiporus, Nigrofomes, Nigroporus, Oligoporus, Cladoderris. Osmoporus, Pachykytospora, Pachyma, Panus, Paramy 1922 1573. The bioactive agent according to item 1565, ces, Perenniporia, PerennipOriella, Persooniana, Peta wherein Basidiomycete cell is selected from the genus of loides, Phaeolus, Phaeotrametes, Pherina, Phorima, Coralloderma. Phyllodontia, Physisporus, Piloporia, Placodes, Pleuro 1923 1574. The bioactive agent according to item 1565, pus, Pocillaria, Podofomes, Pogonomyces, Polyporellus, wherein Basidiomycete cell is selected from the genus of Polyporus, Polyporus, Polyporus, Poria, Porodisculus, Cotylidia. Porodiscus, Poronidulus, Poroptyche, Pseudofavoilus, 1924, 1575. The bioactive agent according to item 1565, Pseudophaeolus, Pseudopiptoporus, Pseudotrametes, wherein Basidiomycete cell is selected from the genus of Ptychogaster, Pycnoporellus, Pycnoporus, Pyrofomes, Craterella. Riopa, Romelia, Royoporus, Rubroporus, Ryvardenia, 1925 1576. The bioactive agent according to item 1565, Scenidium, Sclerodepsis, Sistotrema, Skeletocutis, Spar wherein Basidiomycete cell is selected from the genus of situbus, Spongiosus, Stiptophyllum, Tinctoporellus, Cymatoderma. Tomentoporus, Trametella, Trametes, Trichaptum, Trun 1926 1577. The bioactive agent according to item 1565, cospora, Tuberaster, Tvromyces, Ungulina, Vanderbylia, wherein Basidiomycete cell is selected from the genus of Velolentinus, Xerotinus, Xerotus, Xvlometron and Xvlopi Cyphellostereum. lus. 1927. 1578. The bioactive agent according to item 1565, 1935. 1586. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Granulobasidium. Abundisporus. 1928 1579. The bioactive agent according to item 1565, 1936) 1587. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Inflatostereum. Agarico-igniarium. 1929. 1580. The bioactive agent according to item 1565, 1937 1588. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Podoscypha. Agaricum. 1930. 1581. The bioactive agent according to item 1565, 1938 1589. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudolasiobolus. Amyloporia. 1931) 1582. The bioactive agent according to item 1565, 1939 1590. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stereogloeocystidium. Amyloporiella. 1932 1583. The bioactive agent according to item 1565, 1940 1591. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stereophyllum. Antromycopsis. 1933 1584. The bioactive agent according to item 1565, 1941 1592. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stereopsis. ApOXOna. 1934 1585. The bioactive agent according to item 264, wherein said Basidiomycete cell belongs to a genus 1942) 1593. The bioactive agent according to item 1585, Selected from the group consisting of Abundisporus, wherein Basidiomycete cell is selected from the genus of Agarico-igniarium, Agaricum, Amyloporia, Amylopori Artolenzites. ella, Antromycopsis, Apoxona, Artolenzites, Asterochaete, 1943 1594. The bioactive agent according to item 1585, Atroporus, Aurantiporellus, Australoporus, Austrolenti wherein Basidiomycete cell is selected from the genus of nus, Bresadolia, Bridgeoporus, Bulliardia, Burgoa, Asterochaete. Caloporus, Cellularia, Ceriomyces, Cerioporus, Cerrena, 1944 1595. The bioactive agent according to item 1585, Choriphyllum, Cladoporus, Coriolopsis, Coriolus, Cryp wherein Basidiomycete cell is selected from the genus of tomphalina, Cryptoporus, Cubamyces, Cyanosporus, Cys Atroporus. tidiophorus, Cystostiptoporus, Daedaleopsis, Datronia, 1945 1596. The bioactive agent according to item 1585, Dendrochaete, Dendropolyporus, Dextrinosporium, wherein Basidiomycete cell is selected from the genus of Dichomitus, Digitellus, Earliella, Echinochaete, Elf Aurantiporellus. ingiella, Enslinia, Fabisporus, Faerberia, Favolus, 1946 1597. The bioactive agent according to item 1585, Fibroporia, Flabellophora, Fomes, Fomitella, Funalia, wherein Basidiomycete cell is selected from the genus of Fuscocerrena, Gemmularia, Geopetalum, Globifomes, Australoporus. US 2009/O 143280 A1 Jun. 4, 2009 62

1947 1598. The bioactive agent according to item 1585, 1968 1619. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austrolentinus. Datronia. 1948. 1599. The bioactive agent according to item 1585, 1969 1620. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bresadolia. Dendrochaete. 1949 1600. The bioactive agent according to item 1585, 1970 1621. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bridgeoporus. Dendropolyporus. 1950 1601. The bioactive agent according to item 1585, 1971 1622. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bulliardia. Dextrinosporium. 1951 1602. The bioactive agent according to item 1585, 1972 1623. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Burgoa. Dichomitus. 1952 1603. The bioactive agent according to item 1585, 1973) 1624. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Caloporus. Digitellus. 1953) 1604. The bioactive agent according to item 1585, 1974 1625. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cellularia. Earliella. 1954) 1605. The bioactive agent according to item 1585, 1975 1626. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Ceriomyces. Echinochaete. 1955 1606. The bioactive agent according to item 1585, 1976 1627. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Cerioporus. Elfvingiella. 1956. 1607. The bioactive agent according to item 1585, 1977. 1628. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cerrena. Enslinia. 1957. 1608. The bioactive agent according to item 1585, 1978 1629. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Choriphyllum. Fabisporus. 1958 1609. The bioactive agent according to item 1585, 1979 1630. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladoporus. Faerberia. 1959 1610. The bioactive agent according to item 1585, 1980) 1631. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolopsis. Favolus. 1960 1611. The bioactive agent according to item 1585, 1981 1632. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolus. Fibroporia. 1961) 1612. The bioactive agent according to item 1585, 1982) 1633. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Cryptomphalina. Flabellophora. 1962. 1613. The bioactive agent according to item 1585, 1983) 1634. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cryptoporus. Fones. 1963. 1614. The bioactive agent according to item 1585, 1984 1635. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cubamyces. Fomitella. 1964) 1615. The bioactive agent according to item 1585, 1985 1636. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyanosporus. Funalia. 1965 1616. The bioactive agent according to item 1585, 1986 1637. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystidiophorus. Fuscocerrena. 1966. 1617. The bioactive agent according to item 1585, 1987. 1638. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystostiptoporus. Gemmularia. 1967. 1618. The bioactive agent according to item 1585, 1988 1639. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Daedaleopsis. Geopetalum. US 2009/O 143280 A1 Jun. 4, 2009

1989 1640. The bioactive agent according to item 1585, 2010 1661. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Globifomes. Leptotrimitus. 1990) 1641. The bioactive agent according to item 1585, 2011 1662. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grammotheliopsis. Leucolenzites. 1991. 1642. The bioactive agent according to item 1585, 2012 1663. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hansenia. Leucoporus. 1992) 1643. The bioactive agent according to item 1585, 2013 1664. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Haploporus. Lignosus. 1993) 1644. The bioactive agent according to item 1585, 2014 1665. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heliocybe. Lithopolyporales. 1994) 1645. The bioactive agent according to item 1585, 2015 1666. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Hexagonia. Loweporus. 1995. 1646. The bioactive agent according to item 1585, 2016. 1667. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hirschioporus. Macrohyporia. 1996 1647. The bioactive agent according to item 1585, 2017. 1668. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hornodermoporus. Macroporia. 1997. 1648. The bioactive agent according to item 1585, 2018 1669. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Incrustoporia. Megasporoporia. 1998 1649. The bioactive agent according to item 1585, 2019 1670. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laccocephalum. Melanoporella. 1999) 1650. The bioactive agent according to item 1585, 2020 1671. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetifomes. Melanoporia. 2000 1651. The bioactive agent according to item 1585, 2021. 1672. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetiporus. Melanopus. 2001 1652. The bioactive agent according to item 1585, 2022 1673. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lasiochlaena. Merulioporia. 2002 1653. The bioactive agent according to item 1585, 2023. 1674. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Lentinopanus. Meruliporia. 2003) 1654. The bioactive agent according to item 1585, 2024, 1675. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Lentinus. Microporellus. 2004) 1655. The bioactive agent according to item 1585, 2025 1676. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentodiellum. Microporus. 2005 1656. The bioactive agent according to item 1585, 2026 1677. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentodium. Mollicarpus. 2006 1657. The bioactive agent according to item 1585, 2027 1678. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentus. Mycelithe. 2007 1658. The bioactive agent according to item 1585, 2028 1679. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lenzites. Navisporus. 2008 1659. The bioactive agent according to item 1585, 2029, 1680. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptopora. Neolentinus. 2009 1660. The bioactive agent according to item 1585, 2030 1681. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptoporellus. Neolentiporus. US 2009/O 143280 A1 Jun. 4, 2009 64

2031 1682. The bioactive agent according to item 1585, 2052 1703. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nigrofomes. Pleuropus. 2032 1683. The bioactive agent according to item 1585, 2053) 1704. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nigroporus. Pocillaria. 2033 1684. The bioactive agent according to item 1585, 2054 1705. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Oligoporus. Podofomes. 2034 1685. The bioactive agent according to item 1585, 2055 1706. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Osmoporus. Pogonomyces. 2035. 1686. The bioactive agent according to item 1585, 2056. 1707. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pachykytospora. Polyporellus. 2036. 1687. The bioactive agent according to item 1585, 2057 1708. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pachyma. Polyporus. 2037 1688. The bioactive agent according to item 1585, 2058 1709. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Panus. Poria. 2038 1689. The bioactive agent according to item 1585, 2059 1710. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Paramyces. Porodisculus. 2039) 1690. The bioactive agent according to item 1585, 2060. 1711. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Perenniporia. Porodiscus. 2040 1691. The bioactive agent according to item 1585, 2061 1712. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of PerennipOriella. Poronidulus. 2041 1692. The bioactive agent according to item 1585, 2062 1713. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Persooniana. Poroptyche. 2042) 1693. The bioactive agent according to item 1585, 2063. 1714. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Petaloides. Pseudofavoilus. 2043 1694. The bioactive agent according to item 1585, 2064. 1715. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeolus. Pseudophaeolus. 2044 1695. The bioactive agent according to item 1585, 2065. 1716. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeotrametes. Pseudopiptoporus. 2045. 1696. The bioactive agent according to item 1585, 2066 1717. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Pherina. Pseudotrametes. 2046. 1697. The bioactive agent according to item 1585, 2067 1718. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phorima. Ptychogaster. 2047 1698. The bioactive agent according to item 1585, 2068 1719. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phyllodontia. Pycnoporellus. 2048 1699. The bioactive agent according to item 1585, 2069 1720. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Physisporus. Pycnoporus. 2049 1700. The bioactive agent according to item 1585, 2070 1721. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Piloporia. Pyrofomes. 2050. 1701. The bioactive agent according to item 1585, 2071 1722. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Piloporia. Riopa. 2051 1702. The bioactive agent according to item 1585, 2072. 1723. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Placodes. Romelia. US 2009/O 143280 A1 Jun. 4, 2009

2073 1724. The bioactive agent according to item 1585, 2094. 1745. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Royoporus. Xerotinus. 2074 1725. The bioactive agent according to item 1585, (2095) 1746. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rubroporus. Xerotus. 2075) 1726. The bioactive agent according to item 1585, 2096 1747. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ryvardenia. Xylometron. 2076 1727. The bioactive agent according to item 1585, 2097. 1748. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scenidium. Xylopilus. 2077 1728. The bioactive agent according to item 1585, 2098. 1749. The bioactive agent according to item 265, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Sclerodepsis. selected from the group consisting of Cristelloporia, Echi 2078 1729. The bioactive agent according to item 1585, notrema, Fibriciellum, Fibuloporia, Galziniella, Hep wherein Basidiomycete cell is selected from the genus of tasporium, Hydnotrema, Ingoldiella, Minimedusa, Osteo Sistotrema. morpha, Paulicorticium, Repetobasidiellum, 2079) 1730. The bioactive agent according to item 1585, Repetobasidium, Sistotrema, Sistotremastrum, Sisto wherein Basidiomycete cell is selected from the genus of tremella, Sphaerobasidium, Tomentella, Trechispora and Skeletocutis. Urnobasidium. 2080 1731. The bioactive agent according to item 1585, 2099 1750. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparsitubus. Cristelloporia. 2081 1732. The bioactive agent according to item 1585, 2100 1751. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Spongiosus. Echinotrema. 2082 1733. The bioactive agent according to item 1585, 2101 1752. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stiptophyllum. Fibriciellum. 2083) 1734. The bioactive agent according to item 1585, 2102 1753. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tinctoporellus. Fibuloporia. 2084 1735. The bioactive agent according to item 1585, 2103 1754. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Tomentoporus. Galziniella. 2085 1736. The bioactive agent according to item 1585, 2104 1755. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trametella. Heptasporium. 2086 1737. The bioactive agent according to item 1585, 2105 1756. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trametes. Hydnotrema. 2087 1738. The bioactive agent according to item 1585, 2106 1757. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Trichaptum. Ingoldiella. 2088 1739. The bioactive agent according to item 1585, 2107 1758. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Truncospora. Minimedusa. 2089. 1740. The bioactive agent according to item 1585, 2108 1759. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tuberaster: Osteomorpha. 2090 1741. The bioactive agent according to item 1585, 2109 1760. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tvromyces. Paulicorticium. 2091. 1742. The bioactive agent according to item 1585, 2110) 1761. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ungulina. Repetobasidiellum. 2092] 1743. The bioactive agent according to item 1585, 2111 1762. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Vanderbylia. Repetobasidium. 2093 1744. The bioactive agent according to item 1585, 2112 1763. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Velolentinus. Sistotrema. US 2009/O 143280 A1 Jun. 4, 2009 66

2113 1764. The bioactive agent according to item 1749, 2132) 1783. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sistotremastrum. Diplomitoporus. 2114 1765. The bioactive agent according to item 1749, 2133 1784. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sistotremella. Etheirodon. 2115 1766. The bioactive agent according to item 1749, 2134 1785. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sphaerobasidium. Fibricium. 2116, 1767. The bioactive agent according to item 1749, 2135 1786. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tomentella. Flaviporus. 2117, 1768. The bioactive agent according to item 1749, 2136) 1787. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trechispora. Flavodon. 2118 1769. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of 2137 1788. The bioactive agent according to item 1775, Urnobasidium. wherein Basidiomycete cell is selected from the genus of 2119 1770. The bioactive agent according to item 266, Irpex. wherein said Basidiomycete cell belongs to a genus 2138 1789. The bioactive agent according to item 1775, Selected from the group consisting of Bondarcevomyces, wherein Basidiomycete cell is selected from the genus of Masseeola, Sparassiella and Sparassis. Junghuhnia. 2120 1771. The bioactive agent according to item 1770, 2139 1790. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bondarcevomyces. Lamelloporus. 2121 1772. The bioactive agent according to item 1770, 2140 1791. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Masseeola. Laschia. 2122 1773. The bioactive agent according to item 1770, 2141 1792. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparassiella. Leptodon. 2123, 1774. The bioactive agent according to item 1770, 2142 1793. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparassis. Metuloidea. 2124 1775. The bioactive agent according to item 267, 2143 1794. The bioactive agent according to item 1775, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Amethicium, Antro Mycoleptodon. diella, Aschersonia, Australohydnum, Baeostratoporus, 2144 1795. The bioactive agent according to item 1775, Chaetoporus, Cinereomyces, Diplomitoporus, Etheiro wherein Basidiomycete cell is selected from the genus of don, Fibricium, Flaviporus, Flavodon, Irpex, Junghuhnia, Mycoleptodonoides. Lamelloporus, Laschia, Leptodon, Metuloidea, Mycolept 2145 1796. The bioactive agent according to item 1775, Odon, Mycoleptodonoides, Mycorrhaphium, Odontia, wherein Basidiomycete cell is selected from the genus of Odontina, Spathulina, Steccherinum and Stegiacantha. Mycorrhaphium. 2125 1776. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of 2146 1797. The bioactive agent according to item 1775, Amethicium. wherein Basidiomycete cell is selected from the genus of 2126 1777. The bioactive agent according to item 1775, Odontia. wherein Basidiomycete cell is selected from the genus of 2147 1798. The bioactive agent according to item 1775, Antrodiella. wherein Basidiomycete cell is selected from the genus of 2127 1778. The bioactive agent according to item 1775, Odontina. wherein Basidiomycete cell is selected from the genus of 2148 1799. The bioactive agent according to item 1775, Aschersonia. wherein Basidiomycete cell is selected from the genus of 2128 1779. The bioactive agent according to item 1775, Spathulina. wherein Basidiomycete cell is selected from the genus of 2149) 1800. The bioactive agent according to item 1775, Australohydnum. wherein Basidiomycete cell is selected from the genus 2129 1780. The bioactive agent according to item 1775, Steccherinum. wherein Basidiomycete cell is selected from the genus of 2150 1801. The bioactive agent according to item 1775, Baeostratoporus. wherein Basidiomycete cell is selected from the genus of 2130 1781. The bioactive agent according to item 1775, Stegiacantha. wherein Basidiomycete cell is selected from the genus of 2151 1802. The bioactive agent according to item 268, Chaetoporus. wherein said Basidiomycete cell belongs to a genus 2131, 1782. The bioactive agent according to item 1775, selected from the group consisting of Granulocystis, Lei wherein Basidiomycete cell is selected from the genus of fia, Litschauerella, Tubulicium, Tubulicrinis and Tubulix Cinereomyces. a2SiO. US 2009/O 143280 A1 Jun. 4, 2009 67

2152 1803. The bioactive agent according to item 1802, 2170 1821. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus augustus. Granulocystis. 2171 1822. The bioactive agent according to item 1819, 2153 1804. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus benesi. wherein Basidiomycete cell is selected from the genus of 2172 1823. The bioactive agent according to item 1819, Leifia. wherein Basidiomycete cell is Agaricus bernardii. 2154 1805. The bioactive agent according to item 1802, 2173. 1824. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus bitorquis. Litschauerella. 2174 1825. The bioactive agent according to item 1819, 2155 1806. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus Californicus. wherein Basidiomycete cell is selected from the genus of 2175 1826. The bioactive agent according to item 1819, Tubulicium. wherein Basidiomycete cell is Agaricus campestris. 2156) 1807. The bioactive agent according to item 1802, 2176 1827. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus comptulus. Tubulicrinis. 2177 1828. The bioactive agent according to item 1819, 2157 1808. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus cupreo-brunneus. wherein Basidiomycete cell is selected from the genus of 2178 1829. The bioactive agent according to item 1819, Tubulixenasma. wherein Basidiomycete cell is Agaricus diminutivus. 2179 1830. The bioactive agent according to item 1819, 2158) 1809. The bioactive agent according to item 268, wherein Basidiomycete cell is Agaricus fuscofibrillosus. wherein said Basidiomycete cell belongs to a genus 2180 1831. The bioactive agent according to item 1819, Selected from the group consisting of Aphanobasidium, wherein Basidiomycete cell is Agaricus fiscovelatus. Clitopilina, Cunninghammyces, Lepidomyces, Phlebiella, 2181 1832. The bioactive agent according to item 1819, Xenasma, Xenasmatella and Xenosperma. wherein Basidiomycete cell is Agaricus hondensis. 2159 1810. The bioactive agent according to item 1809, 2182 1833. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus lilaceps. Aphanobasidium. 2183 1834. The bioactive agent according to item 1819, 2160 1811. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus micromegathus. wherein Basidiomycete cell is selected from the genus of 2184 1835. The bioactive agent according to item 1819, Clitopilina. wherein Basidiomycete cell is Agaricus praeclaresquamo 2161 1812. The bioactive agent according to item 1809, S.S. wherein Basidiomycete cell is selected from the genus of 2185 1836. The bioactive agent according to item 1819, Cunninghammyces. wherein Basidiomycete cell is Agaricus pattersonae. 2162, 1813. The bioactive agent according to item 1809, 2186 1837. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus perobscurus. Lepidomyces. 2187. 1838. The bioactive agent according to item 1819, 2163 1814. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus semotus. wherein Basidiomycete cell is selected from the genus of 2188 1839. The bioactive agent according to item 1819, Phlebiella. wherein Basidiomycete cell is Agaricus Silvicola. 2164) 1815. The bioactive agent according to item 1809, 2189 1840. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus subrutilescens. Xenasma. 2190 1841. The bioactive agent according to item 1819, 2165 1816. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus xanthodermus. wherein Basidiomycete cell is selected from the genus of 2191 1842. The bioactive agent according to item 925, Xenasmatella. wherein said Basidiomycete cell belongs to a species 2166 1817. The bioactive agent according to item 1809, selected from the group consisting of Schizophyllum wherein Basidiomycete cell is selected from the genus of album, Schizophyllum alneum, Schizophyllum alneum, Xenosperma. Schizophyllum amplum, Schizophyllum brasiliense, 2167 1818. The bioactive agent according to item 363, Schizophyllum brevillamellatum, Schizophyllum commune, wherein said Basidiomycete cell belongs to a species Schizophyllum egelingianum, Schizophyllum exiguum, Selected from the group consisting of Agaricus arorae, Schizophyllum fasciatum, Schizophyllum flabellare, Agaricus arvensis, Agaricus augustus, Agaricus benesi, Schizophyllum leprieurii, Schizophyllum lobatum, Schizo Agaricus bernardii, Agaricus bitorquis, Agaricus Califor phyllum mexicanum, Schizophyllum multifidum, Schizo nicus, Agaricus Campestris, Agaricus Comptulus, Agaricus phyllum murrayi, Schizophyllum mya, Schizophyllum pal cupreo-brunneus, Agaricus diminutivus, Agaricus fisco matum, Schizophyllum radiatum, Schizophyllum fibrillosus, Agaricus fiscovelatus, Agaricus hondensis, umbrinum and Schizophyllum variabile. Agaricus lilaceps, Agaricus micromegathus, Agaricus 2192 1843. The bioactive agent according to item 1842, praeclaresquamosus, Agaricus pattersonae, Agaricus per wherein Basidiomycete cell is Schizophyllum album. obscurus, Agaricus semotus, Agaricus Silvicola, Agaricus 2193 1844. The bioactive agent according to item 1842, subrutilescens and Agaricus xanthodermus. wherein Basidiomycete cell is Schizophylium alneum. 2168 1819. The bioactive agent according to item 1819, 2194 1845. The bioactive agent according to item 1842, wherein Basidiomycete cell is Agaricus arorae. wherein Basidiomycete cell is Schizophyllum alneum. 2169 1820. The bioactive agent according to item 1819, 2195 1846. The bioactive agent according to item 1842, wherein Basidiomycete cell is Agaricus arvensis. wherein Basidiomycete cell is Schizophyllum amplum. US 2009/O 143280 A1 Jun. 4, 2009 68

2196. 1847. The bioactive agent according to item 1842, Ganodermafassioides, Ganodermafici, Ganodermafia wherein Basidiomycete cell is Schizophyllum brasiliense. belliforme, Ganoderma flaviporum, Ganoderma flexipes, 2197 1848. The bioactive agent according to item 1842, Ganoderma formosanum, Ganoderma formosissimum, wherein Basidiomycete cell is Schizophyllum brevilamel Ganoderma formicatum, Ganoderma frondosum, Gano latum. derma fulvellum, Ganoderma fuscum, Ganoderma gale 2198. 1849. The bioactive agent according to item 1842, gense, Ganoderma gelsicola, Ganoderma ghesquierei, wherein Basidiomycete cell is Schizophyllum commune. Ganoderma gibbosum, Ganoderma gilletii, Ganoderma 2199 1850. The bioactive agent according to item 1842, wherein Basidiomycete cell is Schizophyllum egeling guadelupense, Ganoderma guinanense, Ganoderma ianum. guizhouense, Ganoderma hainanense, Ganoderma hen 2200 1851. The bioactive agent according to item 1842, ningsii, Ganoderma hildebrandii, Ganoderma hinnuleum, wherein Basidiomycete cell is Schizophyllum exiguum. Ganoderma hoehnelianum, Ganoderma holidayi, Gano 2201 1852. The bioactive agent according to item 1842, derma hoploides, Ganoderma hypoxanthum, Ganoderma wherein Basidiomycete cell is Schizophyllum fasciatum. impolitum, Ganoderma incrassatum, Ganoderma incrustatum, Ganoderma infilgens, Ganoderma 2202 1853. The bioactive agent according to item 1842, infundibuliforme, Ganoderma insulare, Ganoderma inter wherein Basidiomycete cell is Schizophyllum flabellare. medium, Ganoderma japonicum, Ganoderma jianfenglin 2203 1854. The bioactive agent according to item 1842, gense, Ganoderma koningsbergii, Ganoderma kosteri, wherein Basidiomycete cell is Schizophyllum leprieurii. Ganoderma kunmingense, Ganoderma laccatum, Gano 2204 1855. The bioactive agent according to item 1842, derma lamaoense, Ganoderma leptopum, Ganoderma leu wherein Basidiomycete cell is Schizophyllum lobatum. cocreas, Ganoderma leucophaeum, Ganoderma leytense, 2205 1856. The bioactive agent according to item 1842, Ganoderma lignosum, Ganoderma limushanense, Gano wherein Basidiomycete cell is Schizophyllum mexicanum. derma lingua, Ganoderma linhartii, Ganoderma lioninetii, 2206 1857. The bioactive agent according to item 1842, Ganoderma lipsiense, Ganoderma lovdii, Ganoderma wherein Basidiomycete cell is Schizophyllum multifidum. lobatoideum, Ganoderma lobatum, Ganoderma longipes, 2207 1858. The bioactive agent according to item 1842, Ganoderma longistipatum, Ganoderma longistipitatum, wherein Basidiomycete cell is Schizophyllum murrayi. Ganoderma lorenzianum, Ganoderma lucidum, Gano 2208 1859. The bloactive agent according to item 1842, derma lusambilaense, Ganoderma luteicinctum, Gano wherein Basidiomycete cell is Schizophyllum mya. derma luteomarginiatum, Ganoderma luteum, Ganoderma 2209 1860. The bioactive agent according to item 1842, macer, Ganoderma magniporum, Ganoderma maitlandii, wherein Basidiomycete cell is Schizophyllum palmatum. Ganoderma malayanum, Ganoderma malosporum, Gano 2210 1861. The bioactive agent according to item 1842, derma mangiferae, Ganoderma manoutchehrii, Gano wherein Basidiomycete cell is Schizophyllum radiatum. derma mastoporum, Ganoderma mediosimense, Gano 2211 1862. The bioactive agent according to item 1842, derma megaloma, Ganoderma megalosporum, wherein Basidiomycete cell is Schizophyllum umbrinum. Ganoderma meijiangense, Ganoderma melanophaeum, 2212 1863. The bioactive agent according to item 1842, Ganoderma meredithiae, Ganoderma microsporum, wherein Basidiomycete cell is Schizophyllum variabile. Ganoderma miniatocinctum, Ganoderma mirabile, Gano 2213 1864. The bioactive agent according to item 1406, derma mirivelutinum, Ganoderma mongolicum, Gano wherein said Basidiomycete cell belongs to a species derma multicornum, Ganoderma multipileum, Gano Selected from the group consisting of Ganoderma adsper derma multiplicatum, Ganoderma namutambalaense, sum, Ganoderma africanum, Ganoderma applanatum, Ganoderma neglectus, Ganoderma neojaponicum, Gano Ganoderma arcuatum, Ganoderma areolatum, Gano derma neurosporum, Ganoderma nevadense, Ganoderma derma bakeri, Ganoderma balabacense, Ganoderma nigrolucidum, Ganoderma nitens, Ganoderma initidum, cacainum, Ganoderma calcigenum, Ganoderma calido Ganoderma noukahivense, Ganoderma mutans, Gano philum, Ganoderma camphoratum, Ganoderma derma Obockense, Ganoderma obokensis, Ganoderma cantharelloideum, Ganoderma capense, Ganoderma car ochrolaccatum, Ganoderma Oerstedii, Ganoderma nosum, Ganoderma cehengense, Ganoderma cervinum, Omphalodes, Ganoderma opacum, Ganoderma orbiforme, Ganoderma chafangeonii, Ganoderma chalceum, Gano Ganoderma Oregonense, Ganoderma oroflavum, Gano derma chaperi, Ganoderma chenhaiense, Ganoderma derma Oroleucum, Ganoderma Ostracodes, Ganoderma chilense, Ganoderma chiungchungense, Ganoderma Ostreatum, Ganoderma papillatum, Ganoderma parviun chonoides, Ganoderma cochlear, Ganoderma coffeatum, gulatum, Ganoderma parvulum, Ganoderma pernanum, Ganoderma colossus, Ganoderma comorense, Gano Ganoderma personatum, Ganoderma perturbatum, Gano derma comphoratum, Ganoderma concinnum, Gano derma petchi, Ganoderma pfeifferi, Ganoderma philippi, derma conicus, Ganoderma corrugatum, Ganoderma cos Ganoderma platense, Ganoderma plicatum, Ganoderma tattiS, Ganoderma crebrostriatum, Ganoderma polychromum, Ganoderma polymorphum, Ganoderma cupreolaccatum, Ganoderma cupreum, Ganoderma cupu praelongum Murrill, Ganoderma praetervisum, Giano latiprocerum, Ganoderma curranii, Ganoderma curtisii, derma preussi, Ganoderma pseudoboletus, Ganoderma Ganoderma dahli, Ganoderma daiqingshanense, Gano pseudoferreum, Ganoderma puberulum, Ganoderma derma dejongii, Ganoderma densizonatum, Ganoderma pugilisii, Ganoderma pulchella, Ganoderma pullatum, diaoluoshanense, Ganoderma donki, Ganoderma dor Ganoderma pulverulentum, Ganoderma pygmoideum, sale, Ganoderma dubio-cochlear; Ganoderma dussi, Ganoderma ramosissimum, Ganoderma ravenelil, Gano Ganoderma elmeri, Ganoderma elmerianum, Ganoderma derma renidens, Ganoderma renii, Ganoderma resina eminii, Ganoderma endochrum, Ganoderma europaeum, ceum, Ganoderma reticulatosporum, Ganoderma rha Ganoderma exile, Ganoderma expallens, Ganoderma fas codes, Ganoderma rivulosum, Ganoderma rothwelli, ciatum, Ganoderma fasciculatum, Ganoderma fassii, Ganoderma rotundatum, Ganoderma rubeolum, Gano US 2009/O 143280 A1 Jun. 4, 2009 69

derma rude, Ganoderma rufoalbum, Ganoderma rufoba 2228. 1879. The bioactive agent according to item 1864, dium, Ganoderma rugosissimus, Ganoderma rugosum, wherein Basidiomycete cell is Ganoderma carnosum. Ganoderma Sanmingense, Ganoderma Sarasinii, Gano 2229 1880. The bioactive agent according to item 1864, derma Schomburgkii, Ganoderma sculpturatum, Gano wherein Basidiomycete cell is Ganoderma cehengense. derma septatum, Ganoderma sequoiae, Ganoderma 2230 1881. The bioactive agent according to item 1864, sessile, Ganoderma sessiliforme, Ganoderma Shandon wherein Basidiomycete cell is Ganoderma cervinum. gense, Ganoderma Shangsiens, Ganoderma Sichuanense, 2231, 1882. The bioactive agent according to item 1864, Ganoderma Sikorae, Ganoderma silveirae, Ganoderma wherein Basidiomycete cell is Ganoderma chafangeonii. Simaoense, Ganoderma simulans, Ganoderma sinense, 2232) 1883. The bioactive agent according to item 1864, Ganoderma Soniense, Ganoderma soveri, Ganoderma wherein Basidiomycete cell is Ganoderma chalceum. Sprucei, Ganoderma Staneri, Ganoderma Stevaertanum, 2233 1884. The bioactive agent according to item 1864, Ganoderma stipitatum, Ganoderma Stratoideum, Gano wherein Basidiomycete cell is Ganoderma chaperi. derma subamboinense, Ganoderma subfornicatum, 2234 1885. The bioactive agent according to item 1864, Ganoderma subfilvum, Ganoderma subincrustatum, wherein Basidiomycete cell is Ganoderma chenhaiense. Ganoderma sublucidum, Ganoderma subperforatum, 2235 1886. The bioactive agent according to item 1864, Ganoderma subrenatum, Ganoderma subresinosum, wherein Basidiomycete cell is Ganoderma chilense. Ganoderma subrugosus, Ganoderma substipitata, Gano 2236 1887. The bioactive agent according to item 1864, derma subtornatum, Ganoderma subtuberculosum, Gano wherein Basidiomycete cell is Ganoderma chiungchun derma subumbraculum, Ganoderma sulcatum, Gano gense. derma tenue, Ganoderma testaceum, Ganoderma theaecolum, Ganoderma tibetanum, Ganoderma torna 2237 1888. The bioactive agent according to item 1864, tum, Ganoderma torosum, Ganoderma torrendii, Gano wherein Basidiomycete cell is Ganoderma chonoides. derma trengganuense, Ganoderma triangulum, Gano 2238 1889. The bioactive agent according to item 1864, derma triviale, Ganoderma tropicum, Ganoderma trulla, wherein Basidiomycete cell is Ganoderma cochlear: Ganoderma trulliforme, Ganoderma tsugae, Ganoderma 2239 1890. The bioactive agent according to item 1864, tsunodae, Ganoderma tuberculosum, Ganoderma tumi wherein Basidiomycete cell is Ganoderma coffeatum. dum, Ganoderma umbraculum, Ganoderma umbrinum, 2240 1891. The bioactive agent according to item 1864, Ganoderma ungulatum, Ganoderma valesiacum, Gano wherein Basidiomycete cell is Ganoderma colossus. derma vanheurnii, Ganoderma vanmeelii, Ganoderma 2241 1892. The bioactive agent according to item 1864, variabile, Ganoderma weberianum, Ganoderma william wherein Basidiomycete cell is Ganodermacomorense. sianum, Ganoderma wuhuense, Ganoderma wynaadense, 2242 1893. The bioactive agent according to item 1864, Ganoderma xanthocreas, Ganoderma xingviense, Gano wherein Basidiomycete cell is Ganoderma comphoratum. derma xylodes, Ganoderma xylonoides, Ganoderma Zhen 2243 1894. The bioactive agent according to item 1864, ningense and Ganoderma Zonatum. wherein Basidiomycete cell is Ganoderma concinnum. 2214 1865. The bioactive agent according to item 1864, 2244 1895. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma adspersum. wherein Basidiomycete cell is Ganoderma conicus. 2215 1866. The bioactive agent according to item 1864, 224.5 1896. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma africanum. wherein Basidiomycete cell is Ganoderma corrugatum. 221 6 1867. The bioactive agent according to item 1864, 2246 1897. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma applanatum. wherein Basidiomycete cell is Ganoderma costatus. 2247 1898. The bioactive agent according to item 1864, 2217 1868. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma crebrostriatum. wherein Basidiomycete cell is Ganoderma arcuatum. 2248 1899. The bioactive agent according to item 1864, 2218 1869. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma cupreolacca wherein Basidiomycete cell is Ganoderma areolatum. titlin. 2219 1870. The bioactive agent according to item 1864, 2249, 1900. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma bakeri. wherein Basidiomycete cell is Ganoderma curranii. 2220 1871. The bioactive agent according to item 1864, 2250 1901. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma balabacense. wherein Basidiomycete cell is Ganoderma curtisii. 2221 1872. The bioactive agent according to item 1864, 2251 1902. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma cacainum. wherein Basidiomycete cell is Ganoderma dahlii. 2222 1873. The bioactive agent according to item 1864, 2252) 1903. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma cacainum. wherein Basidiomycete cell is Ganoderma daiqingshanense. 2223 1874. The bioactive agent according to item 1864, 2253) 1904. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma calcigenum. wherein Basidiomycete cell is Ganoderma dejongi. 2224, 1875. The bioactive agent according to item 1864, 2254) 1905. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma calidophilum. wherein Basidiomycete cell is Ganoderma densizonatum. 2225 1876. The bioactive agent according to item 1864, 2255 1906. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma camphoratum. wherein Basidiomycete cell is Ganoderma diaoluoshan 2226, 1877. The bioactive agent according to item 1864, aSé. wherein Basidiomycete cell is Ganoderma cantharelloi 2256, 1907. The bioactive agent according to item 1864, deum. wherein Basidiomycete cell is Ganoderma donki. 2227 1878. The bioactive agent according to item 1864, 2257, 1908. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma capense. wherein Basidiomycete cell is Ganoderma dorsale. US 2009/O 143280 A1 Jun. 4, 2009 70

2258, 1909. The bioactive agent according to item 1864, 2289 1940. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma dubio-co wherein Basidiomycete cell is Ganoderma henningsii. chlear: 2290 1941. The bioactive agent according to item 1864, 2259 1910. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hildebrandii. wherein Basidiomycete cell is Ganoderma dussii. 2291) 1942. The bioactive agent according to item 1864, 2260 1911. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hinnuleum. wherein Basidiomycete cell is Ganoderma elmeri. 2292 1943. The bioactive agent according to item 1864, 2261 1912. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hoehnelianum. wherein Basidiomycete cell is Ganoderma elmerianum. 2293 1944. The bioactive agent according to item 1864, 2262, 1913. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hollidayi. wherein Basidiomycete cell is Ganoderma eminii. 2294 1945. The bioactive agent according to item 1864, 2263. 1914. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hoploides. wherein Basidiomycete cell is Ganoderma endochrum. 2295 1946. The bioactive agent according to item 1864, 2264) 1915. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hypoxanthum. wherein Basidiomycete cell is Ganoderma europaeum. 2296 1947. The bioactive agent according to item 1864, 2265 1916. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma impolitum. wherein Basidiomycete cell is Ganoderma exile. 2297 1948. The bioactive agent according to item 1864, 2266 1917. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma incrassatum. wherein Basidiomycete cell is Ganoderma expallens. 2298 1949. The bioactive agent according to item 1864, 2267 1918. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma incrustatum. wherein Basidiomycete cell is Ganoderma fasciatum. 2299) 1950. The bioactive agent according to item 1864, 2268. 1919. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma infiulgens. wherein Basidiomycete cell is Ganodermafassii. 2300 1951. The bioactive agent according to item 1864, 2269 1920. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma infundibuli wherein Basidiomycete cell is Ganodermafassioides. forme. 2270 1921. The bioactive agent according to item 1864, 2301 1952. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafici. wherein Basidiomycete cell is Ganoderma insulare. 2271) 1922. The bioactive agent according to item 1864, 2302 1953. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flabelliforme. wherein Basidiomycete cell is Ganoderma intermedium. 2272) 1923. The bioactive agent according to item 1864, 2303) 1954. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flaviporum. wherein Basidiomycete cell is Ganoderma japonicum. 2273) 1924. The bioactive agent according to item 1864, 2304 1955. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flexipes. wherein Basidiomycete cell is Ganoderma jianfenglin 2274) 1925. The bioactive agent according to item 1864, gense. wherein Basidiomycete cell is Ganoderma formosanum. 2305 1956. The bioactive agent according to item 1864, 2275) 1926. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma koningsbergii. wherein Basidiomycete cell is Ganoderma formosissi 2306 1957. The bloactive agent according to item 1864, FiFi. wherein Basidiomycete cell is Ganoderma kosteri. 2276) 1927. The bioactive agent according to item 1864, 2307 1958. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma formicatum. wherein Basidiomycete cell is Ganoderma kunmingense. 2277 1928. The bioactive agent according to item 1864, 2308 1959. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafrondosum. wherein Basidiomycete cell is Ganoderma laccatum. 2278 1929. The bioactive agent according to item 1864, 2309 1960. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafiulvellum. wherein Basidiomycete cell is Ganoderma lamaoense. 2279 1930. The bioactive agent according to item 1864, 2310 1961. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma fiscum. wherein Basidiomycete cell is Ganoderma leptopum. 2280, 1931. The bioactive agent according to item 1864, 2311 1962. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gallegense. wherein Basidiomycete cell is Ganoderma leucocreas. 2281, 1932. The bioactive agent according to item 1864, 2312 1963. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gelsicola. wherein Basidiomycete cell is Ganoderma leucophaeum. 2282) 1933. The bioactive agent according to item 1864, 2313, 1964. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ghesquierei. wherein Basidiomycete cell is Ganoderma leytense. 2283) 1934. The bioactive agent according to item 1864, 2314 1965. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gibbosum. wherein Basidiomycete cell is Ganoderma lignosum. 2284) 1935. The bioactive agent according to item 1864, 2315 1966. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gilletii. wherein Basidiomycete cell is Ganoderma limushanense. 2285 1936. The bioactive agent according to item 1864, 2316 1967. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma guadelupense. wherein Basidiomycete cell is Ganoderma lingua. 2286, 1937. The bioactive agent according to item 1864, 2317 1968. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma guinanense. wherein Basidiomycete cell is Ganoderma linhartii. 2287 1938. The bioactive agent according to item 1864, 2318, 1969. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma guizhouense. wherein Basidiomycete cell is Ganoderma lionnetii. 2288 1939. The bioactive agent according to item 1864, 2319 1970. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hainanense. wherein Basidiomycete cell is Ganoderma lipsiense. US 2009/O 143280 A1 Jun. 4, 2009

2320 1971. The bioactive agent according to item 1864, 2350 2001. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma lovdii. wherein Basidiomycete cell is Ganoderma multicornum. 2321 1972. The bioactive agent according to item 1864, 2351 2002. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma lobatoideum. wherein Basidiomycete cell is Ganoderma multipileum. 2322 1973. The bioactive agent according to item 1864, 2352 2003. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma lobatum. wherein Basidiomycete cell is Ganoderma multiplicatum. 2323 1974. The bioactive agent according to item 1864, 2353 2004. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma longipes. wherein Basidiomycete cell is Ganoderma namutambal 2324 1975. The bioactive agent according to item 1864, CéSé. wherein Basidiomycete cell is Ganoderma longistipatum. 2354 2005. The bioactive agent according to item 1864, 2325 1976. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neglectus. wherein Basidiomycete cell is Ganoderma lorenzianum. 2355 2006. The bioactive agent according to item 1864, 2326 1977. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neojaponicum. wherein Basidiomycete cell is Ganoderma lucidum. 2356 2007. The bioactive agent according to item 1864, 2327 1978. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neurosporum. wherein Basidiomycete cell is Ganoderma lusambilaense. 2357 2008. The bioactive agent according to item 1864, 2328 1979. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma nevadense. wherein Basidiomycete cell is Ganoderma luteicinctum. 2358 2009. The bioactive agent according to item 1864, 2329, 1980. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma nigrolucidum. wherein Basidiomycete cell is Ganoderma luteomar 2359 2010. The bioactive agent according to item 1864, ginatum. wherein Basidiomycete cell is Ganodermanitens. 2360 2011. The bioactive agent according to item 1864, 2330 1981. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermanitidum. wherein Basidiomycete cell is Ganoderma luteum. 2361 2012. The bioactive agent according to item 1864, 2331, 1982. The bioactive agent according to item 1864, wherein Basidiomycete cell Ganoderma noukahivense. wherein Basidiomycete cell is Ganoderma macer. 2362 2013. The bioactive agent according to item 1864, 2332) 1983. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mutans. wherein Basidiomycete cell is Ganoderma magniporum. 2363. 2014. The bioactive agent according to item 1864, 2333 1984. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Obockense. wherein Basidiomycete cell is Ganoderma maitlandii. 2364 2015. The bioactive agent according to item 1864, 2334 1985. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma obokensis. wherein Basidiomycete cell is Ganoderma malayanum. 2365 2016. The bioactive agent according to item 1864, 2335) 1986. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ochrolaccatum. wherein Basidiomycete cell is Ganoderma malosporum. 2366 2017. The bioactive agent according to item 1864, 2336, 1987. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oerstedii. wherein Basidiomycete cell is Ganoderma mangiferae. 2367 2018. The bioactive agent according to item 1864, 2337) 1988. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Omphalodes. wherein Basidiomycete cell is Ganoderma manoutchehrii. 2368 2019. The bioactive agent according to item 1864, 2338 1989. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma opacum. wherein Basidiomycete cell is Ganoderma mastoporum. 2369 2020. The bioactive agent according to item 1864, 2339) 1990. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma orbiforme. wherein Basidiomycete cell is Ganoderma mediosimense. 2370 2021. The bioactive agent according to item 1864, 2340 1991. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oregonense. wherein Basidiomycete cell is Ganoderma megaloma. 2371 2022. The bioactive agent according to item 1864, 2341) 1992. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma oroflavum. wherein Basidiomycete cell is Ganoderma megalosporum. 2372 2023. The bioactive agent according to item 1864, 2342) 1993. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oroleucum. wherein Basidiomycete cell is Ganoderma meijiangense. |2373 2024. The bioactive agent according to item 1864, 2343) 1994. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Ostracodes. wherein Basidiomycete cell is Ganoderma mel 2374 2025. The bioactive agent according to item 1864, anophaeum. wherein Basidiomycete cell is ostreatum. 2344) 1995. The bioactive agent according to item 1864, 2375 2026. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma meredithiae. wherein Basidiomycete cell is Ganoderma papillatum. 2345) 1996. The bioactive agent according to item 1864, 2376 2027. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma microsporum. wherein Basidiomycete cell is Ganoderma parviungula 2346) 1997. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma miniatocinc 2377 2028. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma parvulum. 2347 1998. The bioactive agent according to item 1864, 2378. 2029. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mirabile. wherein Basidiomycete cell is Ganoderma pernanum. 2348, 1999. The bioactive agent according to item 1864, 2379 2030. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mirivelutinum. wherein Basidiomycete cell is Ganoderma personatum. 2349 2000. The bioactive agent according to item 1864, 238.0 2031. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mongolicum. wherein Basidiomycete cell is Ganoderma perturbatum. US 2009/O 143280 A1 Jun. 4, 2009 72

2381 2032. The bioactive agent according to item 1864, 2412 2063. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma petchii. wherein Basidiomycete cell is Ganoderma rufobadium. 2382 2033. The bioactive agent according to item 1864, 2413, 2064. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pfeifferi. wherein Basidiomycete cell is Ganoderma rugosissimus. 2383 2034. The bioactive agent according to item 1864, 2414 2065. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma philippi. wherein Basidiomycete cell is Ganoderma rugosum. 2384 2035. The bioactive agent according to item 1864, 2415 2066. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma platense. wherein Basidiomycete cell is Ganoderma Sanmingense. 2385 2036. The bioactive agent according to item 1864, 2416 2067. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma plicatum. wherein Basidiomycete cell is Ganoderma Sarasinii. 2386 2037. The bioactive agent according to item 1864, 2417 2068. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma polychromum. wherein Basidiomycete cell is Ganoderma schomburgkii. 2387 2038. The bioactive agent according to item 1864, 2418 2069. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma polymorphum. wherein Basidiomycete cell is Ganoderma sculpturatum. 2388. 2039. The bioactive agent according to item 1864, 2419, 2070. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma praelongum. wherein Basidiomycete cell is Ganoderma septatum. 2389 2040. The bioactive agent according to item 1864, 2420 2071. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma praetervisum. wherein Basidiomycete cell is Ganoderma sequoiae. 2390 2041. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma preussii. 2421. 2072. The bioactive agent according to item 1864, 2391. 2042. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma sessile. wherein Basidiomycete cell is Ganoderma pseudoboletus. 2422, 2073. The bioactive agent according to item 1864, 2392. 2043. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma sessiliforme. wherein Basidiomycete cell is Ganoderma pseudofer 2423 2074. The bioactive agent according to item 1864, FeliFi. wherein Basidiomycete cell is Ganoderma Shandongense. 2393) 2044. The bioactive agent according to item 1864, 2424. 2075. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma puberulum. wherein Basidiomycete cell is Ganoderma Shangsiens. 2394 2045. The bioactive agent according to item 1864, 2425 2076. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pugilisii. wherein Basidiomycete cell is Ganoderma Sichuanense. 2395 2046. The bioactive agent according to item 1864, 2426 2077. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermapulchella. wherein Basidiomycete cell is Ganoderma Sikorae. 2396 2047. The bioactive agent according to item 1864, 2427 2078. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pullatum. wherein Basidiomycete cell is Ganoderma silveirae. 2397 2048. The bioactive agent according to item 1864, 2428 2079. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pulverulentum. wherein Basidiomycete cell is Ganoderma Simaoense. 2398. 2049. The bioactive agent according to item 1864, 2429 2080. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pygmoideum. wherein Basidiomycete cell is Ganoderma simulans. 2399. 2050. The bioactive agent according to item 1864, 2430) 2081. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ranosissimum. wherein Basidiomycete cell is Ganoderma sinense. 2400 2051. The bioactive agent according to item 1864, 2431 2082. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ravenehii. wherein Basidiomycete cell is Ganoderma Soniense. 2401) 2052. The bioactive agent according to item 1864, 2432 2083. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma renidens. wherein Basidiomycete cell is Ganoderma soveri. 2402. 2053. The bioactive agent according to item 1864, 2433) 2084. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma renii. wherein Basidiomycete cell is Ganoderma sprucei. 2403 2054. The bioactive agent according to item 1864, 2434) 2085. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma resinaceum. wherein Basidiomycete cell is Ganoderma staneri. 2404 2055. The bioactive agent according to item 1864, 2435 2086. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma reticu wherein Basidiomycete cell is Ganoderma Stevaertanum. latosporum. 2436 2087. The bioactive agent according to item 1864, 2405 2056. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma stipitatum. wherein Basidiomycete cell is Ganoderma rhacode. 2437. 2088. The bioactive agent according to item 1864, 2406. 2057. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Stratoideum. wherein Basidiomycete cell is Ganoderma rivulosum. 2438 2089. The bioactive agent according to item 1864, 24.07 2058. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subamboin wherein Basidiomycete cell is Ganoderma rothwellii. aSé. 2408 2059. The bioactive agent according to item 1864, 2439 2090. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rotundatum. wherein Basidiomycete cell is Ganoderma subformica 2409. 2060. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma rubeolum. 2440 2091. The bioactive agent according to item 1864, 2410 2061. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subfiulvum. wherein Basidiomycete cell is Ganoderma rude. 2441. 2092. The bioactive agent according to item 1864, 2411) 2062. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subin wherein Basidiomycete cell is Ganoderma rufoalbum. Crtistattlin. US 2009/O 143280 A1 Jun. 4, 2009

2442 2093. The bioactive agent according to item 1864, 2473 2124. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma sublucidum. wherein Basidiomycete cell is Ganoderma vanheurnii. 2443. 2094. The bioactive agent according to item 1864, 2474) 2125. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subperforatum. wherein Basidiomycete cell is Ganoderma vanmeehii. 2444) 2095. The bioactive agent according to item 1864, 2475 2126. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subrenatum. wherein Basidiomycete cell is Ganoderma variabile. 2445 2096. The bioactive agent according to item 1864, 2476) 2127. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subresinosum. wherein Basidiomycete cell is Ganoderma weberianum. 2446. 2097. The bioactive agent according to item 1864, 2477 2128. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subrugosus. wherein Basidiomycete cell is Ganoderma williamsianum. 2447. 2098. The bioactive agent according to item 1864, 2478 2129. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma substipitata. wherein Basidiomycete cell is Ganoderma wuhuense. 2448 2099. The bioactive agent according to item 1864, 2479. 2130. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subtornatum. wherein Basidiomycete cell is Ganoderma w’naadense. 2449 2100. The bioactive agent according to item 1864, 2480 2131. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subtuberculo wherein Basidiomycete cell is Ganoderma xanthocreas. St. 2481. 2132. The bioactive agent according to item 1864, 2450 2101. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Xingyiense. wherein Basidiomycete cell is Ganoderma subumbracu lum. 2482) 2133. The bioactive agent according to item 1864, 2451 2102. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma xylodes. wherein Basidiomycete cell is Ganoderma sulcatum. 2483 2134. The bioactive agent according to item 1864, 2452. 2103. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma xylonoides. wherein Basidiomycete cell is Ganoderma tenue. 2484 2135. The bioactive agent according to item 1864, 2453 2104. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Zhenningense. wherein Basidiomycete cell is Ganoderma testaceum. 2485 2136. The bioactive agent according to item 1864, 2454 2105. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Zonatum. wherein Basidiomycete cell is Ganoderma theaecolum. 2486 2137. The bioactive agent according to item 1498, 2455 2106. The bioactive agent according to item 1864, wherein said Basidiomycete cell belongs to a species wherein Basidiomycete cell is Ganoderma tibetanum. selected from the group consisting of Grifola acanthoides, 2456 2107. The bioactive agent according to item 1864, Grifola albicans, Grifola armeniaca, Grifola badia, Gri wherein Basidiomycete cell is Ganoderma tornatum. fola colensoi, Grifolia eos, Grifola fractipes, Grifola fron 2457 2108. The bioactive agent according to item 1864, dosa, Grifola gargal, Grifola gigantea, Grifola intybacea, wherein Basidiomycete cell is Ganoderma torosum. Grifola lentifrondosa, Grifola Obducta, Grifola platypora, 2458 2109. The bioactive agent according to item 1864, Grifola rosularis, Grifola SOrdulenta, Grifola sulphurea, wherein Basidiomycete cell is Ganoderma torrendii. Grifola sumstinei and Grifola tuckahoe. 2459 2110. The bioactive agent according to item 1864, 2487 2138. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trengganuense. wherein Basidiomycete cell is Grifola acanthoides. 2460 2111. The bioactive agent according to item 1864, 2488 2139. the bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma triangulum. wherein Basidiomycete cell is Grifola albicans. 2461. 2112. The bioactive agent according to item 1864, 2489 2140. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma triviale. wherein Basidiomycete cell is Grifola armeniaca. 2462) 2113. The bioactive agent according to item 1864, 2490 2141. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tropicum. wherein Basidiomycete cell is Grifola badia. 2463. 2114. The bioactive agent according to item 1864, 2491) 2142. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trulla. wherein Basidiomycete cell is Grifola colensoi. 2464. 2115. The bioactive agent according to item 1864, 2492) 2143. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trulliforme. wherein Basidiomycete cell is Grifola eos. 2465 2116. The bioactive agent according to item 1864, 2493 2144. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tsugae. wherein Basidiomycete cell is Grifola fractipes. 2466 2117. The bioactive agent according to item 1864, 2494 2145. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tsunodae. wherein Basidiomycete cell is Grifola frondosa. 2467 2118. The bioactive agent according to item 1864, 2495 2146. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tuberculosum. wherein Basidiomycete cell is Grifola gargal. 2468 2119. The bioactive agent according to item 1864, 2496 2147. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tumidium. wherein Basidiomycete cell is Grifola gigantea. 2469. 2120. The bioactive agent according to item 1864, 2497 2148. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma umbraculum. wherein Basidiomycete cell is Grifola intybacea. 2470 2121. The bioactive agent according to item 1864, 2498 2149. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma umbrinum. wherein Basidiomycete cell is Grifola lentifrondosa. 2471. 2122. The bioactive agent according to item 1864, 2499 2150. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma ungulatum. wherein Basidiomycete cell is Grifola obducta. 2472. 2123. The bioactive agent according to item 1864, 2500 2151. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma valesiacum. wherein Basidiomycete cell is Grifola platypora. US 2009/O 143280 A1 Jun. 4, 2009 74

2501 2152. The bioactive agent according to item 2137, 2528 2179. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola rosularis. wherein Basidiomycete cell is Lentinus suffrutescens. 2502. 2153. The bioactive agent according to item 2137, 2529 2180. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola sordulenta. wherein Basidiomycete cell is Lentinus tuber-regium. 2503 2154. The bioactive agent according to item 2137, 2530 2181. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola sulphurea. wherein Basidiomycete cell is Lentinus Zelandicus. 2504 2155. The bioactive agent according to item 2137, 2531) 2182. The bioactive agent according to item 1737, wherein Basidiomycete cell is Grifola sumstinei. wherein said Basidiomycete cell belongs to a species 2505 2156. The bioactive agent according to item 2137, selected from the group consisting of Trametes cervina, wherein Basidiomycete cell is Grifola tuckahoe. Trametes cingulata, Trametes cotonea, Trametes gibbosa, 2506 2157. The bioactive agent according to item 1654, Trametes hirsuta, Trametes incerta, Trametes lactine, wherein said Basidiomycete cell belongs to a species Trametes maxima, Trametes meyenii, Trametes morganii, Selected from the group consisting of Lentinus albOveluti Trametes ochracea, Trametes pubescens, Trametes robin nus, Lentinus anthocephalus, Lentinus badius, Lentinus iophila, Trametes suaveolens, Trametes subsinuosa, Tram castoreus, Lentinus chrysopeplus, Lentinus cochleatus, etes tegularis, Trametes tenuis, Trametes trabea, Trametes Lentinus concinnus, Lentinus delicatus, Lentinus edodes, umbrina, Trametes unicolor; Trametes versicolor; Trametes Lentinus fasciatus, Lentinus hyracinus, Lentinus lepideus villosa and Trametes Zonata. sensu, Lentinus lepideus, Lentinus novaezelandiae, Lenti 2532 2183. The bioactive agent according to item 2182, nus pulvinulus, Lentinus punctaticeps, Lentinus punctati wherein Basidiomycete cell is Trametes cervina. Ceps, Lentinus pygmaeus, Lentinus Sajor-Caju, Lentinus 2533 2 184. The bioactive agent according to item 2182, squarrulosus, Lentinus Strigosus, Lentinus suffrutescens, wherein Basidiomycete cell is Trametes cingulata. Lentinus tuber-regium and Lentinus Zelandicus. 2534 2185. The bioactive agent according to item 2182, 2507 2158. The bioactive agent according to item 2157, wherein Basidiomycete cell is Trametes Cotonea. wherein Basidiomycete cell is Lentinus albovelutinus. 2535 2186. The bioactive agent according to item 2182, 2508 2159. The bioactive agent according to item 2157. wherein Basidiomycete cell is Trametes gibbosa. wherein Basidiomycete cell is Lentinus albovelutinus. 2509 2160. The bioactive agent according to item 2157. 2536 2187. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus anthocephalus. wherein Basidiomycete cell is Trametes hirsuta. 2510 2161. The bioactive agent according to item 2157. 2537 2188. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus badius. wherein Basidiomycete cell is Trametes incerta. 2511 2162. The bioactive agent according to item 2157. 2538 2189. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus castoreus. wherein Basidiomycete cell is Trametes lactine. 2512. 2163. The bioactive agent according to item 2157. 2539. 2190. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus chrysopeplus. wherein Basidiomycete cell is Trametes maxima. 2513 2164. The bioactive agent according to item 2157. 2540. 2191. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus cochleatus. wherein Basidiomycete cell is Trametes meyenii. 2514 2165. The bioactive agent according to item 2157. 2541. 2192. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus concinnus. wherein Basidiomycete cell is Trametes morganii. 2515 2166. The bioactive agent according to item 2157. 2542 2193. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus delicatus. wherein Basidiomycete cell is Trametes ochracea. 2516. 2167. The bioactive agent according to item 2157. 2543 2194. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus edodes. wherein Basidiomycete cell is Trametes pubescens. 2517 2168. The bioactive agent according to item 2157. 2544, 2195. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus fasciatus. wherein Basidiomycete cell is Trametes robiniophila. 2518. 21.69. The bioactive agent according to item 2157. 2545. 2196. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus hyracinus. wherein Basidiomycete cell is Trametes suaveolens. 2519. 2170. The bioactive agent according to item 2157. 2546 2197. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus lepideus sensu. wherein Basidiomycete cell is Trametes subsinuosa. 2520 2171. The bioactive agent according to item 2157. 2547 2198. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus lepideus. wherein Basidiomycete cell is Trametes tegularis. 2521. 2172. The bioactive agent according to item 2157. 2548 2199. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus novaezelandiae. wherein Basidiomycete cell is Trametes tenuis. 2522 2173. The bioactive agent according to item 2157. 2549 2200. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus pulvinulus. wherein Basidiomycete cell is Trametes trabea. 2523 2174. The bioactive agent according to item 2157. 2550 2201. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus punctaticeps. wherein Basidiomycete cell is Trametes umbrina. 2524, 2175. The bioactive agent according to item 2157. 2551 2202. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus pygmaeus. wherein Basidiomycete cell is Trametes unicolor. 2525 2176. The bioactive agent according to item 2157. 2552 2203. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus Sajor-caju. wherein Basidiomycete cell is Trametes versicolor: 2526 2177. The bioactive agent according to item 2157. 2553 2204. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus squarrulosus. wherein Basidiomycete cell is Trametes villosa. 2527 2178. The bioactive agent according to item 2157. 2554 2205. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus Strigosus. wherein Basidiomycete cell is Trametes Zonata. US 2009/O 143280 A1 Jun. 4, 2009

2555 2206. A composition comprising the bioactive agent 2571 agents comprising or consisting of a polysaccha according to any of the items above and a physiologically ride, acceptable carrier. 2572 agents comprising or consisting of an optionally 2556 2207. A pharmaceutical composition comprising glycosylated peptide, the bioactive agent according to any of the items above and 2573 agents comprising or consisting of an optionally a pharmaceutically acceptable carrier. glycosylated polypeptide, 2557 2208. Use of the pharmaceutical composition 2574 agents comprising or consisting of an oligonucle according to item 2207 in the manufacture of a medica otide, ment. 2575 agents comprising or consisting of a polynucle 2558. In one embodiment, the bioactive agent is an Agari otide, cus bioactive agent. A bioactive agent from any of the below 2576 agents comprising or consisting of a lipid, Agaricus species may be used in the present invention, Such 2577 agents comprising or consisting of a fatty acid, as any bioactive agents from the group consisting of Agari 2578 agents comprising or consisting of a fatty acid cus arorae, Agaricus arvensis, Agaricus augustus, Agaricus ester and benesi, Agaricus bernardii, Agaricus bisporus, Agaricus 2579 agents comprising or consisting of secondary bitorquis, Agaricus blazei Murill yh (has reclassified as metabolites. Agaricus brasiliensis), Agaricus Californicus, Agaricus 2580 Thus, in one preferred embodiment of the present campestris, Agaricus Comptulus, Agaricus cupreo-brunneus, invention, the Agaricus bioactive agent is selected from the Agaricus diminutives, Agaricus fiascofibrillosus, Agaricus group consisting of an agent selected from an oligosaccha fiscovelatus, Agaricus hondensis, Agaricus lilaceps, Agari ride, a polysaccharide and an optionally glycosylated cus micromegathus, Agaricus praeclaresquamosus, Agaricus polypeptide. pattersonae, Agaricus perobscurus, Agaricus semotus, 2581. In another preferred embodiment of the present Agaricus Silvicola, Agaricus subrutilescens, Agaricus xian invention, the Agaricus bioactive agent is a polysaccharide. thodermus. 2582. In another preferred embodiment of the present 2559. It is preferred that the Agaricus bioactive agent is invention, the Agaricus bioactive agent is an oligosaccharide. from any of the following: A. blazei, A. blazei Murill, A. 2583. In another preferred embodiment of the present bisporus, A. hortensis, A. campestris. invention, the Agaricus bioactive agent is an optionally gly 2560. In a particularly preferred embodiment of the cosylated polypeptide. present invention, the Agaricus bioactive agent is from A. 2584. In another preferred embodiment of the present blazei, preferably A. blazei Murill. invention, the Agaricus bioactive agent is a homopolymer 2561. In another preferred embodiment of the present 2585. In another preferred embodiment of the present invention, the Agaricus bioactive agent is from A. bisporus. In invention, the Agaricus bioactive agent is a heteropolymer another preferred embodiment of the present invention, the 2586. Further Characterisation of the Agaricus Bioactive Agaricus bioactive agent is from A. hortensis. In another Species: preferred embodiment of the present invention, the Agaricus 2587. In one preferred embodiment of the present inven bioactive agent is from A. Campestris tion, the Agaricus bioactive agent comprises or consists of an 2562 Accordingly, in a preferred embodiment of the optionally glycosylated peptide. present invention the compositions disclosed herein have 2588. In another preferred embodiment of the present been produced by an Agaricus fungus. Preferably, the com invention, the Agaricus bioactive agent comprises or consists positions have been purified from the extracellular environ of a polypeptide ment of an Agaricus fungus. Even more preferably the fun 2589. In another preferred embodiment of the present gus, preferably a fungal mycelium, has been cultivated in a invention, the Agaricus bioactive agent comprises or consists liquid growth medium and said composition has been purified of an oligonucleotide from said liquid growth medium. 2590. In another preferred embodiment of the present 2563. It is thus preferred that the composition of the inven invention, the Agaricus bioactive agent comprises or consists tion has been produced by a method comprising the steps of of a polynucleotide. 2564 i) cultivating an Agaricus fungus, such as an 2591. In another preferred embodiment of the present Agaricus fungal mycelium, in a liquid growth medium, invention, the Agaricus bioactive agent comprises or consists and of a lipid. 2565 ii) isolating the composition from said liquid 2592. In another preferred embodiment of the present growth medium invention, the Agaricus bioactive agent comprises or consists 2566 By fungal mycelium is intended any fungal biom of a fatty acid. ass, which can be grown in a submerged culture. The fungal 2593. In another preferred embodiment of the present biomass may be in the form of single hyphae, spores, aggre invention, the Agaricus bioactive agent comprises or consists gates of mycelium, and partly differentiated mycelium. offatty acid esters. 2567. The liquid growth medium may be any of the liquid 2594. In another preferred embodiment of the present growth media described herein below. invention, the Agaricus bioactive agent comprises or consists 2568. The Agaricus bioactive agent comprised in the kit of of secondary metabolite(s). Such as steroids, shikimic acids, parts according to the present invention may be in Solid or alkaloids and benzodiazepins. liquid form. 2595. In one embodiment, the Agaricus bioactive agent is 2569. In one preferred embodiment, the Agaricus bioac a polysaccharide, Such as a polysaccharide having a molar tive agent is selected from the group consisting of: ratio of galactose:mannose:glucose of 1:10 to 20:30 to 50, 2570 agents comprising or consisting of an oligosac such as 1:12 to 18:35 to 45; for example 1:14 to 16:38 to 42, charide, such as 1:about 15:about 40, for example 1:15:40. US 2009/O 143280 A1 Jun. 4, 2009 76

2596 Accordingly, the Agaricus bioactive agent may in (4) In another preferred embodiment of the present invention, one embodiment comprise one or more polypeptides and/or a the Agaricus bioactive agent comprises or consists of the mixture of polysaccharides, wherein the majority of the beta-(1-6)-D-glucan described by Kobayashi et al., (“Sup polysaccharides of the composition has a molecular weight of pressing effects of daily oral Supplementation of beta-glucan at least 10,000 Da and wherein said one or more polypeptides extracted from Agaricus blazei Murill on spontaneous and and/or said mixture of polysaccharides comprises the peritoneal disseminated metastasis in mouse model”, JCan monosaccharides galactose, mannose and glucose in the ratio cer Res Clin Oncol. 2005 May 10) (galactose:mannose:glucose) of 1:0 to 25:1 to 50, Such as (5) In another preferred embodiment of the present invention, 1:10 to 20:30 to 50, such as 1:12 to 18:35 to 45; for example the Agaricus bioactive agent comprises or consists of the 1:14 to 16:38 to 42, such as 1:about 15:about 40, for example HM3-G (molecular mass 380 kDa), mainly (1-4)-alpha D 1:15:40. glucan with (1-6)-beta branching, described by Fujimiya et 2597. In another one embodiment, the Agaricus bioactive al., (“Selective Tumoricial effect of soluble proteoglucan agent according to the present invention has a molar ratio of extracted from the basidiomycete, Agaricus blazei Murill, galactose:mannose:glucose of 1:0.5 to 5:6 to 12. Such as 1:1 mediated via natural killer cell activation and apoptosis, Can to 4:7 to 11; for example 1:1.5 to 3.5:7.5 to 10, such as 1:2.0 cer Immunol Immunother (1998) 46: 147-159). to 3.0:7.5 to 9.5, for example 1:2.2 to 2.8:8.0 to 9.0, such as (6) In another preferred embodiment of the present invention, 1:about 2.5:8.0 to 9.0, for example 1:2.5:8.0 to 9.0, such as the Agaricus bioactive agent comprises or consists of Gluco 1:25:86. mannan with a main chain of beta-1,2-linked D-mannopyra 2598. Accordingly, the Agaricus bioactive agent accord nosyl residues and beta-D-glucopyranosyl-3-O-beta-D-glu ing to the present invention can comprise one or more copyranosyl residues as a side chain described by Mizuno et polypeptides and/or a mixture of polysaccharides, wherein al. (Anti-tumor polysaccharide from the mycelium of liquid the majority of the polysaccharides of the composition has a cultured Agaricus blazei mill, Biochem Mol Biol Int. 1999 molecular weight of at least 10,000 Da and wherein said one April; 47(4):707-14) or more polysaccharides and/or said mixture of polysaccha (7) In another preferred embodiment of the present invention, rides comprises the monosaccharides galactose, mannose and the Agaricus bioactive agent comprises or consists of the glucose in the ratio (galactose:mannose:glucose) of 1:0 to polysaccharide fraction prepared using cold or hot NaOH extraction described by Ohno et al., (Antitumor beta glucan 25:1 to 50, for example 1:0.5 to 5:6 to 12, such as 1:1 to 4:7 to from the cultured fruit body of Agaricus blazei. Biol Pharm 11; for example 1:1.5 to 3.5:7.5 to 10, such as 1:2.0 to 3.0:7.5 Bull. 2001 July; 24(7):820-8). to 9.5, for example 1:2.2 to 2.8:8.0 to 9.0, such as 1:about (8) In another preferred embodiment of the present invention, 2.5:8.0 to 9.0, for example 1:2.5:8.0 to 9.0, such as 1:2.5:8.6. the Agaricus bioactive agent comprises or consists of the 2599 Particularly Preferred Embodiments of the Agari Glucomannan with a main chain of beta-1,2-linked D-man cus Bioactive Agent nopyranosyl residues and beta-D-glucopyranosyl-3-O-beta 2600 Particularly preferred embodiments of the Agaricus D-glucopyranosyl residues as a side chain described by bioactive agent for use in the present invention are described Mizuno et al. (Anti-tumor polysaccharide from the myce below: lium of liquid-cultured Agaricus blazei mill, Biochem Mol (1) In one preferred embodiment of the present invention, the Biol Int. 1999 April; 47(4):707-14) Agaricus bioactive agent comprises or consists of the (1-4)- (9) In another preferred embodiment of the present invention, alpha D glucan and/or (1-6)-beta-D-glucan described by the Agaricus bioactive agent comprises or consists of the Fujimiya et al., (“Selective Tumoricial effect of soluble pro alpha-1,4-glucan-beta-1,6-glucan complex with an average teoglucan extracted from the basidiomycete, Agaricus blazei molecular weight of 20 kDa described by Fujimiya et al., Murill, mediated via natural killer cell activation and apop (Tumor-specific cytocidal and immunopotentiating effects of tosis, Cancer Immunol Immunother (1998) 46: 147-159) relatively low molecular weight products derived from the (2) In another preferred embodiment of the present invention, basidiomycete, Agaricus blazei Murill. Anticancer Res. 1999 the Agaricus bioactive agent comprises or consists of the January-February; 19(1A): 113-8) soluble beta-(1-6)-glucans described by Fujimiya et al., (10) In another preferred embodiment of the present inven (“Peroral effect on tumour progression of soluble beta-(1,6)- tion, the Agaricus bioactive agent comprises or consists of the glucans prepared by acid treatment from Agaricus blazei. complex of alpha-1,6- and alpha-1,4-glucan described by Murr (Agaricaceae, Higher basidiomycetes). International Mizuno et al., (Polysaccharides from Agaricus blazei stimu Journal of Medicinal Mushrooms 2, 43–49). late lymphocyte T-cell subsets in mice. Biosci Biotechnol (3) In another preferred embodiment of the present invention, Biochem. 1998 March; 62(3):434-7) the Agaricus bioactive agent comprises or consists of any of (11) In another preferred embodiment of the present inven the following compounds described by Smith et al., (“Medici tion, the Agaricus bioactive agent comprises or consists of the nal mushrooms: their therapeutic properties and current ergosterol described by Takaku et al., (Isolation of an antitu medical usage with special emphasis on cancer treatments. mor compound from Agaricus blazei Murill and its mecha downloadable from http://sci.cancerresearchuk.org/labs/ nism of action. J. Nutr. 2001 May: 131(5):1409-13) med mush/med mush.html): FI-a-beta (beta-glucan from (12) In another preferred embodiment of the present inven the fruiting body), FIII2-beta (beta glucan-protein from the tion, the Agaricus bioactive agent comprises or consists of fruiting body), FA-1a-beta (hetero-beta glucan from the fruit ATOM (glucomannan-protein, isolated from Submerged cul ing body), FA-2b-beta (RNA from the fruiting body), FV-1 tured mycelial biomass) described by Ito et al., “Antitumour (insoluble beta-glucan from the fruiting body), ATOM (glu effects of a new polysaccharide-protein complex (ATOM) comannan-protein, isolated from Submerged cultured myce prepared from Agaricus blazei (Iwade strain 101) “Himemat lial biomass), AB-FP (mannan protein, isolated from the liq Sutake and its mechanisms in tumor-bearing mice'. Antican uid cultured broth), Beta (1-6)-D-glucan. cer research 17:277-284 (1997) US 2009/O 143280 A1 Jun. 4, 2009 77

(13) In another preferred embodiment of the present inven any of the basidiolipids BI-1, BI-2, BI-3 or BI-4 as described tion, the Agaricus bioactive agent comprises or consists of the by Jennemann et al., “Novel glycoinositolphosphosphin FIII-2-b ((1-6)-beta-D-glucan complex) described by golipds, basidiolipds, from Agaricus'. Eur. J. Biochem. 259, Kawagishi et al. (“Formolysis of a potent antitumor (1-6)- 331-338 (1999). beta-D-glucan-protein complex from Agaricus blazei fruit (25) In another preferred embodiment of the present inven ing bodies and antitumor activity of the resulting products. tion, the Agaricus bioactive agent is a composition compris Carbohydrpolymers 12:393-403, 1990) ing one or more polypeptides and a mixture of polysaccha (14) In another preferred embodiment of the present inven rides, wherein the majority of the polysaccharides of the tion, the Agaricus bioactive agent comprises or consists of the composition has a molecular weight of at least 10,000 Da and Isoflavone-beta-D-glucan, produced by culturing Agaricus wherein said mixture of polysaccharides comprises the blazei mycelia in isoflavone-containing liquid medium monosaccharides galactose, mannose and glucose in the ratio described in US2005069989. 1:0 to 25:1 to 50. (15) In another preferred embodiment of the present inven 2602. In another preferred embodiment of the present tion, the Agaricus bioactive agent comprises or consists of the invention, the compound may be Beta-(1-3)-D-glucan, Beta Glucomannan having a mannose chain of -1, -2 bonds as its (1-4)-a-D-glucan or Beta-(1-6)-D-glucan. primary chain described in JP 11080206. 2603) The bioactive agent can be obtained from the extra (16) In another preferred embodiment of the present inven cellular medium after having been Subjected to at least one tion, the Agaricus bioactive agent comprises or consists of the further method step selected from a purification step or a polysaccharide described by Fan et al., “Production of precipitation step, such as precipitation by mixing the extra polysaccharide by culinary-medicinal mushroom Agaricus cellular medium with an alcohol. The mycelium is removed brasiliensis S Wasser et al. LPB 03 (Agaricomycetideae) in from the liquid growth medium prior to the isolation of the Submerged fermentation and its antitumor effect’. Interna bioactive agent. The fungal mycelium can be removed e.g. by tional Journal of Medicinal Mushrooms 2003), 5(1), 17-23. filtration or centrifugation. (17) In another preferred embodiment of the present inven 2604) The bioactive agent can also be precipitated by tion, the Agaricus bioactive agent comprises or consists of the ultracentrifugation. The bioactive agent can be size fraction Linoleic acid; and/or 13-hydroxy cis-9, trans-11-octadecadi ated prior to precipitation or centrifugation and the bioactive enoic acid (13ZE-LOH) described in “Fruit body of a basidi agent can be further purified by one or more steps involving omycete Agaricus-Blazei, Yakugaku Zasshi-Journal of the washing, desalting, size fractionation, and affinity chroma Pharmaceutical Society of Japan 1994 tography, Such as ion-exchange chromatography. In one (18) In another preferred embodiment of the present inven embodiment, the bioactive agent is further purified by wash tion, the Agaricus bioactive agent comprises or consists of the ing and ion-exchange chromatography. Ab-FP described by Liu et al., ("Fractionation of extracellular 2605. The precipitated immune stimulating agent can also polysaccharide from Agaricus blazeimurill and its antitumor be further purified by size exclusion chromatography or gel activity”. ShipinYu Fajiao Gongye (2001), 27(11), 27-29) filtration. 2601 (19). In another preferred embodiment of the present 2606. In one embodiment, the bioactive agent isolatable invention, the Agaricus bioactive agent comprises or consists from the liquid growth medium is also produced intracellu of the Glucan-protein complex described by Gonzaga et al., larly in said Basidiomycete sp. The bioactive agent isolatable (“Isolation and characterisation of polysaccharides from from the liquid growth medium can be immunologically dis Agaricus blazei Murill', Carbohydrate polymers 2005, Vol. tinct from an intracellularly produced bioactive variant of the 60, Iss 1, p. 43-49) agent having essentially the same activity. (20) In another preferred embodiment of the present inven 2607. The liquid growth medium can comprise one or tion, the Agaricus bioactive agent comprises or consists of the more of malt extract, yeast extract, peptone, glucose, Sucrose, Ap-MP (water-soluble mycelia polysaccharide) described by salts providing phosphate, magnesium and potassium, corn Liu et al., “Study on antitumor activity of Agaricus blazei”. steep liquor and vitamins, such as thiamine. In one embodi (21) In another preferred embodiment of the present inven ment, the liquid growth medium comprises malt extract, yeast tion, the Agaricus bioactive agent comprises or consists of the extract, peptone, and glucose. The liquid growth medium is 1SY16 described by Lee et al. (“1SY16 isolated from Agari agitated and Supplied with an oxygen Source and the growth cus blazei Murill Kas a potent multipotential chemopreven temperature is preferably in the range of from 23°C. to 32°C. tative agent, Cancer Epidemiology Biomarkers and Preven tion 2004, Vol 13, 1ss 11, p 1861S). Modulation of the Immune System (22) In another preferred embodiment of the present inven 2608. The compositions according to the invention may be tion, the Agaricus bioactive agent comprises or consists of the immune modulating, preferably, the compositions are Sodium pyroglutamate described by Kimura et al. (“Isolation immune stimulating. The stimulation of the immune system of an anti-angiogenic Substance from Agaricus blazei Murill: can be demonstrated by e.g. increased antibody production, Its antitumor and antimetastatic actions’. Cancer Science by activation of helper T-cells, or by increased production of 2004, Vol 95, Iss 9, p 758-764). interleukins such as Interleukin 1 and Interleukin 2. (23) In another preferred embodiment of the present inven 2609 Any assay known to the skilled person, which is tion, the Agaricus bioactive agent comprises or consists of the Suitable for testing whether a composition is immune modu Blazeispirane derivatives described by Hirotani et al., lating may be employed to test whether a composition of the (“Blazeispirane and protoblazeispirane derivatives from the present invention is immune modulating. Such an assay may cultured mycelia of the fungus Agaricus blazei, Phytochem be an in vitro or an in vivo assay. istry 2002, Vol. 61, Iss 5, p. 589-595). 2610 One preferred assay is to test whether the composi (24) In another preferred embodiment of the present inven tion is capable of inducing IL-1 production, Such as IL1-C. tion, the Agaricus bioactive agent comprises or consists of and/or IL 1-B production. Thus, in a preferred embodiment of US 2009/O 143280 A1 Jun. 4, 2009 the invention, the composition according to the present inven on tumour progression of soluble beta-(1,6)-glucans prepared tion is capable of inducing IL-1 production from at least one by acid treatment from Agaricus blazei. Murr (Agaricaceae, kind of IL-1 producing cells in an in-vitro assay. The cells Higher basidiomycetes). International Journal of Medicinal may be any IL-1 producing cells, such as P388 mouse mac Mushrooms 2, 43–49); Smith et al., (“Medicinal mushrooms: rophage cells. IL-1 production may be determined using any their therapeutic properties and current medical usage with Suitable assay. In general, assays involving the use of specific special emphasis on cancer treatments... downloadable from IL-1 antibodies, such as specific IL1-C, and/or IL 1-?3 antibod http://sci.cancerresearchuk.org/labs/med mush/med mush. ies, are useful. Such assays may for example be Western html); Kobayashi et al., (“Suppressing effects of daily oral blotting, ELISA or similar assays. The assay may be per Supplementation of beta-glucan extracted from Agaricus formed as described in example 4. 2611 Because it is difficult to calibrate an IL1 assay, the blazei Murill on spontaneous and peritoneal disseminated assay is preferably performed using a specific composition as metastasis in mouse model”, J Cancer Res Clin Oncol. 2005 reference. Thus in one preferred embodiment of the present May 10); Fujimiya et al., (“Selective Tumoricial effect of invention, the composition is capable of inducing production soluble proteoglucan extracted from the basidiomycete, of at least 1.5, preferably at least 2, such as at least 4, for Agaricus blazei Murill, mediated via natural killer cell acti example at least 6, Such as at least 8, for example at least 10, vation and apoptosis, Cancer Immunol Immunother (1998) such as at least 15, for example at least 20, such as at least 30, 46: 147-159); Mizuno et al. (Anti-tumor polysaccharide for example at least 40 times more IL1-C, than the amount of from the mycelium of liquid-cultured Agaricus blazei mill', IL1-C, induced using the commercially available Lentinan for Biochem Mol Biol Int. 1999 April: 47(4):707-14): Ohno et injection (Eureka Bio-Chemicals Pty, Little Collins Street. al., (Antitumor beta glucan from the cultured fruit body of Melbourne 3000, Australia) in a reference experiment per Agaricus blazei. Biol Pharm Bull. 2001 July; 24(7):820-8); formed in parallel. In one preferred embodiment of the Mizuno et al. (Anti-tumor polysaccharide from the myce present invention, the composition is capable of inducing lium of liquid-cultured Agaricus blazei mill, Biochem Mol production of at least 1.5, preferably at least 2, Such as at least Biol Int. 1999 April; 47(4):707-14); Fujimiya et al., (Tumor 4, for example at least 6, Such as at least 8, for example at least specific cytocidal and immunopotentiating effects of rela 10, such as at least 15, for example at least 20 times more tively low molecular weight products derived from the basidi IL 1-3, than the amount of IL1-B induced using Lentinan for omycete, Agaricus blazei Murill. Anticancer Res. 1999 injection from Eureka Biochemicals Pty. in a reference January-February; 19(1A): 113-8); Mizuno et al., (Polysac experiment performed in parallel. Preferably, the aforemen charides from Agaricus blazei stimulate lymphocyte T-cell tioned assays are performed as described in example 4. It is most preferred that the composition induced production of subsets in mice. Biosci Biotechnol Biochem. 1998 March; both IL1C. and IL1B as described above. 62(3):434-7); Takaku et al., (Isolation of an antitumor com 2612 In another embodiment of the invention, the com pound from Agaricus blazei Murill and its mechanism of position is capable of enhancing antibody production in a action. J. Nutr. 2001 May: 131(5):1409-13); Ito et al., “Anti mammal, when administered to said mammal. The mammal tumour effects of a new polysaccharide-protein complex may for example be a mouse, rat, rabbit or even a human (ATOM) prepared from Agaricus blazei (Iwade strain 101) being. Preferably such an assay is performed by administer "Himematsutake' and its mechanisms in tumor-bearing ing the composition to a mammal prior to and simultaneously mice'. Anticancer research 17:277-284 (1997); Kawagishi et with administration of an antigen, optionally in the presence al. (“Formolysis of a potent antitumor (1-6)-beta-D-glucan of an adjuvant. Preferably, the composition is administered in protein complex from Agaricus blazei fruiting bodies and the range of 1 to 30 days, preferably in the range of 1 to 10 antitumor activity of the resulting products. Carbohydrpoly days, more preferably in the range of 1 to 3 days prior to mers 12:393-403, 1990); US2005069989; JP 11080206; Fan administration of the antigen. Subsequently, antibody pro et al., “Production of polysaccharide by culinary-medicinal duction in the mammal may be determined. The composition mushroom Agaricus brasiliensis S Wasser et al. LPB 03 is preferably capable of inducing production of at least 1.5. (Agaricomycetideae) in Submerged fermentation and its anti more preferably at least 2, even more preferably at least 2.5, tumor effect”, International Journal of Medicinal Mushrooms Such as at least 3, for example at least 4, Such as 6 times more 2003), 5(1), 17-23; “Fruit body of a basidiomycete Agaricus antibody compared to the amount of antibody produced with Blazei”. Yakugaku Zasshi-Journal of the Pharmaceutical out administration of the composition. An example of Such an Society of Japan 1994; Liu et al., ("Fractionation of extracel assay is outlined in example 6. lular polysaccharide from Agaricus blazeimurill and its anti 2613. It is preferred that the composition is immune tumor activity”. Shipin Yu Fajiao Gongye (2001), 27(11), modulating in more than one assay system, Such as in a 27-29;); Gonzaga et al., (“Isolation and characterisation of combination of any of the assay systems described herein polysaccharides from Agaricus blazei Murill', Carbohydrate above. polymers 2005, Vol. 60, Iss 1, p. 43–49); Liu et al., “Study on antitumor activity of Agaricus blazei; Lee et al. (“1SY16 Manufacture of an Agaricus Bioactive Agent isolated from Agaricus blazei Murill K as a potent multipo 2614 Methods of manufacture of the bioactive agent for tential chemopreventative agent'. Cancer Epidemiology use in the present invention are well-known to those skilled in Biomarkers and Prevention 2004, Vol 13, Iss 11, p 1861S); the art, such as disclosed in any of the following references, Kimura et al. (“Isolation of an anti-angiogenic Substance incorporated herein by reference: Fujimiya et al., (“Selective from Agaricus blazei Murill: Its antitumor and antimetastatic Tumoricial effect of soluble proteoglucan extracted from the actions”, Cancer Science 2004, Vol 95, Iss 9, p 758-764); basidiomycete, Agaricus blazei Murill, mediated via natural Hirotani et al., (“Blazeispirane and protoblazeispirane killer cell activation and apoptosis, Cancer Immunol Immu derivatives from the cultured mycelia of the fungus Agaricus nother (1998) 46: 147-159); Fujimiya et al., (“Peroral effect blazei, Phytochemistry 2002, Vol. 61, Iss 5, p 589-595): US 2009/O 143280 A1 Jun. 4, 2009 79

Jennemann et al., “Novel glycoinositolphosphosphingolipds, 2625) Any suitable transport molecules known to the basidiolipds, from Agaricus’. Eur. J. Biochem. 259, 331-338 skilled person may be used, such as liposomes, micelles, (1999). and/or microspheres. 2615. It is preferred that the Agaricus species is produced 2626 Conventional liposomes are typically composed of in a liquid medium using Submerged fermentation tech phospholipids (neutral or negatively charged) and/or choles niques. The liquid growth medium may in one embodiment terol. The liposomes are vesicular structures based on lipid comprise one or more of malt extract, yeast extract, peptone, bilayers Surrounding aqueous compartments. They can vary glucose, Sucrose, salts providing phosphate, magnesium and in their physiochemical properties Such as size, lipid compo potassium, corn-steep liquor and vitamins, such as thiamine. sition, Surface charge and number and fluidity of the phos Agaricus may also be grown in a liquid growth medium pholipids bilayers. The most frequently used lipid for lipo comprising malt extract, yeast extract, peptone, and glucose. Some formation are: 1,2-Dilauroyl-sn-Glycero-3- 2616 For use in the present invention, the Agaricus may Phosphocholine (DLPC), 1,2-Dimyristoyl-sn-Glycero-3- be grown in a liquid growth medium which is agitated and Phosphocholine (DMPC), 1,2-Dipalmitoyl-sn-Glycero-3- Supplied with an oxygen source. Phosphocholine (DPPC), 1,2-Distearoyl-sn-Glycero-3- 2617 For use in the present invention, the Agaricus may Phosphocholine (DSPC), 1,2-Dioleoyl-sn-Glycero-3- be grown at a temperature in the range of from 23°C. to 32 Phosphocholine (DOPC), 1,2-Dimyristoyl-sn-Glycero-3- C Phosphoethanolamine (DMPE), 1,2-Dipalmitoyl-sn Glycero-3-Phosphoethanolamine (DPPE), 1,2-Dioleoyl-sn 2618 For use in the present invention, the Agaricus myce Glycero-3-Phosphoethanolamine (DOPE), 1,2-Dimyristoyl lium may be removed from the liquid growth medium prior to sn-Glycero-3-Phosphate (Monosodium Salt) (DMPA), 1,2- the isolation of the Agaricus bioactive agent. Dipalmitoyl-sn-Glycero-3-Phosphate (Monosodium Salt) 2619 For use in the present invention, the Agaricus fungal (DPPA), 1,2-Dioleoyl-sn-Glycero-3-Phosphate (Monoso mycelium may be removed from the initial Agaricus culture dium Salt) (DOPA), 1,2-Dimyristoyl-sn-Glycero-3-Phos by filtration or centrifugation. pho-rac-(1-glycerol) (Sodium Salt) (DMPG), 1,2-Dipalmi toyl-sn-Glycero-3-Phospho-rac-(1-glycerol) (Sodium Salt) Individual Treated Using the Compositions of the Present (DPPG), 1,2-Dioleoyl-sn-Glycero-3-Phospho-rac-(1-glyc Invention erol) (Sodium Salt) (DOPG), 1,2-Dimyristoyl-sn-Glycero 2620 Any individual may be treated using the kit-of-parts 3-Phospho-L-Serine (Sodium Salt) (DMPS), 1,2-Dipalmi according to the invention, for example in any of the uses or toyl-sn-Glycero-3-Phospho-L-Serine) (Sodium Salt) methods described herein. Preferably, said individual is a (DPPS), 1,2-Dioleoyl-sn-Glycero-3-Phospho-L-Serine mammal. Such as a human being. In one embodiment of the (Sodium Salt) (DOPS), 1,2-Dioleoyl-sn-Glycero-3-Phos present invention, the individual is immunocompromised. phoethanolamine-N-(glutaryl) (Sodium Salt) and 1,1,2,2'- 2621. In one embodiment of the present invention, said Tetramyristoyl Cardiolipin (Ammonium Salt). Formulations individual is elderly, such as 60-120 years old, for example composed of DPPC in combination with other lipid or modi 70-120 years old, such as 80-120 years old, for instance fiers of liposomes are preferred e.g. in combination with 90-120 years old. In another embodiment of the present cholesterol and/or phosphatidylcholine. invention, said individual is 20-60 years old, such as 30-50 2627 Long-circulating liposomes are characterized by years old. In another embodiment of the present invention, their ability to extravasate at body sites where the permeabil said individual is a child, such as from 0-20 years old, for ity of the vascular wall is increased. The most popular way to example 0-15 years old, such as 0-10 years old, for example produce long circulating liposomes is to attach hydrophilic 0-5 years old, such as 0-1 years old, such as a newborn child polymer polyethylene glycol (PEG) covalently to the outer less than 2 months old. surface of the liposome. Some of the preferred lipids are: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N- Pharmaceutical Composition Methoxy(Polyethylene glycol)-2000 (Ammonium Salt), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N- 2622. While it is possible for the compounds or salts Methoxy(Polyethylene glycol)-5000 (Ammonium Salt), thereof useful in the present invention to be administered as 1,2-Dioleoyl-3-Trimethylammonium-Propane (Chloride the raw chemical, it is preferred to present them in the form of Salt) (DOTAP). a pharmaceutical composition. The anti-cancer compound 2628. A variety of methods are available for preparing and Agaricus bioactive agent may be co-formulated as two liposomes, as described in, e.g., Szoka et al., Ann. Rev. Bio separate pharmaceutical compositions. phys. Bioeng.9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501, 2623) In one particular embodiment the invention relates 728 and 4.837,028, all of which are incorporated herein by to the use of a pharmaceutical composition comprising a reference. One method is described in example 9. Another mixture of at least two different Agaricus bioactive com method produces multilamellar vesicles of heterogeneous pounds and/or at least one or two anti-cancer medicaments. sizes. In this method, the vesicle-forming lipids are dissolved 2624 The pharmaceutical composition may comprise any in a suitable organic solvent or solvent system and dried under anti-cancer agent and/or Agaricus bioactive agent or a phar vacuum or an inert gas to form a thin lipid film. If desired, the maceutically acceptable salt thereof, and pharmaceutically film may be redissolved in a suitable solvent, such as tertiary acceptable carriers, vehicles and/or excipients. Said compo butanol, and then lyophilized to form a more homogeneous sition may further optionally comprise transport molecules. lipid mixture which is in a more easily hydrated powder like The transport molecules are primarily added in order to form. This film is covered with an aqueous solution of the increase the half-life of the compound(s). Transport mol targeted drug and the targeting component and allowed to ecules act by having incorporated into or anchored to it the hydrate, typically over a 15-60 minute period with agitation. compound according to the invention. The size distribution of the resulting multilamellar vesicles US 2009/O 143280 A1 Jun. 4, 2009 can be shifted toward smaller sizes by hydrating the lipids delivery, sublingual delivery, transdermal delivery, inhalation under more vigorous agitation conditions or by adding solu and needle-free injection, such as using the methods devel bilizing detergents such as deoxycholate. Additionally, the oped by Powderjet. liposome Suspension may include lipid-protective agents 2634 For inhalation, the compounds of the present inven which protect lipids against free-radical and lipid-peroxida tion can be formulated as using methods known to those tive damages on storage. Lipophilic free-radical quenchers, skilled in the art, for example an aerosol, dry powder or Such as alpha-tocopherol and water-soluble iron-specific solubilized such as in micro droplets, preferably in a device chelators, such as ferrioxianine, are preferred. intended for such delivery (such as commercially available 2629 Micelles are formed by surfactants (molecules that from Aradigm, Alkerme or Nektar). contain a hydrophobic portion and one or more ionic or oth 2635 Pharmaceutical compositions of the present inven erwise strongly hydrophilic groups) in aqueous Solution. As tion may contain a physiologically tolerable carrier together the concentration of a solid Surfactant increases, its monolay with at least one compound according to the present inven ers adsorbed at the air/water or glass/water interfaces become tion, dissolved or dispersed therein as an active ingredient. so tightly packed that further occupancy requires excessive 2636. As used herein, the terms “pharmaceutically accept compression of the Surfactant molecules already in the two able”, “physiologically tolerable' and grammatical varia tions thereof, as they refer to compositions, carriers, diluents monolayers. Further increments in the amount of dissolved and reagents, are used interchangeably and represent that the Surfactant beyond that concentration cause amounts equiva materials are capable of administration to or upon a human lent to the new molecules to aggregate into micelles. This without the production of undesirable physiological effects process begins at a characteristic concentration called "criti Such as nausea, dizziness, gastric upset and the like. cal micelle concentration'. 2637. The preparation of a pharmacological composition 2630. The shape of micelles formed in dilute surfactant that contains active ingredients dissolved or dispersed therein Solutions is approximately spherical. The polar head groups is well understood in the art. Typically Such compositions are of the Surfactant molecules are arranged in an outer spherical prepared as sterile injectables either as liquid Solutions or shell whereas their hydrocarbon chains are oriented toward Suspensions, aqueous or non-aqueous, however, Solid forms the center, forming a spherical core for the micelle. The Suitable for Solution, or Suspensions, in liquid prior to use can hydrocarbon chains are randomly coiled and entangled and also be prepared. The preparation can also be emulsified. the micellar interior has a nonpolar, liquid-like character. In 2638. The active ingredient can be mixed with excipients the micelles of polyoxyethylated non-ionic detergents, the which are pharmaceutically acceptable and compatible with polyoxyethlene moieties are oriented outward and permeated the active ingredient and in amounts suitable for use in the by water. This arrangement is energetically favourable since therapeutic methods described herein. Suitable excipients the hydrophilic head groups are in contact with water and the are, for example, water, Saline, dextrose, glycerol, ethanol or hydrocarbon moieties are removed from the aqueous medium the like and combinations thereof. In addition, if desired, the and partly shielded from contact with water by the polar head composition can contain minor amounts of auxiliary Sub groups. The hydrocarbon tails of the Surfactant molecules, stances such as wetting or emulsifying agents, pH buffering located in the interior of the micelle, interact with one another agents and the like which enhance the effectiveness of the by weak van der Waals forces. active ingredient. It is preferred that the formulation has a pH 2631. The size of a micelle or its aggregation number is within the range of 3.5-8, such as in the range 4.5-7.5, such as governed largely by geometric factors. The radius of the in the range 5.5-7, such as in the range 6-7.5, most preferably hydrocarbon core cannot exceed the length of the extended around 7.3. However, as is understood by one skilled in the hydrocarbon chain of the surfactant molecule. Therefore, art, the pH range may be adjusted according to the individual increasing the chain length or ascending homologous series treated and the administration procedure. For example, in increases the aggregation number of spherical micelles. If the another preferred embodiment of the invention the formula Surfactant concentration is increased beyond a few percent tion has a pH within the range 3.5-7, such as 4-6, such as 5-6, and if electrolytes are added (in the case of ionic Surfactants) such as 5.3-5.7., such as 5.5. or the temperature is raised (in the case of non-ionic Surfac 2639 The pharmaceutical composition of the present tants), the micelles increase in size. Under these conditions, invention can include pharmaceutically acceptable salts of the micelles are too large to remain spherical and become the compounds therein. These salts will be ones which are ellipsoidal, cylindrical or finally lamellar in shape. acceptable in their application to a pharmaceutical use. By 2632 Common surfactants well known to one of skill in that it is meant that the salt will retain the biological activity the art can be used in the micelles of the present invention. of the parent compound and the salt will not have untoward or Suitable surfactants include sodium laureate, sodium oleate, deleterious effects in its application and use in treating dis Sodium lauryl Sulfate, octaoxyethylene glycol monododecyl CaSCS. ether, octoxynol 9 and PLURONIC F-127 (Wyandotte 2640 Pharmaceutically acceptable salts are prepared in a Chemicals Corp.). Preferred surfactants are nonionic poly standard manner. If the parent compound is a base it is treated oxyethylene and polyoxypropylene detergents compatible with an excess of an organic or inorganic acid in a Suitable with IV injection such as, TWEEN-80. PLURONIC F-68. Solvent. If the parent compound is an acid, it is treated with an n-octyl-beta.-D-glucopyranoside, and the like. In addition, inorganic or organic base in a suitable solvent. phospholipids, such as those described for use in the produc 2641. The compounds of the invention may be adminis tion of liposomes, may also be used for micelle formation. tered in the form of an alkali metal or earth alkali metal salt 2633. In another preferred embodiment, the compounds of thereof, concurrently, simultaneously, or together with a the present invention are formulated as described in the lit pharmaceutically acceptable carrier or diluent, especially and erature for an administration route selected from: buccal preferably in the form of a pharmaceutical composition US 2009/O 143280 A1 Jun. 4, 2009

thereof, whether by e.g. oral, rectal, or parenteral (including 2649 Suitable pharmaceutical carriers include inert solid Subcutaneous) route, in an effective amount. diluents or fillers, sterile aqueous Solution and various 2642 Examples of pharmaceutically acceptable acid organic solvents. Examples of Solid carriers are lactose, terra addition salts for use in the present inventive pharmaceutical alba, Sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, composition include those derived from mineral acids, Such magnesium Stearate, Stearic acid or lower alkyl ethers of as hydrochloric, hydrobromic, phosphoric, metaphosphoric, cellulose. Examples of liquid carriers are syrup, peanut oil, nitric and Sulfuric acids, and organic acids, Such as tartaric, olive oil, phospholipids, fatty acids, fatty acid amines, poly acetic, citric, malic, lactic, fumaric, benzoic, glycolic, glu oxyethylene or water. Administered by nasal aerosol or inha conic, Succinic, p-toluenesulphonic acids, and arylsulphonic, lation formulations may be prepared, for example, as solu for example. tions in Saline, employing benzyl alcohol or other Suitable preservatives, absorption promoters to enhance bioavailabil 2643. Other suitable pharmaceutically acceptable salts ity, employing fluorocarbons, and/or employing other solu include the acid addition salts (formed with the free amino bilizing or dispersing agents. groups of the polypeptide). Other examples of salts include 2650. The pharmaceutical compositions formed by com pharmaceutically acceptable acid addition salts, pharmaceu bining the compounds of the invention and the pharmaceuti tically acceptable metal salts, ammonium salts and alkylated cal acceptable carriers are then readily administered in a ammonium salts. Acid addition salts include salts of inor variety of dosage forms suitable for the disclosed routes of ganic acids as well as organic acids. Representative examples administration. The formulations may conveniently be pre of Suitable inorganic acids include hydrochloric, hydrobro sented in unit dosage form by methods known in the art of mic, hydriodic, phosphoric, Sulpfuric and nitric acids and the pharmacy. like. Representative examples of Suitable organic acids 2651. In a preferred embodiment of the invention the for include formic, acetic, trichloroacetic, trifluoroacetic, propi mulation comprises the compound or salt(s) thereof as a onic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, lyophilisate and the formulation further comprises a solvent, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, said lyophilisate and said solvent being in separate compart salicylic, Succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene Salicylic, ethanedisulfonic, ments until administration. gluconic, citraconic, aspartic, Stearic, palmitic, ethylenedi Administration aminetetraacetic (EDTA), p-aminobenzoic, glutamic, benze nesulfonic and ptoluenesulfonic acids and the like. Further 2652 The components of the kit-of-parts according to the examples of pharmaceutically acceptable inorganic or present invention do not have to be administered concur organic acid addition salts include the pharmaceutical accept rently, however in one preferred embodiment the anti-cancer able salts listed in J. Pharm. Sci. 1977, 66, 2, which is incor medicament is administered simultaneously with the admin porated herein by reference. Examples of metal salts include istration of the Agaricus bioactive agent, such as in a co lithium, Sodium, potassium and magnesium salts and the like. formulation. In another preferred embodiment, the anti-can 2644 Examples of ammonium and alkylated ammonium cer medicament and the bioactive agent are administered salts include ammonium, methylammonium, dimethylam sequentially, in any order, Such as first the Agaricus bioactive monium, trimethylammonium, ethylammonium, hydroxy agent and then the anti-cancer medicament. ethylammonium, diethylammonium, butylammonium and 2653. In one preferred embodiment of the present inven tion, the medicament and/or agent are administered Subcuta tetramethylammonium salts and the like. neously. 2645 Salts formed with the free carboxyl groups can also 2654. In another preferred embodiment of the present be derived from inorganic bases such as, for example, invention, the medicament and/or agent are administered Sodium, potassium, ammonium, calcium or ferric hydrox nasally. ides, and Such organic bases as isopropylamine, trimethy 2655. In another preferred embodiment of the present lamine, 2-ethylamino ethanol, histidine, procaine and the invention, the medicament and/or agent are administered via like. the pulmonary route, such as via aerosol administration. 2646. Also included within the scope of compounds or 2656. In another preferred embodiment of the present pharmaceutical acceptable acid addition salts thereof in the invention, the medicament and/or agent are administered via context of the present invention are any hydrates (hydrated parenteral administration. forms) thereof. 2657. In another preferred embodiment of the present 2647 For parenteral administration, solutions of the invention, said medicament and/or agent are administered present compounds in sterile aqueous solution, aqueous pro orally. pylene glycolor sesame or peanut oil may be employed. Such 2658. In another preferred embodiment of the present aqueous solutions should be suitably buffered if necessary, invention, said medicament and/or agent are administered and the liquid diluent first rendered isotonic with sufficient topically. saline or glucose. The aqueous solutions are particularly Suit 2659. In another preferred embodiment of the present able for intravenous, intramuscular, Subcutaneous and intra invention, said medicament and/or agent are co-formulated in peritoneal administration. The sterile aqueous media a composition. employed are all readily available by standard techniques 2660. The kit-of-parts according to the present invention known to those skilled in the art. may comprise two or more administration types, but co 2648 Liquid compositions can also contain liquid phases formulation or at least the same administration route is pre in addition to and to the exclusion of water. Exemplary of ferred for all the elements in the kit-of-parts. Such additional liquid phases are glycerin, vegetable oils such 2661. In another aspect the Agaricus agent and/or anti as cottonseed oil, organic esters such as ethyl oleate, and cancer medicament is administered as a bolus, wherein the water-oil emulsions. administration form may be any Suitable parenteral form. US 2009/O 143280 A1 Jun. 4, 2009

2662. In a preferred embodiment the Agaricus agent and/ solubilizers, lubricants, Suspending agents, binders, preser oranti-cancer medicament is administered Subcutaneously in Vatives, wetting agents, tablet disintegrating agents, or an abolus. encapsulating material. 2663 Pharmaceutical compositions for parenteral admin 2669 Preferably, the composition will be about 0.5% to istration include sterile aqueous and non-aqueous injectable 75% by weight of a compound or compounds of the inven Solutions, dispersions, Suspensions or emulsions, as well as tion, with the remainder consisting of Suitable pharmaceuti sterile powders to be reconstituted in sterile injectable solu cal excipients. For oral administration, such excipients tions or dispersions prior to use. include pharmaceutical grades of mannitol, lactose, starch, magnesium Stearate, Sodium saccharine, talcum, cellulose, 2664. Other suitable administration forms include Sup glucose, gelatin, Sucrose, magnesium carbonate, and the like. positories, sprays, ointments, cremes, gels, inhalants, dermal 2670. In powders, the carrier is a finely divided solid patches, implants, pills, tablets, lozenges and capsules. which is a mixture with the finely divided active component. 2665. The compounds of the present invention may be In tablets, the active component is mixed with the carrier formulated for nasal administration. The solutions or Suspen having the necessary binding capacity in Suitable proportions sions are applied directly to the nasal cavity by conventional and compacted in the shape and size desired. The powders means, for example with a dropper, pipette or spray. The and tablets preferably containing from one to about seventy compositions may be provided in a single or multidose form. percent of the active compound. Suitable carriers are magne In the latter case of a dropper or pipette this may be achieved sium carbonate, magnesium Stearate, talc, Sugar, lactose, pec by the patient administering an appropriate, predetermined tin, dextrin, starch, gelatin, tragacanth, methylcellulose, Volume of the Solution or Suspension. In the case of a spray Sodium carboxymethylcellulose, a low melting wax, cocoa this may be achieved for example by means of a metering butter, and the like. The term “preparation' is intended to atomizing spray pump. include the composition of the active compound with encap 2666. The compounds of the present invention may be Sulating material as carrier providing a capsule in which the formulated for aerosol administration, particularly to the res active component, with or without carriers, is Surrounded by piratory tract and including intranasal administration. The a carrier, which is in association with it. Similarly, cachets and compound will generally have a small particle size for lozenges are included. Tablets, powders, capsules, pills, example of the order of 5 microns or less. Such a particle size cachets, and lozenges can be as Solid forms suitable for oral may be obtained by means known in the art, for example by administration. micronization. The active ingredient is provided in a pressur 2671. Drops according to the present invention may com ized pack with a Suitable propellant such as a chlorofluoro prise sterile or non-sterile aqueous or oil solutions or Suspen carbon (CFC) for example dichlorodifluoromethane, trichlo sions, and may be prepared by dissolving the active ingredient rofluoromethane, or dichlorotetrafluoroethane, carbon in a suitable aqueous Solution, optionally including a bacte dioxide or other Suitable gas. The aerosol may conveniently ricidal and/or fungicidal agent and/or any other Suitable pre also contain a surfactant such as lecithin. The dose of drug servative, and optionally including a surface active agent. The may be controlled by a metered valve. Alternatively the active resulting solution may then be clarified by filtration, trans ingredients may be provided in a form of a dry powder, for ferred to a suitable container which is then sealed and steril example a powder mix of the compound in a Suitable powder ized by autoclaving or maintaining at 98-100° C. for half an base such as lactose, starch, starch derivatives such as hydrox hour. Alternatively, the solution may be sterilized by filtration ypropylmethyl cellulose and polyvinylpyrrolidine (PVP). and transferred to the container aseptically. Examples of bac The powder carrier will form a gel in the nasal cavity. The tericidal and fungicidal agents suitable for inclusion in the powder composition may be presented in unit dose form for drops are phenylmercuric nitrate or acetate (0.002%), benza example in capsules or cartridges of e.g., gelatin or blister lkonium chloride (0.01%) and chlorhexidine acetate (0.01%). packs from which the powder may be administered by means Suitable solvents for the preparation of an oily solution of an inhaler. include glycerol, diluted alcohol and propylene glycol. 2667 Compositions administered by aerosols may be pre 2672 Also included are solid form preparations which are pared, for example, as solutions in Saline, employing benzyl intended to be converted, shortly before use, to liquid form alcohol or other suitable preservatives, absorption promoters preparations for oral administration. Such liquid forms to enhance bioavailability, employing fluorocarbons, and/or include solutions, Suspensions, and emulsions. These prepa employing other solubilizing or dispersing agents. rations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural Sweeteners, dispersants, thickeners, solubilizing agents, and Compositions for Oral Administration the like. 2668 Those compound types capable of remaining bio 2673. Other forms suitable for oral administration include logically active in an individual after oral administration liquid form preparations including emulsions, syrups, elixirs, (such as e.g. Small molecules and short peptides) can be aqueous solutions, aqueous Suspensions, toothpaste, gelden formulated in a wide range of oral administration dosage tifrice, chewing gum, or solid form preparations which are forms. The pharmaceutical compositions and dosage forms intended to be converted shortly before use to liquid form may comprise the compounds of the invention or its pharma preparations. Emulsions may be prepared in Solutions in ceutically acceptable salt or a crystal form thereof as the aqueous propylene glycol solutions or may contain emulsi active component. The pharmaceutically acceptable carriers fying agents such as lecithin, Sorbitan monooleate, or acacia. can be either solid or liquid. Solid form preparations include Aqueous Solutions can be prepared by dissolving the active powders, tablets, pills, capsules, cachets, Suppositories, and component in water and adding Suitable colorants, flavours, dispersible granules. A Solid carrier can be one or more Sub stabilizing and thickening agents. Aqueous Suspensions can stances which may also act as diluents, flavouring agents, be prepared by dispersing the finely divided active compo US 2009/O 143280 A1 Jun. 4, 2009

nent in water with Viscous material. Such as natural or syn order to minimize or eliminate irritation at the site of injec thetic gums, resins, methylcellulose, sodium carboxymethyl tion, such compositions may contain one or more nonionic cellulose, and other well known Suspending agents. Solid surfactants having a hydrophile-lipophile balance (HLB) of form preparations include solutions, Suspensions, and emul from about 12 to about 17. The quantity of surfactant in such sions, and may contain, in addition to the active component, compositions will typically range from about 5 to about 15% colorants, flavours, stabilizers, buffers, artificial and natural by weight. Suitable surfactants include polyethylene sorbitan Sweeteners, dispersants, thickeners, solubilizing agents, and fatty acid esters, such as Sorbitan monooleate and the high the like. molecular weight adducts of ethylene oxide with a hydropho bic base, formed by the condensation of propylene oxide with Compositions for Parenteral Administration propylene glycol. The parenteral compositions can be pre 2674. The compounds of the present invention may be sented in unit-dose or multi-dose sealed containers, such as formulated for parenteral administration (e.g., by injection, ampules and vials, and can be stored in a freeze-dried (lyo for example bolus injection or continuous infusion) and may philized) condition requiring only the addition of the sterile be presented in unit dose form in ampoules, pre-filled liquid excipient, for example, water, for injections, immedi Syringes, Small Volume infusion or in multi-dose containers ately prior to use. Extemporaneous injection Solutions and with an added preservative. The compositions may take Such Suspensions can be prepared from sterile powders, granules, forms as Suspensions, Solutions, or emulsions in oily or aque and tablets of the kind previously described. ous vehicles, for example solutions in aqueous polyethylene 2679 The pharmaceutical dosage forms suitable for injec glycol. Examples of oily or nonaqueous carriers, diluents, tion or infusion can include sterile aqueous solutions or dis Solvents or vehicles include propylene glycol, polyethylene persions comprising the active ingredient that are adapted for glycol, vegetable oils (e.g., olive oil), and injectable organic administration by encapsulation in liposomes. In all cases, the esters (e.g., ethyl oleate), and may contain formulatory agents ultimate dosage form must be sterile, fluid and stable under Such as preserving, wetting, emulsifying or Suspending, sta the conditions of manufacture and storage. bilizing and/or dispersing agents. Alternatively, the active 2680 Sterile injectable solutions are prepared by incorpo ingredient may be in powder form, obtained by aseptic isola rating the compound or pharmaceutically acceptable salt tion of sterile solid or by lyophilisation from solution for thereof in the required amount in the appropriate solvent with constitution before use with a suitable vehicle, e.g., sterile, various of the other ingredients enumerated above, as pyrogen-free water. Aqueous Solutions should be suitably required, followed by filter sterilization. buffered if necessary, and the liquid diluent first rendered isotonic with Sufficient saline or glucose. The aqueous solu Compositions for Topical Administration tions are particularly Suitable for intravenous, intramuscular, 2681. The compounds of the invention can also be deliv Subcutaneous and intraperitoneal administration. The sterile ered topically. Regions for topical administration include the aqueous media employed are all readily available by standard skin Surface and also mucous membrane tissues of the rec techniques known to those skilled in the art. tum, nose, mouth, and throat. Compositions for topical 2675 Solutions of the compound(s) or pharmaceutically administration via the skin and mucous membranes should acceptable salt(s) thereof (and for example antigenic not give rise to signs of irritation, such as Swelling or redness. epitopes and protease inhibitors) can be prepared in water or 2682. The topical composition may include a pharmaceu saline, and optionally mixed with a nontoxic Surfactant. Com tically acceptable carrier adapted for topical administration. positions for intravenous or intra-arterial administration may Thus, the composition may take the form of a Suspension, include sterile aqueous solutions that may also contain buff Solution, ointment, lotion, cream, foam, aerosol, spray, Sup ers, liposomes, diluents and other suitable additives. pository, implant, inhalant, tablet, capsule, dry powder, syrup, 2676 Oils useful in parenteral compositions include balm or lozenge, for example. Methods for preparing Such petroleum, animal, vegetable, or synthetic oils. Specific compositions are well known in the pharmaceutical industry. examples of oils useful in Such compositions include peanut, 2683. The compounds of the present invention may be Soybean, Sesame, cottonseed, corn, olive, petrolatum, and formulated for topical administration to the epidermis as oint mineral. Suitable fatty acids for use in parenteral composi ments, creams or lotions, or as a transdermal patch. Oint tions include oleic acid, Stearic acid, and isostearic acid. Ethyl ments and creams may, for example, be formulated with an oleate and isopropyl myristate are examples of Suitable fatty aqueous or oily base with the addition of Suitable thickening acid esters. and/or gelling agents. Lotions may be formulated with an 2677 Suitable soaps for use in parenteral compositions aqueous or oily base and will in general also containing one or include fatty alkali metal, ammonium, and triethanolamine more emulsifying agents, stabilizing agents, dispersing salts, and Suitable detergents include (a) cationic detergents agents, Suspending agents, thickening agents, or coloring Such as, for example, dimethyl dialkyl ammonium halides, agents. Compositions Suitable for topical administration in and alkylpyridinium halides; (b) anionic detergents such as, the mouth include lozenges comprising active agents in a for example, alkyl, aryl, and olefin Sulfonates, alkyl, olefin, flavoured base, usually sucrose and acacia or tragacanth; ether, and monoglyceride Sulfates, and SulfoSuccinates, (c) pastilles comprising the active ingredient in an inert base Such nonionic detergents such as, for example, fatty amine oxides, as gelatin and glycerin or Sucrose and acacia; and mouth fatty acidalkanolamides, and polyoxyethylenepolypropylene washes comprising the active ingredient in a Suitable liquid copolymers, (d) amphoteric detergents such as, for example, carrier. alkyl-beta.-aminopropionates, and 2-alkyl-imidazoline qua 2684 Creams, ointments or pastes according to the ternary ammonium salts, and (e) mixtures thereof. present invention are semi-solid compositions of the active 2678. The parenteral compositions typically will contain ingredient for external application. They may be made by from about 0.5 to about 25% by weight of the active ingredi mixing the active ingredient in finely-divided or powdered ent in solution. Preservatives and buffers may be used. In form, alone or in Solution or Suspension in an aqueous or US 2009/O 143280 A1 Jun. 4, 2009

non-aqueous fluid, with the aid of Suitable machinery, with a 2690. A further embodiment of this invention will utilize a greasy or non-greasy base. The base may comprise hydrocar hydrogel matrix patch. Typically, the hydrogel matrix will bons such as hard, soft or liquid paraffin, glycerol, beeswax, comprise alcohol, water, drug, and several hydrophilic poly a metallic Soap; a mucilage; an oil of natural origin Such as mers. This hydrogel matrix can be incorporated into a trans almond, corn, arachis, castor or olive oil; wool fat or its dermal patch between the backing and the adhesive layer. derivatives or a fatty acid Such as steric or oleic acid together 2691. The liquid reservoir patch will also find use in the with an alcohol Such as propylene glycol or a macrogel. The methods described herein. This patch comprises an imperme composition may incorporate any Suitable surface active able or semipermeable, heat sealable backing material, a heat sealable membrane, an acrylate based pressure sensitive skin agent such as an anionic, cationic or non-ionic Surfactant Such adhesive, and a siliconized release liner. The backing is heat as a sorbitan ester or a polyoxyethylene derivative thereof. sealed to the membrane to form a reservoir which can then be Suspending agents such as natural gums, cellulose derivatives filled with a solution of the complex, enhancers, gelling or inorganic materials such as silicaceous silicas, and other agent, and other excipients. ingredients such as lanolin, may also be included. 2692 Foam matrix patches are similar in design and com 2685 Lotions according to the present invention include ponents to the liquid reservoir system, except that the gelled those Suitable for application to the skin or eye. An eye lotion compound solution is constrained in a thin foam layer, typi may comprise a sterile aqueous solution optionally contain cally a polyurethane. This foam layer is situated between the ing a bactericide and may be prepared by methods similar to backing and the membrane which have been heat sealed at the those for the preparation of drops. Lotions or liniments for periphery of the patch. application to the skin may also include an agent to hasten 2693 For passive delivery systems, the rate of release is drying and to cool the skin, Such as an alcohol or acetone, typically controlled by a membrane placed between the res and/or a moisturizer Such as glycerol or an oil such as castor ervoir and the skin, by diffusion from a monolithic device, or oil or arachis oil. by the skin itself serving as a rate-controlling barrier in the 2686 The compounds described herein can be adminis delivery system. See U.S. Pat. Nos. 4,816,258; 4.927,408; tered transdermally. Transdermal administration typically 4,904,475; 4,588,580, 4,788,062; and the like. The rate of involves the delivery of a pharmaceutical agent for percuta drug delivery will be dependent, in part, upon the nature of the neous passage of the drug into the systemic circulation of the membrane. For example, the rate of drug delivery across patient. The skin sites include anatomic regions for transder membranes within the body is generally higher than across mally administering the drug and include the forearm, abdo dermal barriers. The rate at which the compound(s) is deliv men, chest, back, buttock, mastoidal area, and the like. ered from the device to the membrane is most advantageously 2687 Transdermal delivery is accomplished by exposing controlled by the use of rate-limiting membranes which are a source of the complex to a patient's skin for an extended placed between the reservoir and the skin. Assuming that the period of time. Transdermal patches have the added advan skin is sufficiently permeable to the compound (i.e., absorp tage of providing controlled delivery of a pharmaceutical tion through the skin is greater than the rate of passage agent-chemical modifier complex to the body. See Transder through the membrane), the membrane will serve to control mal Drug Delivery: Developmental Issues and Research Ini the dosage rate experienced by the patient. tiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., 2694 Suitable permeable membrane materials may be (1989); Controlled Drug Delivery: Fundamentals and Appli selected based on the desired degree of permeability, the cations, Robinson and Lee (eds.), Marcel Dekker Inc., nature of the complex, and the mechanical considerations (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydo related to constructing the device. Exemplary permeable nieus and Berner (eds.), CRC Press, (1987). Such dosage membrane materials include a wide variety of natural and forms can be made by dissolving, dispersing, or otherwise synthetic polymers. Such as polydimethylsiloxanes (silicone incorporating the pharmaceutical agent-chemical modifier rubbers), ethylenevinylacetate copolymer (EVA), polyure complex in a proper medium, Such as an elastomeric matrix thanes, polyurethane-polyether copolymers, polyethylenes, material. Absorption enhancers can also be used to increase polyamides, polyvinylchlorides (PVC), polypropylenes, the flux of the compound across the skin. The rate of such flux polycarbonates, polytetrafluoroethylenes (PTFE), cellulosic can be controlled by either providing a rate-controlling mem materials, e.g., cellulose triacetate and cellulose nitratefac brane or dispersing the compound in a polymer matrix or gel. etate, and hydrogels, e.g., 2-hydroxyethylmethacrylate 2688. A variety of types of transdermal patches will find (HEMA). use in the methods described herein. For example, a simple 2695 Other items may be contained in the device, such as adhesive patch can be prepared from a backing material and other conventional components of therapeutic products, an acrylate adhesive. The compound(s) are formulated into depending upon the desired device characteristics. For the adhesive casting solution and allowed to mix thoroughly. example, the compositions according to this invention may The solution is cast directly onto the backing material and the also include one or more preservatives or bacteriostatic casting solvent is evaporated in an oven, leaving an adhesive agents, e.g., methyl hydroxybenzoate, propyl hydroxyben film. The release liner can be attached to complete the system. Zoate, chlorocresol, benzalkonium chlorides, and the like. 2689 Alternatively, a polyurethane matrix patch can be These pharmaceutical compositions also can contain other employed to deliver the compound(s). The layers of this patch active ingredients such as antimicrobial agents, particularly comprise a backing, a polyurethane drug/enhancer matrix, a antibiotics, anesthetics, analgesics, and antipruritic agents. membrane, an adhesive, and a release liner. The polyurethane matrix is prepared using a room temperature curing polyure Compositions for Administration as Suppositories thane prepolymer. Addition of water, alcohol, and complex to 2696. The compounds of the present invention may be the prepolymer results in the formation of a tacky firm elas formulated for administration as Suppositories. A low melting tomer that can be directly cast only the backing material. wax, such as a mixture offatty acid glycerides or cocoa butter US 2009/O 143280 A1 Jun. 4, 2009 is first melted and the active component is dispersed homo 2705. In one preferred embodiment of the present inven geneously, for example, by Stirring. The molten homoge tion, the Agaricus bioactive agent stimulates the immune neous mixture is then poured into convenient sized molds, system of an animal or a human when administered to said allowed to cool, and to solidify. animal or human in a pharmaceutically active amount. Pref 2697 The active compound may be formulated into a Sup erably, said agent is capable of stimulating in an individual in pository comprising, for example, about 0.5% to about 50% need of Such stimulation, the production of one or more of of a compound of the invention, disposed in a polyethylene antibodies, such as IgG, IgA, and IgE, T helper cells, inter glycol (PEG) carrier (e.g., PEG 1000 96% and PEG 4000 leukins, such as IL-1 and IL-2, interferon, such as IFN 4%. gamma, natural killer cells, and macrophages. Dosage 2706. It is further envisaged that any of the uses and prod ucts described herein may be used in a method for the treat 2698 Suitable dosing regimens for the various com ment of a neoplastic disease in an individual, said method pounds and methods of the present invention are preferably comprising the steps of determined taking into account factors well known in the art 2707 a. providing any of the kit of parts as described including type of Subject being dosed; age, weight, sex and herein, and medical condition of the subject; the route of administration; 2708 b. administering any of the anti-cancer medica the renal and hepatic function of the subject; the desired ments and Agaricus bioactive agents described hereinto effect; and the particular compound employed. said individual. 2699 Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's avail EXAMPLES ability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. 2709 The following examples describe illustrative 2700 The compositions of the invention may be adminis embodiments of the invention and should not be regarded as tered using any Suitable administration form; usually how limiting for the invention. ever, administration will be oral or parenteral. Oral adminis tration in the form of a syrup comprising the composition Example 1 and/or a capsule containing a syrup comprising the compo sition or in a powder form of the composition is preferred. 2710 Protocol for cultivation of Basidiomycete cells 2701 The dosage requirements will vary with the particu according to the present invention. The protocol is used in the lar composition employed, the route of administration and the further examples unless otherwise stated. particular individual being treated. Ideally, an individual to be treated by the present method will receive a pharmaceutically Cultivation Conditions: effective amount of the compound in the maximum tolerated dose. Temperature: 25°C.i.1° C. 2702. In general the daily (preferably oral) dosage regi pH: Medium pH men may be about 0.001 to about 100 mg/kg, preferably in the range of 0.01 to 50 mg/kg, more preferably in the range of 0.1 2711 Water: Tap water to 10, even more preferably in the range of 1 to 2 mg/kg of Medium: Glucose 30 g/l; total body weight. It will also be recognised by one skilled in 2712 Mycological peptone 10 g/l; the art that the optimal quantity and spacing of individual 2713 Yeast extract 6 g/1 dosages of the composition will be determined by the nature and extent of the condition being treated, the form, route and 2714 Malt extract 6 g/1 site of administration, and the particular patient being treated, and that Such optimums can be determined by conventional Plate Cultivation of Basidiomycete Cells techniques. It will also be appreciated by one skilled in the art 2715 15 cm Petri dishes containing about 60 ml of the that the optimal course of treatment, i.e., the number of doses medium--agar at a concentration corresponding to 15 g/l. of the composition given per day for a defined number of Inoculate the plates by scraping off the top layer of mycelium days, can be ascertained by those skilled in the art using on a Petri dish using a sterile scalpel and spread it onto the conventional course of treatment determination tests. new plate. One Petri dish will yield enough mycelium to 2703. It is preferred that the kit according to the present inoculate three new plates. Cultivate the plates at 25°C. for at invention comprises dosage regime instructions with guide least three weeks prior to use. They can be kept at this tem lines for dose and time administration. perature for a total of 7 more weeks before they should be discarded. Medical Methods and Use Shake Flask Cultivation of Basidiomycete Cells 2704) One aspect of the present invention relates to use of any of the anti-cancer medicaments described herein and any 2716 500 ml Ehrlenmeyer flasks containing 200 ml of of the Agaricus bioactive agents described herein for the medium. Scrape off the top layer of mycelium on two plates manufacture of a kit of parts Suitable for administration to an using a sterile scalpel and place in a 300 ml Ehrlenmeyer flask individual in need thereof, preferably for treatment or pro containing 100 ml of medium. Homogenise the resulting phylaxis of a neoplastic disease. Such as any of the diseases mixture. Inoculate the 500 ml flasks with 50 ml of the described herein. homogenised material per flask. Put on orbital shaker at 25° US 2009/O 143280 A1 Jun. 4, 2009

C. and 140 rpm and leave for 7-10 days. If required, longer 2726 Method: The bacteriostatic effect of the bioactive fermentation periods can also be used. Such as e.g. 15-30 agent was determined by measuring the cell-density of E. coli days. K12 cultures grown in Antibiotic assay medium 3 with dif ferent dilutions of the bioactive agent. A culture without the Fermenter (3 Litres) Cultivation of Basidiomycete Cells bioactive agent in the medium was used as control. 2717 Place 1.7 litres of the medium in the fermenter and 2727 Cells were grown in a 50 ml conical flask at 34°C. sterilise at 121° C. for 20 mins. Set the fermentation condi for 26 h. The dilutions of the bioactive agent in the growth tions: 25°C., 200-300 rpm and air at 0.2-0.5 VVm. Decant as medium were 1:10, 1:20 and 1:40. The optical density was much liquid as possible from two shake flasks and inoculate measured robotically every 2 h at 660 nm. the fermenter with the remaining broth (this will normally 2728 Results: Results are shown in FIG. 1. The optical amount to 300-500 ml). Add a suitable antifoam agent when density significantly decreased in the cultures with a 1:10 and required (normally throughout the run). Harvests after 6-8 1:20 dilution of the bioactive agent in the stationary phase days. If required, longer fermentation periods can also be (between 15 and 26 h). The incubation with a 1:40 dilution of used. Such as e.g. 15-30 days. the bioactive agent does not lead to a significant decrease in optical density in comparison with the control. Harvesting of Basidiomycete Cells 2729 Conclusion: The bioactive agent is shown to have a 2718 Biomass: Remove the biomass from the broth using bacteriostatic effect on E. coli K12. a nylon cloth with pore size 45 as a filter medium. Wash the Example 5 biomass thoroughly with water and dry in a microwave oven set at defrost until dry (normal sample size will require about Anti-Tumor Effect 15 mins). Store in a desiccator until cool and weigh. 2730. In this example it is demonstrated that human and 2719 Fermentation liquor: The concentration of bioactive mouse cancer cell lines are sensitive to treatment with bioac agent in the fermentation liquor is determined by precipita tive agent obtained by the method as described in example 1 tion with abs ethanol. Sterile, distilled water is added if nec (precipited from the Fermentation liquor). essary to adjust the concentration to the desired level. The 2731 Method: The anti-tumor effect of the bioactive agent resulting liquid is autoclave and stored. was determined by measuring the cell-viability of different 2720 Medical grade: Pass the biomass-free fermentation human and mouse cell lines after exposure to different con liquor through a UF filter having a suitable cut-off value, such centrations of Lentinex. The MRC-5 cell line from normal as e.g. a cut-off value of 300 kD. When 70-80% of the liquid human fetal lung fibroblasts was used as control. has been removed add water to the retentate to wash the 2732 Cells were grown in a 96 well dish to a sub confluent Solution. Repeat until the Solution has lost much (at least most cell layer. The medium was removed and the cells washed of) its colour and appears clean. with PBS. Fresh medium without the bioactive agent (nega tive control) or containing 0.1; 0.2; 0, 3 or 0.4 mg/mlbioactive Example 2 agent was added and cells were incubated for 24h at 37°C. 2721 Protocol for cultivation of Trametes sp. and 2733) A MTT-Assay, which measures the activity of the polysaccharides obtained from Such a cultivation. mitochondrial Succinate-dehydrogenase, was used to deter Trametes versicolour mine the cytotoxic effect of the bioactive agent. In living cells 2722. A Trametes sp. fermentation, in the cultivation this enzyme converts the yellow water-soluble 3-(4,5-dimeth medium used in Example 1, takes about 7 days. The initial pH ylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) to is 4.7, final pH is 3. The final biomass concentration is about blue water-insoluble formazan, whereas there is no conver 7 g/land precipitated compound is about 0.3 g/l, the monosac sion in dead cells. Thus the amount of formazan directly charide composition of which is about 1:0.15:1:4 (glucose: correlates to the number of living cells. galactose:mannose). The fermentation liquid contains, after 2734 10 ul MTT solution was added to each well and the removal of biomass, no detectable free glucose, plates were incubated for additional 2 h. 70 ul of supernatant were removed from each well and 100 ul acidic isopropanol Example 3 was added to extract the formazan. After 1 h the absorption 2723) Protocol for cultivation of Schizophyllum sp. and was measured at 590 nm. polysaccharides obtained from Such a cultivation. 2735. Results: Results are shown in FIG. 2. The number of Schizophyllum commune viable cells was significantly decreased in all cancer cell lines after incubation with the bioactive agent for 24 h. This effect 2724. This fermentation, using the same medium as in increased with the concentration of the bioactive agent in the example 1, takes about 3 days. pH falls from 4.7 to 3.3 and the medium. In all cancer cell lines, fewer than 50% of the cells biomass concentration at the end of the fermentation is about were viable after incubation with 0.4 mg/ml bioactive agent 8 g/l. The fermentation broth, after removal of biomass, con for 24 h. The most severe effect of the bioactive agent was tains no detectable free glucose. The precipitated product observed in the mouse colon cancer cell line C-26, where concentration is about 0.6 g/l. The monosaccharide compo there were almost no viable cells after the incubation with 0.4 sition is about 1:0.1:0.65. mg/ml bioactive agent for 24 h. Example 4 2736 Conclusion: The bioactive agent is shown to have a cytotoxic effect specifically directed against cancer cells, and Bacteriostatic Effect not normal cells. 2725. In this example it is demonstrated that the bioactive agent obtained by the method as described in example 1 Example 7 (precipited from the Fermentation liquor) has a bacteriostatic 2737 For a determination of immunostimulating charac effect on E. coli K12. teristics, the following method may be used: 12 weeks old US 2009/O 143280 A1 Jun. 4, 2009

Sprague Dawley rats receives 1 mg of the composition 113. The kit according to claim 1, wherein the bioactive according to the invention in 0.5 ml 0.09 saline (i.p.) 2 days agent is a polysaccharide. before the immunisation. Control animals receives 1 mg 114-116. (canceled) casein. The animals are immunised with BSA (0.5 mg) in 117. The kit according to claim 1, wherein the polysaccha 0.25 “Freunds Complete Adjuvant” and blood samples are ride is a heteropolymer. obtained after 11 days for measurement of the antibody 118-158. (canceled) response. The specific anti-BSA antibody concentration is 159. The kit according to claim 1, wherein the bioactive determined againstan absolute standard of antibody BSA by agent is precipitated by ultracentrifugation. means of “sandwich' ELISA. 1. A pharmaceutical kit of parts comprising 160-163. (canceled) a) an anti-cancer medicament, 164. The kit according to claim 1, wherein the bioactive b) a Basidiomycete bioactive agent in Solid or liquid form, agent is extracellularly located and can be isolated from the and, optionally liquid growth medium and optionally is also produced intra c) instructions for a dosing regime. cellularly in said Basidiomycete sp. 2-111. (canceled) 165-171. (canceled) 111. The kit according to claim 1, wherein the Basidi 172. The kit according to claim 1, wherein said anticancer omycete medicament is Suitable for administration simultaneously bioactive agent is selected from the group consisting of: with the administration of the bioactive agent. an oligosaccharide, 173-191. (canceled) a polysaccharide, an optionally glycosylated peptide, 192. A method for the treatment of a neoplastic disease in an optionally glycosylated polypeptide, an individual, said method comprising the steps of an oligonucleotide, a. providing the kit of parts according to claim 1, and a polynucleotide, b. administering the anti-cancer medicament and a Basidi a lipid, Omycete sp. bioactive agent to said individual. a fatty acid, 193. (canceled) a fatty acid ester and 194. A method for enhancing the therapeutic effect of an secondary metabolites. anti-cancer drug, comprising co-administering with said anti 112. The kit according to claim 1, wherein the bioactive cancer drug a Basidiomycete sp. bioactive agent. agent is selected from the group consisting of an oligosac 195. (canceled) charide, a polysaccharide and an optionally glycosylated polypeptide.